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ABSTRACT 
Title: Development and Validation of software solutions to eliminate bottlenecks 
in the application of high-throughput quantitative immunohistochemistry 
 
Author: Catherine Conway 
Tissue Microarrays facilitate high-throughput immunohistochemistry; however, there 
are key bottlenecks apparent in their analysis, particularly in the domain of 
performing manual reviews by eye using microscopes.  
 
The advent of Virtual Slides has permitted the review of tissue slides across the 
Internet. Virtual slides also enable the creation of software solutions to assist in the 
review of Tissue Microarrays. The Virtual Tissue Matrix, a web application that 
allows the online review of digitised Tissue Microarrays, was created as part of this 
work. The performance of the Virtual Tissue Matrix was validated by comparing the 
accuracy and reproducibility of human assessment of immunohistochemically 
stained Tissue Microarrays using this and the conventional microscope-based 
approach. Results illustrated that this means of review was as accurate as 
microscope-based reviews. However, neither method of assessment was truly 
reproducible, particularly when intensity of membrane immunohistochemistry was 
assessed.  Inherent flaws in human vision prohibit the accurate determination of 
membrane staining intensity, resulting in low inter- and intra-observer agreement. 
 
As a result, an image analysis algorithm to quantify intensity of membrane-bound 
immunohistochemical staining was created. The feasibility of utilising computer-
assisted image analysis algorithms as an alternative to human microscope-based 
reviews was extensively assessed across clinical and research datasets. Membrane-
bound immunohistochemical staining was assessed by image analysis and compared 
with protein and gene expression levels when assessed by enzyme-linked 
immunosorbent assay, Western blots, and fluorescent in situ hybridisation. In 
addition, protein expression levels when assessed by human and image analysis were 
compared. Results illustrated that image analysis surpassed the performance of 
human analysis when identifying prognostic outcome of urothelial cell carcinoma of 
the bladder and as good as humans in assessment of HER-2 status of invasive 
carcinoma. Image analysis was capable of higher-throughput, greater objectivity, and 
reproducibility in quantifying membrane staining intensity. 
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CHAPTER 1: OVERVIEW OF TISSUE MICROARRAYS, 
MICROSCOPE AND COMPUTER-ASSISTED REVIEW 
OF IMMUNOHISTOCHEMICALLY STAINED TISSUE 
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1.1 Introduction 
Proteins are vital parts of living organisms, as they control the main components of 
the physiological metabolic pathways of the cell. The majority of diagnostic and drug 
targets are comprised of specific receptors, enzymes or ion channels, all of which are 
protein localised either on or within the diseased cell or within the surrounding cells. 
Although traditional methods of investigations have yielded abundant information 
about individual proteins, they have been less successful at providing an integrated 
understanding of biological systems. By studying many components simultaneously 
the mechanism by which proteins interact with each other, as well as with other 
molecules, to control complex processes within cells, tissues and even whole 
organisms can be determined (MacBeath, 2002). Therefore, examination of protein 
expression within sub-cellular compartmentalisation and cellular distribution on a 
large number of specimens is of particular importance in proteomic research 
(Tzankov et al., 2005). 
 
Numerous platforms are available for the examination of protein expression. 
Methods include; 2-D Electrophoresis/Mass spectrometry, Surface Enhanced Laser 
Desorption /Ionization, ICAT, and Protein Arrays. However, these high-throughput 
methods have prohibitive limitations including; relying on serum samples with 
known protein sequences, (2-D Electrophoresis/Mass Spectrometry), dependence on 
instruments that are difficult to calibrate and which produce lot-to-lot variability of 
reagents (Surface enhanced laser desorption / ionisation), high costs, technical 
difficulties and relative scarcity of the method (ICAT), stability of arrays is uncertain 
and difficulties with labelling methods (Protein arrays) (Hewitt et al., 2004). In 
addition, such methods are disadvantaged by the fact that actual tissue is 
disintegrated before analysis is performed, therefore, identification of the cell type 
and localisation expression of the protein is not possible (Simon et al., 2003).  
 
Table 1.1-1 illustrates numerous methods of tissue analysis (Camozzi and Razvi, 
2004). Lysate arrays allow the analysis of entire protein profiles in single or multiple 
signalling pathways; they are so sensitive that measurements are reliably done on one 
cell equivalent and with very small reagent volumes, which allows the measurement 
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of protein profiles in a cost and time-efficient way. However, cell type and protein 
localisation can not be identified when using Lysate arrays. Using blot technology is 
possible to identify DNA (Southern blot), RNA (Northern blot) and Protein 
expression levels (Western blot). However, throughput of analysis is low. 
 
Immunohistochemistry (IHC) is a method of evaluating protein expression within 
cells by localising specific antigens in tissues based on antigen-antibody recognition. 
Immunohistochemistry is the assay of choice when performing protein expression 
profiling, as disintegration of the cell prior to protein expression profiling is not 
required. In addition, immunohistochemistry is a widely used and versatile 
technique. However, validations of newly identified potential target candidates 
require analysis of hundreds of individual tissue specimens. Conventional 
immunohistochemical analysis of tissue specimens on the molecular level is labour 
intensive, time-consuming and semi-quantitative at best and, in the long run, will not 
allow scientists to keep up with the rate at which new targets for tissue investigation 
are identified (Hoos and Cordon-Cardo, 2001). Therefore, new technologies that 
facilitate, high-throughput, standardisation, localisation identification and reagent 
economy are required for protein expression profiling. 
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Table 1.1-1: Comparison of different methods of tissue analysis. ++++ excellent, +++ very good. ++ good, + possible, -- limited, --- not possible 
(Camozzi and Razvi, 2004).  
Methods Whole Section 
IHC 
Lysate Array Western blot Northern blot Southern blot 
Compartment-specific antibodies +++ --- --- --- --- 
DNA Copy Number Analysis +++ --- --- --- ++ 
RNA Expression Analysis (Frozen tissue) ++ --- --- +++ --- 
Protein Expression Analysis +++ +++ +++ --- --- 
Detection of RNA splice variants --- --- --- +++ --- 
Detection of Protein Isoforms + ++ +++ --- --- 
Mutation Analysis --- --- --- --- --- 
Standardisation of Analysis -- ++++ + + + 
Quantification Analysis + ++ + + + 
Reagent Economy -- +++ + + + 
Analysis Speed --- +++ -- -- -- 
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1.2 Tissue Microarrays 
The development of high-throughput analytical platforms utilising nucleic acids for 
analysis of cells and tissues has resulted in the demand for higher throughput 
platforms for the confirmation of these findings. Analysis of tissue for the expression 
of genes, either at the nucleic acid level or at the protein level, remains the gold 
standard validation of experimental data obtained by other methods. The two most 
common methods of validation have been in situ hybridisation (ISH) and 
immunohistochemistry on tissue with interpretation of the histomorphology to 
discern the complexity of expression patterns that cannot be determined from 
methods that rely on the extraction of biomolecules (Hewitt, 2006). Recent advances 
in molecular biology have centred on increases in throughput and quantification of 
biologic phenomena. No longer is experimental design focused on one gene or one 
protein, but rather on tens to hundreds of genes, proteins or tissue on analytical 
platform (MacBeath, 2002).   
 
The use of Tissue Microarrays (TMAs) has become a common tool to both validate 
and generalize the results of microarray experiments. Prior to Tissue Microarray 
(TMA) development, the validation of microarray data had become a bottleneck for 
both basic and clinical research (Hewitt, 2006). Tissue Microarrays provide high-
throughput analysis of histomorphologic examination of tissue for in situ 
hybridisation and immunohistochemistry, by means of arranging multiple tissue 
samples in a uniform structure on the surface of a glass slide. Tissue Microarrays 
allow for large numbers of tissue samples to be analysed simultaneously based on 
fluorescence in situ hybridisation (FISH) for genetic rearrangements, RNA in situ 
hybridisation for genetic expression, or immunohistochemistry for protein 
overexpression. Tissue Microarray technology was developed by Kononen et al. 
(1998) in order to facilitate gene expression and copy number surveys of large 
cohorts of tumours. Due to the nature of Tissue Microarray construction which 
allows multiple sections to be obtained from a single Tissue Microarray block. Rapid 
analysis of hundreds of molecular markers on the same cohort of specimens is now 
possible.  
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Utilising Tissue Microarrays disease-specific expression of a gene can be identified 
and, therefore, a possible diagnostic test and therapeutic target can be developed 
(Simon et al., 2003). Tissue Microarrays provide substantial value in rapidly 
translating genomic and proteomic information into clinical applications (Torhorst et 
al., 2001). When initially created, Tissue Microarrays were envisioned to make a 
dramatic impact on basic cancer research and anatomic pathology (Moch et al., 
2001); in almost ten years since Tissue Microarrays development this hypothesis has 
been realised through various studies. 
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1.3 Evolution of Tissue Microarrays 
Historically, immunoassays are the predominant method utilised for protein 
quantification. As early as 1929, antibodies were used in serology to precipitate 
antigens for subsequent quantification. Analytical immunoassay technology was 
greatly advanced with the introduction of the radioimmunoassay (RIA) by Yarlow 
and Berson in 1959 and enzyme-linked immunosorbant assay (ELISA) by Engvall 
and Perlman in 1971. In late 1980s, Roger Ekins argued that extremely sensitive 
quantitative assays could be developed using microspots of antibodies on solid 
supports and that multianalyte assays could be carried out using spatially separated 
arrays of such spots.  It was not until the late 1990s that the benefits of 
deoxyribonucleic acid (DNA) microarray technology were well recognised and that 
equipment to manufacturer microarrays became more accessible, that attention 
shifted to quantitative proteomics (MacBeath, 2002).  
 
 Due to advances in high density, high-throughout complementary DNA microarray 
(cDNA) and oligonucleotide technologies and the completion of the sequencing of 
the human genome, the rate of discovery of new genes that potentially could be used 
in determining disease diagnosis, prognosis and response to specific therapeutics 
regimens increased rapidly. Validations of newly identified potential target 
candidates require analysis of hundreds of individual tissue specimens. Tissue-based 
molecular analysis has traditionally been dependent on the serial examinations of 
candidate genes expression at the DNA, messenger ribonucleic acid (mRNA) or 
protein level by FISH, chromagen based in situ hybridisation or 
immunohistochemistry performed on individual whole block tissue sections. The 
analysis of hundreds of individual biopsies is highly labour intensive. More over, 
inherent variability in experimental conditions from batch-to-batch of specimens 
analysed is unavoidable. A serious drawback is that human tissue resources are finite 
in amount, and typical paraffin tissue block will be exhausted after only a few 
hundred sections (Wang et al., 2002a). In response to the need for high-throughput 
analytical analysis of large number of tissue samples, a predecessor of Tissue 
Microarray technology was developed. 
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The term “multitissue” or “sausage block” is used to describe the first attempt to 
create high density tumour arrays. Battifora et al. (1986) described the “sausage 
block” methods in which 1 mm thick rods of tissue were wrapped carefully in a sheet 
of small intestine, this was then embedded in a paraffin wax block from which 
sections were cut (Battifora, 1986, Shergill et al., 2004) and stained for analysis. 
Later this technique was updated to the “checkerboard” configuration, which allowed 
the examination of multiple samples under a more uniform structure; however, it was 
limited by its inability to create individual rods (Battifora and Mehta, 1990). These 
original efforts were limited in the orientation and density of specimens. Only with 
the development of instruments that could place cores of tissue in a recipient block 
did the utility of a multitissue platform come about (Hewitt, 2006). In 1998, 
Kononen et al., published the utility of Tissue Microarrays for high-throughput 
molecular profiling of tumour specimens (Kononen et al., 1998). In contrast to 
previous efforts to create high density tumour assays, Tissue Microarrays had an 
extremely orderly and uniform structure which is amenable to automation, is more 
agreeable when performing reviews, and results in a higher order of magnitude of 
samples per slide than was previously possible.  
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1.4 Applications of Tissue Microarrays 
Tissue Microarrays were originally developed for high-throughput molecular 
profiling of tumour specimens and confirmation of data from DNA microarrays 
(Kononen et al., 1998). Subsequently, Tissue Microarrays have expanded to function 
as a staring point for biomarker discovery and validation and in support of molecular 
epidemiology. In addition to biomarker validation, Tissue Microarrays have 
numerous applications and are extensively used in biomedical research. It has been 
suggested that, in the future, Tissue Microarrays will be used in clinical diagnostics 
as a cost-reduction method (Braunschweig et al., 2004).  
 
The major applications of Tissue Microarrays can be broadly divided into the 
following categories: 
 
1.4.1  Translational Research  
To date the majority of analysis applied to Tissue Microarrays have been associated 
with clinical translational research, particularly the confirmation of tumour markers 
identified by gene expression profiling methods in association with cancer research 
(Wang et al., 2002a). Prior to the advent of Tissue Microarrays, the development of a 
potential biomarker was accomplished by repetitive validation on different cohorts of 
specimen to demonstrate its application, utilising whole section analysis. These 
different cohorts start with samples taken from the original microarray experiment 
and expand to samples in the same laboratory, to samples from different laboratories, 
until the biomarker is validated on a population based cohort (Hewitt, 2006). Tissue 
Microarrays offer the opportunity to profile the expression of a gene product in a 
broad range of tissues on a single slide (Braunschweig et al., 2004).  
 
With the advent of targeted therapeutics, it is essential to have knowledge of 
associated expression pathways. Previous chemotherapeutic agents (for example 
cisplatin) were non specific and targeted replicating cells rather than non-replicating 
cells. Recent developments in chemotherapeutics agents have meant the 
developments of drugs that target particular proteins or pathways, for example 
Gleevac, Herceptin and Tarceva. Utilising predictive Tissue Microarrays it is 
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possible to investigate what tumour expresses a particular target, therefore aiding in 
constructing clinical trials (Braunschweig et al., 2004).  
 
1.4.2  Quality Control  
Tissue Microarrays can be used as important controls in clinical laboratories 
(Braunschweig et al., 2004). Tissue Microarray sections can be used as internal or 
external controls in tandem with surgical specimens to serve as positive and negative 
quality controls for diagnostic immunohistochemistry and in situ tests (Hoos et al., 
2001). Therefore, Tissue Microarrays will have underwent similar conditions as the 
whole section and can act as “total assay” controls validating sensitivity and 
specificity of the antibodies utilised, the tissue fixation methods and the antigen 
retrieval methods (Moch et al., 2001, Gulmann et al., 2004). 
 
Tissue Microarrays have been used to validate inter- and intra-laboratory quality 
control (Hoos et al., 2001). Miniature Tissue Microarrays have been incorporated on 
whole sections slides as a means of validating quality control in the assessment of 
HercepTest™, which is an immunohistochemical assay utilised to evaluate HER-
2/neu overexpression in breast tumours (Gulmann et al., 2004). The inclusion of cell 
line preparations containing multiple samples of known HER-2 status, characterised 
by FISH and immunohistochemistry, is recommended in HER-2 assessment (Ellis et 
al., 2004).  
 
Currently, HercepTest™ is the only Food and Drug Administration (FDA) approved 
immunohistochemical assay used to determine HER-2 protein overexpression in 
breast cancer tissue. The HercepTest™ kit includes cell line Tissue Microarrays, 
which are used to qualify the procedure and reagents quality. The inclusion of 
normal tissue within Tissue Microarrays also acts as internal controls, and can 
identify excessive antigen retrieval performed in immunohistochemical analysis 
(Ellis et al., 2004).  Tissue Microarrays have also been used to evaluate inter-
laboratory reproducibility when performing immunocytochemistry and FISH 
analysis to evaluate HER-2 overexpression and amplification (Kay et al., 2004).  
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1.5 Advantages of Tissue Microarrays 
There are numerous advantages of using Tissue Microarrays compared with whole 
section analysis. The major benefits are as follows: 
 
1.5.1  Standardisation 
Tissue Microarray introduces standardisation of protocols into histopathology over 
and above what is possible with whole sections. As a result, Tissue Microarrays 
hugely reduce inter- and intra-laboratory variations due to standardisation of 
laboratory procedure (Tzankov et al., 2005). With whole section analysis inherent 
variability in experimental conditions from batch-to-batch of specimens analysed is 
unavoidable.  However, all tissue specimens arrayed on one Tissue Microarray are 
analysed in an identical fashion. Antigen retrieval reagent concentrations, incubation 
times with primary and secondary antibodies, temperatures and wash conditions are 
identical for each core within a Tissue Microarray, resulting in an unprecedented 
level of standardisation which is unattainable utilising whole section techniques 
(Shergill et al., 2004).   
 
1.5.2  High-throughput 
Tissue Microarrays greatly increases throughput of tissue analysis. Analysis of 
prognostic and predictive markers had traditionally been performed by testing one 
marker at a time (Torhorst et al., 2001). However, utilising a single Tissue 
Microarray block containing 1,000 cores which can create 200 slides,  as many as 
200,000 individual assays can be performed (Shergill et al., 2004). Therefore, Tissue 
Microarrays allow serial selection analysis of multiple markers from the same 
molecular pathway in a large number of tissue samples, facilitating direct 
comparison of alterations of multiple molecular targets in virtually identical 
histologically highly conserved tumour regions, all of which are under uniform 
experimental conditions (Wang et al., 2002a). 
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1.5.3  Cost and time  
Tissue Microarrays decrease the cost of reagents and the time taken to review the 
same number of patients when performed using whole section analysis. Cost and 
time are critical factors when comparing whole section and Tissue Microarray 
analysis. Milanes-Yearsley et al. (2002) extensively investigated the cost and time 
involved in creating, immunohistochemically staining and reviewing 4 Tissue 
Microarrays compared with 150 whole sections.  Purchase of materials and reagents 
for immunohistochemistry was 37.1 times more expensive for 150 whole section 
slides compared with 4 Tissue Microarrays. Moreover, the greatest impact in reagent 
savings is typically seen with probes for ISH (Braunschweig et al., 2004). However, 
including technical time it is estimated that the cost of creating 4 replica Tissue 
Microarrays is ≥ $5000, this cost is justified by the fact that potentially hundreds of 
Tissue Microarrays can be produced from one block.  The creation of Tissue 
Microarrays proved to be extremely labour intensive. To prepare, build and section 4 
Tissue Microarrays consisting of 150 cores required 32 hours, in contrast with 8 
hours required to section 150 slides from a single whole section block. However, to 
perform immunohistochemistry on 4 Tissue Microarrays required three hours, in 
comparison with 16 hours to perform immunohistochemistry on 150 whole tissue 
sections. The review of the 4 Tissue Microarrays required considerably less time than 
that required for 150 whole tissue sections. Immunohistochemical review required 1-
2 minutes per case within the Tissue Microarrays, compared with 5-10 minutes per 
whole section tissue. Therefore, when comparing whole sections and Tissue 
Microarrays, histologists and pathologists spend more time in selecting blocks and 
constructing Tissue Microarrays compared to whole sections. However the 
technologist spend considerably less time immunohistochemically staining Tissue 
Microarrays and the pathologists spent less time reviewing Tissue Microarrays, 
compared to whole sections  (Milanes-Yearsley et al., 2002).  
 
It is not always cost effective to construct a Tissue Microarray when less than 25 
specimens are involved. One exception to this model is the creation of cell line 
Tissue Microarrays where the inclusion of 5 or more cell lines can be justified. This 
is largely due to the fact that it is not necessary to review and stain a section of the 
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embedded cells before secting begins. Also the cost of the Tissue Microarray arrayer 
must be taken into account (Braunschweig et al., 2004). 
  
1.5.4  Conservation of tissue 
Human tissue for research purposes can be hard to obtain. Utilising Tissue 
Microarrays, sampling and combining tissue from different sources dramatically 
extend its utility. From a traditional block of tissue, between 300 and 500 whole 
section slides can be obtained. In comparison, if the same block can be repeated in 
between 5 and 50 Tissue Microarrays, results in upwards of  25,000 samples of that 
original block (Braunschweig et al., 2004). This “tissue expansion” capability of 
Tissue Microarray provides for the maximum conservation and utilisation of limited 
valuable, and often irreplaceable tissue (Wang et al., 2002a). 
 
The availability of fresh tissue is often a constricting factor in genomic and 
proteomic research. However, large resources of FFPE tissue are usually catalogued 
in research hospitals. Therefore, retrospective studies with long follow-up 
information are possible. For example, the Radiation Therapy Oncology Group 
(National Cancer Institute, National Institute of Health, USA) have a resource of 
12,262 blocks of prostate, brain, head and neck, gastrointestinal, gynaecological, 
bladder and lung tumours available to qualified investigators (Milanes-Yearsley et 
al., 2002).  The small diameter of Tissue Microarray cores result in minimal damage 
to the original donor block which are often considered vital resources (Shergill et al., 
2004). Therefore, subsequent to sampling, the remaining donor block can be retained 
for future whole section or Tissue Microarray analysis. This has resulted in 
pathologists giving samples more readily to researchers, whilst still retaining the 
tissue blocks for diagnostic purposes (Moch et al., 2001).  
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1.6 Limitations of Tissue Microarrays 
Despite the numerous advantages of Tissue Microarrays, there are also difficulties 
associated with this technology. The majority of their limitations are associated with 
all types of histopathology applications, for example edge effect, fixation problems, 
loss of antigenicity, but these issues are often amplified when using Tissue 
Microarrays due to the small sampling size. The most prevalent limitations of Tissue 
Microarrays are as follows: 
 
1.6.1  Tissue Heterogeneity 
When Tissue Microarray technology was first created in 1998, it was expected that 
tissue heterogeneity would negatively influence the predictive power of Tissue 
Microarray results (Torhorst et al., 2001). Tissue Microarrays have inherently small 
tissue core samples which were suspected not to be fully representative of the 
heterogeneous parent tissue from which they were derived. How representative 
Tissue Microarrays are of the original specimen depends on the degree of 
heterogeneity of the tissue under investigation, the number of replica cores taken 
from the whole sections and the expression pattern of the marker involved (Wang et 
al., 2002a). It is also important to note that Tissue Microarrays have been developed 
to examine tumour populations and not individual tumours (Moch et al., 2001).  
 
Torhorst et al. (2001) assessed the impact of tumour heterogeneity by comparing the 
frequency of ER and PR positivity in 553 whole section breast tissue samples with 4 
Tissue Microarrays constructed from the same tissue. The frequency of ER positivity 
was virtually the same in the whole section and a single Tissue Microarray. By 
comparing a Tissue Microarray with the corresponding whole section agreement was 
slightly lower for PR (88.0%) and 3 x 0.6 mm replica cores were required to achieve 
the same level of positivity as the whole section.  
 
Milanes-Yearsley et al. (2002) examined the correlation between whole sections and 
4 replica multitumour Tissue Microarrays consisting of 150 x 0.6 mm cores for the 
expression of p53. Visual estimations illustrated that by comparing a Tissue 
Microarray with the corresponding whole sections, 86-90% agreement was achieved 
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and agreement increased to 97-100% when 4 Tissue Microarrays with duplicate 
cores were compared with the corresponding whole sections. The impact the type of 
tumour has on agreement was also assessed. Agreement was found to be 84.0% for 
brain tumour, 89.7% for prostate tumour, and 90.0% for head and neck tumours. 
 
Hoos et al. (2001) illustrated that, with complex phenotypes, it is crucial to evaluate 
the number of cores required. Hoos et al. (2001) compared protein expression for Ki-
67, p53 and retinoblastoma protein (pRB) for a group of 59 human fibroblastic 
tumours by whole sections and Tissue Microarray analysis. Tissue Microarrays were 
composed of 3 x 0.6 mm cores per specimen. Results indicated that tumour 
heterogeneity can lead to lower concordance rates if more complex phenotypes are 
analysed. Overall 3 cores per specimen resulted in 96.0-98.0% concordance with 
whole sections. However, concordance decreased to 91.0% for the more complex 
pRB phenotype. 
 
Camp et al. (2000) investigated the phenotypic profiles of ER, PR and HER-2 
expression of 38 breast carcinomas by immunohistochemically, comparing 1 to 10 
0.6 mm cores per specimen with whole sections. Results illustrated greater than 
95.0% concordance between Tissue Microarrays and whole sections when 2 cores 
per specimen were used, concordance increased to 99.5% with 5 cores per specimen. 
 
Literature clearly indicates that Tissue Microarrays can sufficiently represent the 
donor tumours in order to establish associations between molecular alterations and 
clinical endpoints (Torhorst et al., 2001). The general opinion is that at least 3 x 0.6 
mm cores are required from the donor tissue in order for Tissue Microarrays to be 
truly representative. However, due to the homogeneous character of cell line tissue 
pellets, one core per cell line is often enough within a Tissue Microarray constructed 
solely from cell lines. Due to the loss of cores during sectioning, it is recommended 
that cell lines are arrayed in duplicate form to avoid loss of the specimen (Hoos and 
Cordon-Cardo, 2001). 
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1.6.2  Fixation Problems 
A major cause of variation in the reproducibility of immunohistochemical staining is 
induced by tissue fixation. Almost all paraffin-embedded tissue used in Tissue 
Microarrays is formalin fixed. Formalin-fixing is amongst the most popular, due to 
low cost, ease of preparation and because it preserves morphologic detail with few 
artifacts. In addition formalin-fixed tissue is also commonly used in histopathology 
laboratories.  Neutral-buffered formalin (10%) which contains 4% formaldehyde is 
the most common type of formalin used in laboratories (Werner et al., 2000). 
Formaldehyde works under a broad variety of conditions, is stable, functions 
effectively over a five fold or more range of concentrations and is useable with 
almost any tissue. Formaldehyde is not a coagulate fixative; therefore, tissue does not 
contain clumps of coagulated materials nor is cellular detail distorted by the 
formation of coagulum (Fox et al., 1985). In some applications, 70% ethanol may be 
used rather than formalin, and this is more commonly used in cell lines, animal and 
xenograft arrays (Braunschweig et al., 2004).  
 
The most important molecular change induced by formaldehyde is the formation of 
cross-links between proteins, or between protein and nucleic acids, involving 
hydroxymethylene bridges. Cross linkage by formaldehyde is a slow process and 
usually takes between 24 to 48 hours to be completed. Numerous problems are 
associated with incorrect fixation times and delayed fixation. Delayed fixation results 
in an increasing proteolytic degradation. Depending on the antigen, this may cause 
loss of immunoreactivity and therefore irreversible weak or absent 
immunohistochemical staining. Formalin fixation results in a variably reversible loss 
of immunoreactivity by its masking or damaging some epitopes. Epitope retrieval 
methods can be used to unmask the epitope.  For some epitopes, the duration of 
formalin fixation is critical. Too short of a fixation time will lead to cross-linking 
only at the periphery of the tissue block; toward the centre of the block coagulation 
by alcohol during tissue dehydration may occur or the centre may remain raw and 
not fixed. This may cause more intense staining on the periphery or the centre 
depending on which antibody is used. Too long of a fixation time may result in 
excess cross-linkage formation which may lead to weak or absent staining (Werner et 
al., 2000). 
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1.6.3  Loss of Antigenicity  
As described in section 1.12 sectioning and storing multiple Tissue Microarray 
sections at one time conserves tissue by avoiding the unnecessary loss of tissue 
which occurs every time a blocked is faced; however, this assumes that 
immunoreactivity is stable over time.  Literature reports the loss of staining intensity 
in paraffin-embedded whole tissue sections over time, when probed for several 
antibodies (Wester et al., 2000, Bertheau et al., 1998, Jacobs et al., 1996). The 
decline of staining intensity within whole tissue sections and Tissue Microarrays 
prepared from paraffin sections may result in false negative findings. It is assumed 
that this problem may be accentuated in Tissue Microarrays, due to the limited tissue 
representation of each donor case (Fergenbaum et al., 2004).  
 
Fergenbaum et al. (2004) assessed the loss of immunoreactivity of two Tissue 
Microarrays originating from a single Tissue Microarray block. The Tissue 
Microarrays were constructed from FFPE invasive breast carcinomas. A single 
Tissue Microarray was created and stored for 6 months before 
immunohistochemistry was performed. Another Tissue Microarray was created and 
immunohistochemically stained on the same day as creation, for PR, ER and HER-2. 
Protein expression was assessed by microscope-based reviews. The Tissue 
Microarray which was stored for 6 months before staining exhibited a loss in 
immunostaining for ER, PR and HER-2 compared with the Tissue Microarray 
sectioned and stained on the same day. The loss of immunostaining was at its 
greatest for the HER-2. In conjunction with increased length of storage time of 
sections, other factors are known to influence the rate of loss of antigenicity. 
Increased storage temperatures have been found to reduce antigenicity in samples 
stained for PR and HER-2 (Wester et al., 2000, Bertheau et al., 1998); however, 
reducing the cold storage does not eliminate loss of antigenicity. Nuclear and 
cytoplasmic specific stains are less affected by loss of antigenicity than membrane 
specific stains (van den Broek and van de Vijver, 2000). Oxidation may be a factor in 
loss of antigenicity. Currently the storage of unstained Tissue Microarrays under 
nitrogen and shipping in vacuum packed bags is being investigated as the optimal 
methods to reduce the loss of antigenicity. However, as with all 
immunohistochemistry, evaluation of staining intensity is a comparison factor and, as 
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long as all tissues under analysis have a uniform loss of antigenicity, analysis is still 
considered to be valid, as would be the case for tissue within Tissue Microarrays 
(Fergenbaum et al., 2004). 
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1.7 Commercial vs. Public Arrays 
It is now possible to obtain “off the shelf” Tissue Microarrays from commercial 
vendors, academics, government sponsored or consortium based providers. However, 
commercial vendors are the most expensive, as the alternative providers charges are 
either nominal or to cover their costs, and often these providers obtain the tissue 
through donation (Fergenbaum et al., 2004). Commercial arrays charge by the slide 
and are prohibitively expensive for most applications. The cost of the arrayer is quite 
modest in comparison (Hoos et al., 2001). Generally commercial Tissue Microarrays 
offer larger cohorts of tissue but lack annotation and are limited in the number of 
samples that impact statistical significance. As the annotation provided increases so 
to does the cost of the Tissue Microarray. Frequently commercial arrays are limited 
to providing 5 to 10 slides per array block. If slides are re-requested at a later date it 
is assumed they will be from a different block. Commercially available Tissue 
Microarray composed of normal and tumour rodent model systems, cell lines, and 
xenografts are widely available. The general rule of thumb is, if a laboratory requires 
less than 20 Tissue Microarray slides a year, purchasing the slide would be the best 
option. If less than 100 slides a year are required, setting up collaboration with a 
more experienced laboratory is the best alternative. Non-commercial Tissue 
Microarray providers typically do not offer the same level of quality control, 
especially with regard to the design of the Tissue Microarray. However, there are 
often ethical concerns when purchasing a commercial Tissue Microarray. In some 
instances, institutional ethic review boards have required that they approve the use of 
Tissue Microarrays obtained from commercial sources even when these Tissue 
Microarrays have already received broad approval from the originating organizations 
(Hewitt, 2006).  
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1.8 Design of Tissue Microarrays 
Tissue Microarray blocks should be designed in a logical fashion. The orientation of 
the specimens on the array is crucial because confusion about their location can 
threaten the evaluation of the experiment. Tissue Microarrays often include two 
orientation spots in specific positions outside the geometric margins of the usually 
square of rectangular arrays to orient the entire Tissue Microarray (Hoos and 
Cordon-Cardo, 2001). 
 
The general guidelines for designing Tissue Microarrays vary greatly in literature. 
Some experts recommend randomised designs, whereby cores from different 
tumours and features are mixed together in a random fashion. Scattering normal 
tissue throughout the array to ensure even immunohistochemical staining has been 
reported. Also the use of different normal tissue to identify different rows based on 
the tissue morphology may be relevant. For example, distinct morphologic tissue 
such as bone, liver or skeletal muscle have been used (Hoos and Cordon-Cardo, 
2001). However, other experts argue that these approaches can confuse pathologists, 
as some pathologists often rely on some aspects of histopathology to score the 
tumour, and would benefit from similar tumour located in close proximity to each 
other on the Tissue Microarray (Fergenbaum et al., 2004). 
 
Tissue loss during sectioning and staining is a common problem with Tissue 
Microarrays. In addition “edge effect” which is the over staining of artifacts at the 
tissue borders is a well known occurrence in immunohistochemistry, which occurs 
most frequently on the periphery of Tissue Microarrays. To minimise the effect this 
may have on immunohistochemistry and the loss of tissue during sectioning it is 
recommended to frame the arrayed cancer specimens with rows of normal tissue 
(Hoos and Cordon-Cardo, 2001).  
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1.9 Types of Tissue Microarrays 
Since Tissue Microarray development, numerous types of Tissue Microarrays have 
evolved. Tissue Microarrays types are dependant on their function and composition. 
Currently there are numerous types of Tissue Microarrays, outlined as follows: 
 
1.9.1 Multitumour Tissue Microarrays 
Tissue Microarrays can be composed of numerous tumour types, which allow large 
numbers of tumours to be screened simultaneously for molecular abnormalities of 
interest (Shergill et al., 2004). Multitumour Tissue Microarrays have been used for a 
range of applications. 
 
1.9.2 Progression Tissue Microarrays 
Morphological and molecular changes through the different stages of progression of 
one particular tumour type can be assessed in a tumour progression Tissue 
Microarray. Tumours can be extracted from one or multiple sources. An example of 
a prostate cancer progression Tissue Microarray would consist of normal prostate, 
benign prostatic hyperplasia, prostatic intraepithelial neoplasia and different stages of 
prostate cancer from localised disease to metastatic cancer (Shergill et al., 2004).  
 
1.9.3 Prognostic Tissue Microarrays 
Prognostic Tissue Microarrays are highly sought after, as they contain tumours from 
patients whose clinical outcome are known and, therefore, are used to identify 
potential prognostic biomarkers (Moch et al., 2001).  The correlation of Tissue 
Microarray derived data with clinical follow-up data to assess prognosis is of 
significant importance to clinicians and their patients (Shergill et al., 2004).  
 
1.9.4 Predictive Tissue Microarrays 
Tissue Microarrays constructed from tumours “before and after” disease-specific 
treatment are used to investigate predictive markers with respect to response to a 
specific cancer therapy (Braunschweig et al., 2004).  
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1.9.5 Cell Microarrays 
Tissue Microarrays can be constructed solely from cell lines (CMAs). CMAs are 
known as a “western on a slide”, and are often used to test effects of new 
chemotherapeutics. Many methods exist for embedding the cell lines and for 
constructing the arrays; however, this is usually determined by the purpose of the 
CMA and the number of cells available. An example of a Tissue Microarray 
composed solely from cell lines is the NI60 created by TARP in NIH (Braunschweig 
et al., 2004).  
 
1.9.6 Xenograft Tissue Microarrays 
Xenograft tumours are routinely used in the construction of Tissue Microarrays and 
are referred to as XMAs (Hewitt, 2006). Optimal use of xenograft models for drug 
testing requires the use of panels of xenografts that closely mimic the biological 
characteristics of there respective primary tumours. Single xenograft models cannot 
capture the variability of the corresponding cancer. For paediatric cancers, xenograft 
model systems have been used for drug screening with some success. Due to the 
limited amount of tissues available for specific types of cancer in paediatric 
oncology, it is important to prioritise new agents for clinical trials (Whiteford et al., 
2007). Utilising a panel of xenograft models to construct Tissue Microarrays it is 
possible to conserve precious tissue and perform large scale molecular 
characterisation.  XMAs have also been used in adult cancer analysis, such as 
prostate cancer (Glinsky et al., 2003, Bani et al., 2004). 
 
1.9.7 Frozen Tissue Microarrays 
It is appealing to many investigators to construct Tissue Microarray from frozen 
tissue rather than formalin-fixed-paraffin-embedded (FFPE) tissue, as it is possible to 
apply in situ hybridisation and antibodies for immunocytochemistry that do not work 
in FFPE material. Optimal cutting temperature (OCT) arrays or frozen arrays are 
used in cases where certain antibodies do not work in formalin-fixed-paraffin-
embedded tissue. These arrays contain larger, but fewer, cores (Braunschweig et al., 
2004).  However, the limitations of this approach usually outweigh the benefits.  
Frozen Tissue Microarrays are uneconomical with tissue requiring larger cores of 
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tissue, than FFPE Tissue Microarrays. The capacity to target selection of tissue can 
be impaired and the histology on the resultant arrays is typically of limited quality 
(Hewitt, 2006).  
 
1.9.8 Bone marrow Tissue Microarrays 
Until recently very little information was available about the applicability of the 
Tissue Microarrays for the analysis of bone marrow biopsies, because of the specific 
difficulties in constructing arrays generated from small tissue cylinders of bone 
structure. Recent studies have shown the construction of Bone marrow Tissue 
Microarray (BM-TMAs) is hampered by the presence of bony trabeculae in the bone 
marrow biopsies and the heterogeneity of the samples used. This problem was 
reduced by firstly carefully making representative areas rich in leukaemic blasts in 
the bone marrow biopsies selected for Tissue Microarrays construction and, 
secondly, by punching these selected areas exactly. Therefore, the punched bone 
marrow tissue very rarely turned out to be non-representative, due to necrotic or 
normal non-neoplastic bone marrow tissue (< 5%) (Zimpfer et al., 2007).  
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1.10 Selection of Tissue  
A major factor in the loss of satisfactory samples is the quality of tissue utilised. 
Tissue Microarrays can be no better than the tissue they are built from, and often are 
not as good as the original tissue (Hewitt, 2006). The majority of human tissues used 
in Tissue Microarrays are usually sourced from surgical specimens, either from 
removed organs, biopsies or autopsies. The use of autopsy material in Tissue 
Microarrays is limited due to the significant risk of anoxic or autolytic defects which 
can impact immunohistochemistry or ISH results. Autopsy tissue is usually only used 
when there is no alternative, for example, in the case of normal human brain tissue 
(Braunschweig et al., 2004). The quality of the tissue must be noted, for example 
prostatic carcinoma preoperatively treated with radiation may consist only of small 
numbers of remaining tumour cells (Hoos and Cordon-Cardo, 2001).  
 
In addition to the original quality of the tissue when removed from the body, the 
subsequent handling of the tissue also alters the quality. The tissue should be frozen 
or fixed directly (See section 1.6.2) after surgery in order to ensure optimal protein or 
nucleic acid preservation (Braunschweig et al., 2004). If optimal fixation is not 
performed tissue quality can be hugely affected. If donor blocks are over-fixed, the 
tissue tends to be dry and run a greater risk of cracking and breaking into fragments 
than optimally fixed tissue (Hoos and Cordon-Cardo, 2001).  
 
Another consideration when selecting human or animal tissue is the ethical 
regulation. Restrictions vary greatly depending on the type of tissue used and the 
source of tissue. For human tissue, the ethical regulations vary greatly from country 
to country. Animal tissue has been widely used for the construction of Tissue 
Microarrays, (including mouse and rat) as well as other animals used as models of 
human disease such as canine models of human cancer (Hewitt, 2006). For animal 
tissue, it is essential that the protocols for handling the animals are followed.  Tissue 
Microarray are commonly constructed from anonymized tissue, which usually lacks 
clinical follow-up data. Tissue Microarrays composed of anonymized tissue are 
typically used as the tissue is less expensive to purchase, approval from the ethical 
committees is easier, and approval from the ethical offices of the individual end users 
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is not required. Tissue Microarrays with clinical and epidemiology information 
greatly expand the potential benefits of the Tissue Microarray; however, the cost of 
their creation is great and this type of Tissue Microarray is usually not commercially 
available (Braunschweig et al., 2004). 
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1.11 Construction of Tissue Microarray Blocks 
Construction of a high quality Tissue Microarray is not trivial. The cost of staff, time 
and equipment to construct Tissue Microarrays may suggest that collaboration is the 
best solution (Hewitt, 2006). The preparation for constructing Tissue Microarray 
blocks is extremely labour intensive. The majority of time taken to create a Tissue 
Microarray is spent collating tissue, reviewing biopsies, and selecting areas of 
interest for arraying. The actual tissue arraying processing itself is quite simple and is 
considered < 5% of the entire work of creating Tissue Microarrays (Simon et al., 
2003). Haematoxylin and Eosin (H&E) stained full sections from the biopsy blocks 
must be obtained to assess morphology and to identify an area that represents the 
specimen; however, this can vary greatly among tumour types. For example, in 
colorectal cancer it is important that the target areas are small and well defined 
because stromal areas between the glandular structures of the tumour can be large 
and a core biopsy can easily miss the tumour cell regions (Hoos and Cordon-Cardo, 
2001).  
 
Construction of a Tissue Microarray requires access to specialised equipment and 
training (Hewitt, 2006). Low density arrays may be constructed from simple 
equipment, for example using spinal needles (Hidalgo et al., 2003) or a drill grinder 
(Vogel and Bueltmann, 2006). However, the majority of Tissue Microarrays are 
constructed using a manual tissue arrayer. Currently, Beecher Instruments are the 
leaders in the field for providing Tissue Microarray arrayers. They provide three 
generations of machines for constructing Tissue Microarrays, one automated 
machine (ATA-27) and two manual machines (MTA-І, MTA-П). MTA-І consists of 
a recipient block holder, bridge holder for the donor block, matched pair of donor 
and recipient needles available as either 0.6, 1.0, 1.5, or 2.0 mm diameter, an 
adjustable arm which houses the needles, and two digital micrometers used for 
positioning. MTA-І is illustrated in Figure 1.11-1.  
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Figure 1.11-1: MTA-1- First version of Tissue Microarrayer. Adjustable arm, 
controls the movement of the needles. Recipient block holders houses the Tissue 
Microarray block. Donor block holder houses the biopsy tissue. Microtome adjusts 
the x-y positing of the needles. Image provided by Beecher Instruments. 
 
Instrumentation for the construction of Tissue Microarrays is beginning to diversify, 
ranging from the introduction of automated arrayers to supplementary applications to 
assist in the construction process. MTABooster® designed by ALPHELYS, is a 
motorisation kit that can be retrospectively installed on the MTA-1 in order to 
automate the X-Y movement of the stage (ALPHELYS, France). During manual 
construction of tissue arrays, rotation of the micrometers may be required up to 2000 
times. Utilising MTABooster® the movement of the micrometers can be automated 
and visualised by a LED screen. The application of fully-automated arrayers such as 
Beecher’s the ATA-27 is largely limited to industrial and high-volume production 
facilities (Hewitt, 2004). An alternative to Beecher Instruments is the TMArrayer™ 
which is a semi-automated arrayer provided by Pathology Devices (Westminster, 
USA). When purchasing an arrayer cost, ease of use, speed and accuracy are the 
typical considerations. 
 
The process of arraying involves removing a cylindrical core of paraffin from the 
recipient block. The needle used to remove the paraffin has a slightly smaller 
diameter than the second needle (used to remove the donor tissue). An area of 
interest is selected for sampling using H&E stained sections of the donor biopsy. A 
Recipient block holder 
Donor block holder 
Adjustable Arm Microtome 
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cylindrical core of tissue is removed from the biopsy using the second needle, the 
adjustable stage is removed to reveal the recipient block directly underneath. The 
needle is lowered into the cylindrical cavity and the tissue is expelled. The process is 
visualised in Figure 1.11-2. It is critical to place every core the same depth into the 
recipient block. If the donor blocks are not of the same depth double stacking may be 
required. Paraffin must be soft enough at room temperature to punch holes without 
cracking the block. After the recipient block is created, it is placed in the oven at 
37°C for several hours to soften the paraffin and to compound the cylinders with the 
paraffin, this process is known as “tempering” (Fergenbaum et al., 2004).  
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Figure 1.11-2: Tissue Microarray construction (image created by Mark A Rubin MD, Michigan University). 
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The size of the needles utilised in Tissue Microarray construction will affect the number 
of samples present within the Tissue Microarray. When designing a Tissue Microarray, 
it is essential that the ratio of needle size to the number of samples is carefully 
considered. In general, a Tissue Microarray recipient block is 18-22 mm in size, which 
can easily hold up to 500 0.6 mm diameter cores. As the diameter of the needles used 
increase, the distance between the cores within the block should also increase. General 
guidelines are available for designing a Tissue Microarray. Distances between the 
centres of cores must be uniform. Sub-arrays of samples within the Tissue Microarray 
block can be used in order to prevent reviewers loosing their position when performing 
analysis. Sub-arrays of 20-25 cores is considered a workable group (Braunschweig et al., 
2004). An orientation core should be present within the block. Generally between 5-10% 
of all cores present should be normal or control tissue, especially where 
immunohistochemistry will be performed on the sides (Hewitt, 2004). The number of 
duplicate tissue depends on the tissue type and is greatly affected by the issue of tissue 
heterogeneity.  
 
Another consideration is the amount of donor tissue available for sampling. There are 
guidelines for the amount of cores that can be sampled from a 1 cm3 donor tissue block. 
For example, using 0.6 mm needles 256 cores can be sampled, using 1.0 mm needles 
100 cores are possible. The general rule is to always fill the array; the more samples the 
better and in the absence of multiple samples, use larger cores (Braunschweig et al., 
2004). 
 
 31 
1.12 Sectioning of Tissue Microarray Block 
Sectioning of Tissue Microarray blocks is performed utilising a microtome. It is possible 
to cut 200 sections from a single Tissue Microarray block (Kononen et al., 1998). 
However, once more then 70 sections are cut, missing tissue spots may become 
apparent. Sectioning a Tissue Microarray block at different times requires the block to 
be refaced, which results in loss of tissue (Milanes-Yearsley et al., 2002). 
Approximately 5% loss of the tissue occurs each time the block is re-inserted into the 
microtome (Wang et al., 2002a). Therefore, it is often preferable to section a block to its 
entirety in one sitting. It has been reported that between 17.6 - 20.0% of cases lacked a 
satisfactory core when the Tissue Microarray was refaced and sectioned a second time, 
this occurred 50 sections deep into a breast cancer block. However, only 3.2 - 4.8% of 
cases lacked a satisfactory core when Tissue Microarrays were sectioned at one time 
(Fergenbaum et al., 2004). To avoid unnecessary loss of tissue, microtome techniques 
must be perfected and performed by an experienced individual.  
 
1.13 Creation of Tissue Microarray slides 
Due to arraying, transferring of sections, vigorous staining procedures and the depth of 
the donor tissue samples are often missing within Tissue Microarrays. Loss of tissue can 
be minimised by including multiple samples from a specimen, inclusion of good quality 
tissue and maintaining uniform spacing between cores. It has been reported that between 
10 - 30% of cores have been lost due to poor tissue transfer to the slides (Hoos and 
Cordon-Cardo, 2001). The challenge in transferring sections to slides is obtaining tissue 
that is not twisted, stretched or wrinkled and resistant to staining methods including 
harsh antigen retrieval procedures (Fergenbaum et al., 2004).  
 
Currently two methods of transferring tissue to slides are utilised; 
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1.13.1 Adhesive Tape Transfer 
When dealing with large Tissue Microarrays some experts recommend the use of tape 
transfer technique to transfer sections from the microtome to glass slides. An adhesive 
coated slides (Instrumedics, USA) system can be used to assist in tissue sectioning 
(Simon et al., 2003). With the tape transfer method, adhesive tape is placed directly onto 
the block within the microtome prior to sectioning. After sectioning the tissue remains 
on the tape, the tape and tissue is then transferred onto a slide coated in artificial resin. 
The slide is then placed under UV light in order to harden the resin and ensure the tissue 
transfers to the slide. The slides are then placed in solvent to remove the tape 
(Fergenbaum et al., 2004). Although this method is time-consuming, it has been shown 
to reduce tissue loss to less than 2% (Wang et al., 2002a).  
 
1.13.2 Water Bath Transfer 
Utilising water bath transfer achieves less tissue damage, less background staining and 
there are fewer missed cores on smaller Tissue Microarrays than when using adhesive 
tape transfer technique (Milanes-Yearsley et al., 2002). Using the water bath transfer 
technique, the section of tissue is taken from the microtome and placed on the surface of 
warm water; this evens the wrinkles which develop during sectioning on the microtome. 
A glass slide is then used to lift the section from the warm water. The slide is then 
allowed to dry, either in an oven or by air drying. The tissue is then adhered to the glass 
slide. In order to perform immunohistochemistry on the tissue, the adhesion of the tissue 
to the slide must be enhanced. Commercially available coated slides, which have been 
previously coated with organic polymers are used i.e. poly-L-lysine (Fergenbaum et al., 
2004). Using water bath transfer, up to 70 sections from the Tissue Microarray have 
been removed before missing samples emerged (Hoos and Cordon-Cardo, 2001). 
However, large Tissue Microarrays are often twisted and lose their shape when using 
water bath transfer method.  
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1.14 Experimental usage of Tissue Microarray sections 
Tissue Microarrays are suitable for all analyses currently performed on conventional 
whole biopsy sections (Kononen et al., 1998). Three assays are predominantly 
performed on Tissue Microarrays, they are as follows: 
 
1.14.1  Fluorescent in situ hybridisation (FISH) 
FISH is a molecular cytogenetic tool that permits detection of specific chromosomal 
aberrations in metaphase chromosomes and interphase nuclei. The process involves the 
samples DNA being denatured, the fluorescently-labelled probe of interest is added to 
the denatured sample mixture and it hybridises with the sample DNA at the target site as 
it reanneals back into a double helix. The probe signal can then be seen through a 
fluorescence microscope and the sample DNA scored for the presence or absence of the 
signal. FISH technology has been widely used in detection of chromosomal copy 
number changes, amplifications, deletions, and rearrangements both in research and 
clinical settings. The quality of FISH is influenced by several parameters including the 
quality of the probe and the accessibility of the hybridisation targets (Andersen et al., 
2001).  
 
The use of FISH technique on archival FFPE sections has been especially problematic, 
primarily because the formalin fixation greatly affects the accessibility of the 
hybridisation target. In a Tissue Microarray containing hundreds of different specimens 
the age of the individual samples as well as the type and length of the fixation used can 
vary considerably. Improved procedures for performing FISH on FFPE Tissue 
Microarrays have been developed and the new protocol results in greatly increased 
signal intensity and almost 30% increase in the number of tissue samples with invaluable 
hybridisation results (Andersen et al., 2001). There are challenges of FISH on Tissue 
Microarrays as the imaging methodologies require high magnification and counting 
many cells within each core to detect the specific targets and as the nature of tissue in 
histologic section does not result in every cell possessing an intact nucleus. However, 
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the significant savings in fluorescent probes continues to make Tissue Microarrays 
extremely inviting for investigators using FISH (Braunschweig et al., 2004). 
 
1.14.2  In situ hybridisation 
In situ hybridisation for RNA expression is used to characterise spatial and temporal 
response of specific gene targets in tissue sections. Probes were traditionally labelled 
with radioactive nucleotides and required placement of a photo emulsion on the slide 
after hybridisation. Development of the emulsion and visualisation by dark field 
microscopy required two weeks. Alternatively, the slide can be placed on a 
phosphorimager plate and the signal quantified. Chromogenic in situ hybridisation 
(CISH) using digoxigenin-labelled riboprobes, has been used for detection of amplified 
RNA and DNA viral sequences for some time but new protocols incorporating tyramide 
signal amplification (TSA) have recently come to the market. Others have used 
fluorescence probes (Braunschweig et al., 2004). The basic technique of ISH for RNA 
expression has always been challenging and requires meticulous technique for 
reproducibility. Due to manual time-consuming and tedious protocols, the application of 
ISH for RNA expression is limited.  
 
1.14.3  Immunohistochemistry  
The most commonly applied analysis to Tissue Microarrays is immunohistochemistry, 
approximately 80% of all Tissue Microarrays are analysed in this way (Braunschweig et 
al., 2004, Shergill et al., 2004). Immunohistochemistry has a well established role in 
routine pathology. Immunohistochemistry is a technique that allows the identification 
and localisation of a cell-bound antigen of interest; for example, a specific protein, lipid 
or carbohydrate molecule in a cell of tissue preparation detected by means of a specific 
antigen-antibody reaction, which is identified by a visible label that can be evaluated 
using microscopy. Immunohistochemistry is an extremely versatile technique as there is 
no limit to the range of molecules that can be localised in this way in cells and tissue, as 
long as suitable antibodies that recognise them are available (Brooks, 2005). It is 
recommended that, when possible, immunohistochemistry be the assay of choice for 
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biomarker validation (Hewitt, 2006). The main application of immunohistochemistry is 
the detection of differentiation antigens for classifying undifferentiated tumours, 
lymphomas, neuroendocrine and soft tissue tumours. In addition to antibody quality, 
tissue fixation, unmasking of epitopes and sensitivity of the detection system have a 
major affect on immunohistochemistry quality (Werner et al., 2000). 
 
Detection methods for immunohistochemistry are broken down into two primary groups, 
chromogenic, so called “brown stains” and fluorescent detection methods. Detection 
occurs by the attachment of the oxidising colour reagent or fluorescent tag to the 
antibody-antigen complex (Braunschweig et al., 2004). Fluorescent detection methods 
offer increased dynamic range of staining and the capacity to perform multiple stains at 
one time; however, they are not as popular as chromogenic stains within FFPE tissue. 
Fluorescence in immunohistochemistry of Tissue Microarrays it is not widely used as it 
requires specialised equipment, expertise in analysis beyond that of the typical 
histopathologist and can be troubled by autofluorescence. Chromogenic stains are the 
most common approach in immunohistochemical analysis of Tissue Microarrays within 
FFPE tissue. Interpretation requires a standard light microscope with results that are 
relatively permanent. Contrast agents imparted by histochemical stains allow easy 
recognition of the staining pattern at both cytologic and histologic level (Hewitt, 2006).  
 
The repetitive nature of immunohistochemistry is clearly amenable to automation. 
Automated staining minimise variations in the colour spectra of the chromogen 
produced by differences in incubation time and reagent amounts (Johansson et al., 
2001).  Instruments are available that regulate the temperature of slide incubation and 
allow the automation of complete immunohistochemical procedure including de-
paraffinisation and antigen retrieval (Ventana Medical Systems; Vision BioSystems). 
Antigen retrieval is often the most critical factor to the success of an 
immunohistochemical procedure; therefore, these instruments provide a significant 
advantage over manual methods in terms of standardisation (Warford et al., 2004).  
Several instruments that automate immunohistochemical staining are available 
(Biogenex; DakoCytomation; Lab Vision). Properly used, they increase reproducibility 
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and can produce audit trails that are particularly useful in the controlled environment of 
the high-throughput laboratory. They also offer the possibility of continuous working 
beyond normal working hours. The purchase and running costs of automated 
immunostainers are high. However, in comparison with manual immunohistochemistry, 
this cost needs to be set against not only reproducibility, throughput and quality 
assurance issues, but also the freeing of laboratory staff from often long and very 
repetitive methods (Warford et al., 2004).  
 
Immunohistochemically stained Tissue Microarrays provide a degree of consistency and 
standardisation that is not possible when staining multiple whole sections and, therefore, 
its has been suggested that due to technical difficulties of immunohistochemistry, data 
obtained from Tissue Microarrays can be superior to large section data, where 
immunohistochemistry is involved (Torhorst et al., 2001). However, all the challenges 
that are associated with immunohistochemistry on full face sections are also found with 
Tissue Microarrays and are often magnified by the small sample size of the tissue, and 
the diversity of fixation and processing conditions of tissue originating from different 
sources. Immunohistochemistry is not more challenging on Tissue Microarrays 
compared to whole sections; however, due to tissue originating from different sources, 
Tissue Microarray immunohistochemistry is more likely to unmask deficient protocols. 
Also, as previously mentioned, Tissue Microarrays are susceptible to loss of tissue 
during antigen retrieval and “edge effect” staining, as is the case with any small 
fragment of tissue present on a glass slide during immunohistochemistry (Braunschweig 
et al., 2004).  
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1.15 Microscope-based assessment of immunohistochemically stained 
Tissue Microarrays 
Histopathology remains the gold standard for most diagnosis and therapeutic decisions 
in surgical and autopsy pathology. The interpretation of histologic sections; however, is 
an inherently subjective process based primarily on morphologic features (Cregger et al., 
2006). The bulk of cases usually lie between where the research scientists can interpret 
the data; however, the quality of interpretation would improve with consultation by a 
pathologist (Hewitt, 2006). The general parameters of data recorded during assessment 
of immunohistochemically stained tissues using traditional microscopes are, intensity, 
the localisation, and the proportion of cells of interest that meet the first two criteria.  
 
Human assessment of immunohistochemically stained Tissue Microarrays is considered 
the “gold standard” method of evaluation. Analysis of immunohistochemistry is 
considerably easier on Tissue Microarrays compared to whole sections, due to the fact 
that it is possible to compare staining intensities from different specimens on the same 
Tissue Microarray. More importantly, interpretation is limited to within a small 
predefined area. Therefore, the area under investigation is constant for all reviewers, 
unlike whole sections where different reviewers will select different areas of importance.  
 
1.15.1 Observer variability in Immunohistochemistry 
Observer variability can exist in three instances, Inter-observer variability (variability 
between observers), Intra-observer variability (variability by the same observer) and 
Inter-laboratory variability (variability between observers in different institutions).  Poor 
inter-laboratory agreement is usually attributed to variability in tissue fixation, tissue 
processing, immunohistochemical protocols, antibodies and scoring systems used in 
different laboratories (Lacroix-Triki et al., 2006). Intra-observer variability has been 
reported as being less frequent than inter-observer variability. It has been suggested that 
each pathologist adhere to their own internal standards which in some cases, appear to 
be consistently reproducible (Kay et al., 1994). Inter-observer variability in relation to 
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microscope-based reviews of immunohistochemically stained tissue has been well 
documented in literature, especially for the assessment of HER-2. 
 
Tsuada et al. (2002) examined the inter-observer variability of 6 pathologists for the 
assessment of HER-2 expression. One hundred and six whole sections breast carcinomas 
were immunohistochemically stained. The HercepTest™ scoring system, which 
traditionally quantifies staining using 4 categories, was further subdivided into two 
categories. Results from the HercepTest™ illustrated that when comparing 3+ to 
0/1+/2+ a higher percentage of agreement was achieved than when comparing 0/1+ to 
2+/3+. When cases were recorded as 3+, complete inter-observer agreement was almost 
achieved. Conversely, when cases were recorded as 2+ low level of inter-observer 
agreement was achieved (Tsuda et al., 2002).  
 
As previously mentioned, numerous factors are attributed to influencing human 
interpretation of immunohistochemically stained tissue, and therefore introducing inter- 
and intra-observer variability. Human assessments can accurately and consistently 
identify the presence or absence of disease and low or high staining intensity. However, 
human assessment is not as capable when utilising intermediate categories and huge 
amount of variation is introduced as a result of over-using the intermediate category 
available during reviews (Kay et al., 1994).  
 
Inter-observer variability, when performing tumour identification, is hugely dependant 
on the type of tumour assessed, the antibody under assessment and the standard criteria 
available to identify the tumour in question. With the use of standardised  criteria, inter-
observer agreement when assessing tumour presence can be achieved (Schnitt et al., 
1992, Wei et al., 2004). It has also been suggested that Tissue Microarrays reduce intra- 
and inter-observer variability, due to the fact that a cohort of samples are analysed in a 
single review seating whereas traditionally this would have involved multiple review 
seating’s (Tzankov et al., 2005, Zu et al., 2005).  
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1.15.2 Inherent Problems Associated with Human Vision 
Observer variability is the greatest problem associated with human-based microscope 
assessment. The reason this occurs is that the accuracy of human vision is highly 
variable from person to person. Medical diagnostic reasoning is the process of 
assembling evidence to support the identification of diseases. It involves diverse 
cognitive activities including, information gathering, pattern recognition, problem 
solving, decision making, and judgment under uncertainty (Johnston, 2005a). Vision 
allows humans to perceive and understand the world surrounding them. If an image is to 
be analysed by a human, the information should be expressed using variables which are 
easy to perceive. These include psycho-physical parameters such as contrast, brightness, 
shape, texture and colour. Humans will find objects in images only if they may be 
distinguished effortlessly from the background. The replication of human vision would 
be relatively easy if the human visual system has a linear response to composite input 
stimuli; for example, a simple sum of individual stimuli. In fact, the sensitivity of human 
senses is roughly logarithmically proportional to the intensity of an input signal. Human 
perception of images provokes many illusions (Sonka, 1998).  
 
Human vision is a complex process. Light enters the eye through the pupil; it passes 
through the lens and is projected on the retina at the back of the eye. Extraocular 
muscles move the eyeball in orbits and allow the image to be focused on the central 
retinal or fovea. The retina is a mosaic of two basic types of photoreceptors: rods, and 
cones. Rods are sensitive to blue-green light with peak sensitivity at a wavelength of 498 
nm, and are used for vision under dark or dim conditions. There are three types of cones 
that give basic colour vision: L-cones (red) with a peak sensitivity of 564 nm, M-cones 
(green) with a peak sensitivity of 534 nm, and S-cones (blue) with a peak sensitivity of 
420 nm. Cones are highly concentrated in a region near the centre of the retina called the 
fovea region. The maximum concentration of cones is roughly 180,000 per square mm 
in the fovea region and this density decreases rapidly outside of the fovea to a value of 
less than 5,000 per square mm. The standard definition of normal visual acuity (20/20 
vision) is the ability to resolve a spatial pattern separated by a visual angle of one minute 
of arc. Since one degree contains sixty minutes, a visual angle of one minute of arc is 
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1/60 of a degree. The spatial resolution limit is derived from the fact that one degree of a 
scene is projected across 288 µm of the retina by the eye's lens. In this 288 µm, there are 
120 colour-sensing cone cells. Thus, if more than 120 alternating white and black lines 
are crowded side-by-side in a single degree of viewing space, they will appear as a 
single grey mass to the human eye. 
 
1.15.2.1 Acuity 
Visual acuity is the ability of the eye to see fine detail. The human eye is less sensitive to 
slow and fast changes in brightness in the image plane, but is more sensitive to 
intermediate changes (Sonka, 1998). The eye has a visual acuity threshold below which 
an object will go undetected. This threshold varies from person to person. A number of 
factors affect visual acuity such as refractive error, size of the pupil, time of exposure of 
the target, eye movement, illumination and contrast (John Moran Eye Centre University 
of Utah, 2005). 
 
1.15.2.2 Contrast 
Contrast is the local change in brightness and is defined as the ratio between average 
brightness of an object and the background brightness. The human eye is logarithmically 
sensitive to brightness, implying that, for the same perception, higher brightness requires 
higher contrast. Apparent brightness depends very much on the brightness of the local 
background; this effect is called “conditional contrast”. Figure 1.15-1  illustrates the 
fallibility of human perception of contrast. In Figure 1.15-1 A & B the internal squares 
are the same brightness; however, each internal square is surrounding borders of 
different brightness. As a result, the brightness of the internal boxes appear different 
(Sonka, 1998). 
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Figure 1.15-1: Internal squares are an identical shade; however, when surrounded by 
different colours the internal squares appear to be different shades. 
 
A B 
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Figure 1.15-2 illustrates a vertical bar with a single colour throughout. When viewed 
with the contrast of a white background it is quite obvious the vertical bar is a single 
colour. 
Figure 1.15-2: Single coloured bar against white background. 
 
Figure 1.15-3 illustrates the identical vertical bar as in Figure 1.15-2. However, in Figure 
1.15-3 the vertical bar is surrounded by a background with a changing gradient of 
colour. As a result, the vertical bar no longer looks the same colour throughput. 
 
Figure 1.15-3: Single coloured bar against colour gradient background. 
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Contrast is extremely applicable in the assessment of membrane-bound 
immunohistochemical staining. The contrast between membrane and cytoplasmic 
staining may be hugely variable and can affect human perception. Figure 1.15-4 
illustrates two images of bladder tissue probed with the antibody for E-cadherin. Both A 
and B within the image have strong membrane-bound immunohistochemical staining. 
Image A; however, has no cytoplasmic staining and image B is flooded with 
cytoplasmic staining. Within image B it is exceptionally hard to identify the membrane 
regions and to decipher the intensity of membrane staining only, without taking into 
account the cytoplasmic staining intensity.  
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Figure 1.15-4: Image A and B have strong membrane-bound immunohistochemical 
staining; however, Image A has no cytoplasmic staining, and Image B is flooded with 
cytoplasmic staining, therefore making subjective membrane assessment very difficult.  
 
 
 
 
B 
A 
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1.15.2.3 Object border 
Object borders carry a lot of information. Boundaries of objects and simple patterns such 
as blobs or lines enable adaptation effects similar to “conditional contrast”. The 
Ebbinghaus illusion illustrates how humans can misinterpret size of particles when 
displayed in relative comparisons (Plodowski and Jackson, 2001). Figure 1.15-5 (A & 
B) displays two circles of the same diameters; however, as they are surrounded by  
circles of different diameters they appear to have different diameters (Sonka, 1998). 
 
 
 
 
 
Figure 1.15-5: Ebbinghaus illusion illustrates how the interpretations of the size of 
objects are relative to their surroundings. The red circle within image (A) and (B) are 
identical; however, perception of the size of the red circle is altered by the blue circles 
surrounding them. 
 
 
 
 
(A) (B) 
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1.15.2.4 Colour 
Colour is connected with the ability of objects to reflect electromagnetic waves of 
different wavelengths; the chromatic spectrum spans the electromagnetic spectrum from 
approx 400 to 700 nm. Humans detect colours as combinations of the primary colours 
red, green, and blue. Colour is very important for perception, since under normal 
illumination conditions the human eye is more sensitive to colour than to brightness. 
Colour quantification and representation can be expressed as a combination of the three 
basic components, red, green and blue (RGB), but colour perception is better expressed 
in the alternative Hue Saturation and luminosity (HSL) co-ordinate system. The Bezold 
Effect is used to describe how colours appear differently depending on their relationship 
to other colours. Figure 1.15-6 illustrates that the colour red appears lighter when it is 
surrounded by a white border, and darker when surrounded by a black border. 
 
Figure 1.15-6: Bezold Effect illustrates how the appearance of colour is altered by the 
colours that surround them. In this case, the colour red appears lighter when surrounded 
by white, and darker when surrounded by black (Waranabe, 2007). 
 
During the assessment of immunohistochemically stained Tissue Microarrays the 
comparison of colour is paramount. Reviewers often rely on previously reviewed Tissue 
Microarray cores to form their opinion of subsequent cores. For example a moderately 
stained core could be categorised as weak, if the core was reviewed following a series of 
 47 
strongly stained cores, as human assessment is not a true value, rather a form of 
“comparison” of colours. 
 
1.15.3 Reviewers workload 
The aforementioned issues are the physiological factors of vision that introduce 
obstacles in human-based assessment of staining intensity. Those issues are inherent and 
are a constant disadvantage when assessment is performed by humans.  In addition, there 
are difficulties in human-based reviews that are highly variable and are not solely 
restricted to vision. Pathologists must cope with three main areas of difficulty in their 
field, productivity, accuracy, and objectivity. Pathologists are under increasing pressure 
to improve productivity and, therefore, generating more data and process more slides. 
Tackling the mountain of work manually places a constant strain on resources, staff, and 
finances. For those analysing Tissue Microarrays, this burden is likely to worsen rapidly 
due to the volume of samples under analysis. In any field of science dependent on 
observation, accuracy is essential. However, it is well documented that, after prolonged 
visual study, eye and specifically cone-fatigue can significantly affect a person’s ability 
to discern colour changes and identify unusual objects. The Tissue Microarray slide 
format has compounded this effect hundreds of times over. With densities exceeding 600 
samples per slide, fatigue may quickly become an issue. Finally, there is the question of 
objectivity. The nature of the human eye is such that every person sees an object slightly 
differently from the way others see that same object. Subjectivity in this regard is 
therefore innate. Also, tints and shades can appear to change from one setting or context 
to another. Different observers may report seeing different features on the same object, 
as may a single observer at different times. 
 
Visual inspection can also be confounded by the inherently subjective nature of human 
observation, which is affected by context, for example the amount of tumour present, 
background staining, stromal staining and even the order in which the spots are observed 
(Camp, 2005). Productivity, accuracy, and objectivity are further compounded by the 
following issues: 
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1.15.4  Scoring systems 
Manual scoring systems are qualitative or semi-quantitative in nature, none reaching the 
level of true continuous quantitative data. Quantitative scales are either binary (+ or -) or 
normative (0, 1, 2, 3) typically providing categorization of a feature such as intensity. 
Simple qualitative scores are limited, such as percentage of positive cells. Qualitative 
scales have limitations in resolution which can be detected by eye, thus many 
researchers build a simple scale, as 0, 1, 2, according to negative, weak, strong. Manual 
reviews requires interpretative skills of well-trained investigators and frequently the 
efforts of a specialist primarily pathologist. Staining patterns that are anticipated to be 
used in clinical practise are usually scorable as positive or negative, whenever possible. 
Any added complexity in a scoring system introduces inter- and intra-observer 
reproducibility as is seen with challenges in scoring ER, PR, HER-2 (Braunschweig et 
al., 2004).  
 
In comparison with human-based assessment there are numerous advantages of 
automated analysis in that it provides increased throughput, precise, reproducible, 
continuous, objective assessment of protein expression (Divito et al., 2004, Cregger et 
al., 2006). However, the greatest advantage is that it is truly quantitative. In contrast, the 
human eye, even that of a trained pathologist, has a difficult time accurately 
distinguishing subtle differences in staining intensity using a continuous scale. 
Consequently, scoring systems for pathologists tend to be nominal (for example, 0, 1+, 
2+, 3+). In some cases, these can preclude the discovery of subtle sub-populations that 
cannot be identified using manual analysis (Camp et al., 2003, Camp et al., 2002, Camp, 
2005). 
 
1.15.5  Background lighting variation 
Apart from the microscope itself, the next most important item in the reviewing process 
is the means by which the slides are illuminated; for example the microscope lamp 
(Micrographia, 2003).  If too much light is exposed, information about the intensity of 
staining is lost. Adjustments in lighting settings can introduce huge variability in the 
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reviewing process. Consistency of light between slides and reviews is extremely difficult 
during microscope-based assessments. 
 
The advent of virtual slides permitted the review of whole tissue slides across the 
Internet (Johnston et al., 2005). Virtual slides provide users with all the functionality of a 
microscope, but with numerous additional benefits, including concurrent access for 
multiple users, tracking of review movements and image annotation. Virtual slides are 
reminiscent of microscope use, they are favoured by pathologists over static digital 
images, due to the ability to change magnification and scroll laterally while reviewing 
the image. There are a growing number of interactive pathology sites available via the 
Internet. The diversity in their principle of operation, their application in telepathology, 
and their degree of sophistication promises an encouraging future in telepathology 
(Costello et al., 2003). Uniform lighting conditions can be applied across many slides, 
using digital imaging systems and therefore, eliminating the possibility of variance due 
to background lighting. In addition, when imaging analysis is utilised it is possible to 
normalise results across numerous slides (see section 2.6.1)  
 
1.15.6 Reviewers Disorientation 
Analysing Tissue Microarrays under a microscope can lead to misplaced spot 
orientation. It has previously been reported that it is difficult to accurately track the 
location of individual cores within complex Tissue Microarrays. In addition, 
microscope-based assessment typically relies on the manual entry of results first onto a 
worksheet and then subsequently into a spreadsheet or database system. Accurate 
manual tracking of the Tissue Microarray cores is challenging, prone to error and often 
leads to frustration (Tubbs et al., 2007).  
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1.16 Computer-assessed quantification of immunohistochemically 
stained Tissue Microarrays 
The analysis of immunohistochemical staining patterns usually measures specific single 
targets rather than the relatively complex and intricate disease patterns, for example 
those seen on H & E staining. Immunohistochemical studies are, therefore, inherently 
amenable to automated image analysis (Joshi et al., 2007). As described in section 
1.14.3, sources of variability in immunohistochemistry include fixation conditions, 
specimen pre-treatment, reagents, detection methods, and interpretation of results. 
Although it is not possible to standardise all the potential variables in 
immunohistochemistry, the interpretation of immunohistochemical results may be 
standardised through quantitative methods.  
 
It has been proposed that computer-based analysis can quantify staining intensity more 
accurately and with greater reproducibility than human-based assessment (Weaver et al., 
2003, Johansson et al., 2001). There are numerous commercially available, computer-
based systems designed for the quantification of immunohistochemical staining, 
including BLISS and IHCscore of Bacus laboratories, Inc (Lombard, IL, USA); Ariol 
SL-50 Applied Imaging Corporation (USA); AQUA, HistoRx Inc (USA); ACIS 
developed by Chromovision (ChromaVision Medical Systems, Inc., USA). However, 
automated quantification systems can be expensive and time-consuming. Automated 
immunohistochemical protocols, in combination with a device that provides quantitative 
and objective output, could dramatically improve the quality of the data obtained from 
immunohistochemical studies (Cregger et al., 2006). For computer-based systems there 
are two key factors, stain quality and image quality. If image capture does not contain 
the information desired at adequate image resolution, the extraction of this information 
will be inaccurate (Hewitt, 2006).  
 
Automated quantitative analysis (AQUA) is the most widely cited commercially 
available co-localisation application. Developed by Camp et al., 2003 it was specifically 
designed for quantification of immunocytochemistry on Tissue Microarrays (Camp et 
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al., 2002, Camp et al., 2003). Once the images are captured, the AQUA analysis is run 
using a set of algorithms. Rapid exponential subtraction algorithm (RESA), based on the 
principles of deconvolution theory, attempts to reduce the “out-of-focus” noise from 
parts of the specimen that are above and below the plane of focus. By subtracting an out-
of-focus image from an in-focus image, RESA improves the resolution of the image, 
reducing the signal-to-noise ratio. Pixel-based locale assignment for 
compartmentalisation of expression utilises DNA binding fluorescent tags to distinguish 
tumour cells from stroma, as well as to define subcellular compartments (Dolled-Filhart 
et al., 2006). This algorithm also measures expression of a marker of interest within 
cellular and subcellular compartments. The output variable is a pixel intensity to pixel 
area value ranging from 0 to 255, based on the average intensity for all pixels evaluated 
(Cregger et al., 2006). 
 
Automated Cellular Imaging Systems (ACIS) is produced by Clarient, formally known 
as Chromavision. ACIS is a digital microscope system with the ability to detect, count 
and classify cells based on colour shape and size. ACIS uses a combination of co-
localisation and pattern recognition algorithms. ACIS is capable of detecting levels of 
hue, saturation and luminosity. Through the use of a digital camera, a voltage signal is 
produced which is proportional to the transmitted light intensity. The signal is then 
converted into a numerical density measurement. The system also has algorithms built 
into the software that allow it to analyse data and produce numeric scores for various 
parameters defined by the user. This device was originally designed for HER-2 analysis 
(Wang et al., 2002b) and was subsequently improved to allow analysis of Tissue 
Microarrays (Faith et al., 2004). It has been demonstrated in the scientific and pathology 
literature with many publications citing the use of ACIS in the analysis of 
immunohistochemistry (Tawfik et al., 2006, McKay et al., 2006). This system has 
enjoyed the greatest commercial success of all image analysis applications in pathology, 
although market penetration has been estimated only around the 5% level (Cregger et al., 
2006). 
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TMAx is novel pattern recognition software application created by Beecher instruments, 
the leading provider for Tissue Microarray arrayers.  TMAx utilises automatic pattern 
recognition software, with rule based operations and multiple iterative segmentations 
processes, together with fuzzy logic, to automatically identify cells and 
immunohistochemical deposits. As a result, colour channel values of 
immunohistochemistry can be calculated. TMAx also has a cell line application, which 
auto recognises cells, measures several key features describing the 
immunohistochemical staining intensity and counts the fraction of stained cells. 
 
The validity of image analysis systems to be accurate, reproducible and to be at least as 
good as traditional methods of analysis has been extensively tested. Some of the major 
comparisons performed on image analysis systems are as follows:  
 
1.16.1 Computer-assisted quantification of immunohistochemistry 
compared with Human Analysis 
Comparisons of computer-assisted quantification and microscope-based assessment have 
shown some promising results, a number of case studies follow: 
 
Initial validation of AQUA compared its accuracy, intra-observer variability, and 
predictive power to traditional human-based analysis. Tissue Microarrays derived from 
340 node-positive breast carcinoma patients were immunohistochemical stained for the 
presence of ER. The correlation between AQUA and results from a human-based 
evaluation was high (r2 = 0.884). Results illustrated AQUA has slightly better 
reproducibility than human analysis (r2 = 0.824 versus r2 = 0.732) (Camp et al., 2002). 
 
Camp et al. (2003) compared traditional manual scoring with the AQUA system for the 
measurement of HER-2. Correlation of both reviewing methods with prognosis was 
performed. Utilising Tissue Microarrays, a cohort of 300 breast cancers was assessed. 
Manual examination of the immunohistochemical stained Tissue Microarray was 
performed by a single pathologist. As expected both methods identified a population of 
 53 
high HER-2 protein overexpressing tumours with poor 30 years disease related survival. 
However, manual assessment failed to identify a population of tumours with low HER-2 
protein expression, which when using AQUA proved to also be associated with poor 
prognosis.  
 
Regression analysis demonstrated good correlation between the two methods (r2 = 
0.704). The percentage of HER-2-amplified cases in each manual category were 4.0% 
(0), 13.7% (1+), 71.4% (2+), and 75.0% (3+), and in each AQUA category were 17.5% 
(normal), 71.3% (intermediate), and 11.2% (high). There was a clear division between 
scoring 0/1+ and 2+/3+, there was no distinction between tumours scoring 0 and 1+. 
This result shows the difficulty in manually translating a continuous marker into a 
nominal four-point scale. Even for the trained eye of a pathologist, accurate distinction 
between nominal categories is difficult and often arbitrary. Examination of manual and 
automated techniques revealed that both were equally able to define a population of 
tumours expressing high levels of HER-2 and associated with poor outcome (p = 0.0007 
and 0.0013, respectively). However, unlike manual analysis, automated analysis 
revealed that tumours expressing normal levels of HER-2 also showed a significantly 
worse outcome (p = 0.0091). Given the amount of overlap in the 0 and 1+ category from 
manual scoring, it is not surprising that manual assessment of stained slides has not 
previously identified the HER-2 normal population. Automated analysis identified a 
patient population that was otherwise detectable only by established biochemical assays 
(Camp et al., 2003). 
 
Stromberg et al. (2007) compared human-based online assessments with the automated 
analysis performed by TMAx. A single Tissue Microarray which was constructed from 
46 cell lines from different tissue types along with 12 cases of human tissue was 
examined by human and image analysis. Cell lines results from TMAx were compared 
to reviews performed by 7 pathologists who reviewed online intensity and fraction of 
stained cells. Intensity was recorded using a four point scale and fraction as a percentage 
of positive cells. The average result from the 7 reviewers was compared to the TMAx 
for 200 images. The scores from the TMAx were within the human-based review mean 
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of +/- 2 SD for both intensity and percentage of positive cells for a great majority of 
cases. Only 22 of 200 cases scored by TMAx were outside +/- 2 SD of the human 
analysis for both intensity and percentage staining cells. In addition, for each image, a 
combined output score for staining was calculated by multiplying the intensity mean 
value with the fraction mean value for the 7 pathologists. When comparing this score 
with the corresponding combined score from the TMAx, a high degree of correlation 
was observed (r2 = 0.94, p<0.0001) (Stromberg et al., 2007). 
 
Messerssmith et al. (2005) compared the ability of ACIS automated quantification to 
correlate with human-based assessment across a number of antibodies. A blinded 
pathologist scored a Tissue Microarray constructed from 18 human samples of colorectal 
cancers and matched normal mucosa. The pathologist scored the intensity of staining 
using a four graded scale (0 - 3+). Plotting the ACIS scores (normalised to the mean of 
the samples which were scored as 0) against the pathologists scores showed a variable, 
but definite relationship between ACIS and pathologist scoring. One way ANOVA 
analysis showed a significant correlation between ACIS and the pathologist scoring (p< 
0.001) for all six proteins which were examined, including EGFR, Akt, pAkt, MAPK 
and  Pmark (Messersmith et al., 2005).  
 
Clearly automated analysis compares favourably with pathologist based interpretation of 
microarrays; however, the true criterion standard is outcome prediction (Camp et al., 
2002). 
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1.16.2 Computer-assisted quantification of immunohistochemistry 
compared with Prognosis 
Correlation between immunohistochemical staining and prognosis has been performed 
by computer-assisted analysis. A number of examples of these studies are as follows: 
 
The role of B cell lymphoma 2 (Bcl-2) expression in melanoma and it’s associated with 
patient outcome has previously been reviewed. However, inconsistency in association 
with clinical outcome has been reported. Some studies report that up-regulation of Bcl-2 
correlates with advanced stage and poor prognosis, whereas others report that down-
regulation of Bcl-2 is associated with disease progression, advanced stage, and poor 
prognosis. Divito et al. (2004) assessed the role of Bcl-2 in melanoma utilising AQUA. 
Automated quantitative analysis was performed on 2 replica Tissue Microarrays 
constructed from 402 cases of melanoma. Pixels were defined as melanoma and positive 
intensity of Bcl-2 was measured. A continuous index score was generated which was 
subsequently divided into quartiles and correlated with clinical variables.  Kaplan-Meier 
survival curves illustrated that increased membranous/cytoplasmic Bcl-2 expression was 
correlated with better outcome (log-rank p = 0.004). Bcl-2 expression was significantly 
higher in the primary specimens than in the secondary specimens (p < 0.0001). Results 
were reproducible when using a second Tissue Microarray with different cores from the 
same patients (Divito et al., 2004).  
 
Harigopal et al. (2005) assessed the prognostic value of E-cadherin expression in node-
positive breast cancer, utilising AQUA. Automated quantitative analysis was performed 
on one immunohistochemically stained Tissue Microarray constructed from 280 
invasive ductal and 61 invasive lobular breast cases. Results illustrated there was no 
significant difference in mean staining intensity between the primary and nodal 
specimens (p = 0.80). A scatterplot was generated which identified a subset of patients 
(25%) with high E-cadherin expression in nodal metastases, and this top quartile had 
improved survival (p = 0.028). On univariate analysis, increased E-cadherin expression 
in nodal metastases was strongly associated with extended survival (p = 0.007), whereas 
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expression in primary tumours was not (p = 0.130). Strong E-cadherin expression in 
lymph node metastases was highly predictive of improved survival. This suggests that 
expression of adhesion molecules at metastatic sites represents less aggressive tumour 
behaviour. This had not previously been quantitatively assessed (Harigopal et al., 2005).  
 
Zerowski et al. (2007) determined the prognostic value of Cox-2 expression in a large 
cohort of breast cancer Tissue Microarrays. Cox-2 has been associated with the 
development, growth, and spread of cancers by stimulation of angiogenesis, inhibition of 
apoptosis, and enhancement of invasiveness. Previously, the prognostic value of Cox-2 
was not well established. The authors constructed a Tissue Microarray composed of 669 
primary breast cancer biopsies, and Cox-2 protein concentration was quantitatively 
assessed using AQUA. Cox-2 was localised on the membrane / cytoplasm. X-tile, a 
novel software application was used to determine optimum cut points of the continuous 
data. In order to rigorously validate the statistical significance of a cut point, X-tile 
divides the entire cohort into two populations matched for survival, one designated as 
the training set and the other as the validation set.  Within the training set an optimal cut 
point was determined.  When this cut point was tested in the validation set, the P-value 
was 0.0189 and 0.0055 for disease-free and overall survival respectively. This is highly 
significant in light of the fact that the validation set was now half the size of the original 
cohort. Using AQUA and X-tile analysis, the authors illustrated that Cox-2 expression 
was likely to be upregulated in invasive breast tumours (Zerkowski et al., 2007). 
 
The role of ß-catenin in breast cancer and its prognostic value is controversial. The 
prognostic value has been assessed previously in a series of non-quantitative 
immunohistochemical studies, resulting in conflicting results. Using quantitative 
analysis methods, Dolled-Filhart et al. (2006) clarified that low-level membranous ß-
catenin expression is associated with significantly worse outcome for breast cancer 
patients (38% versus 76%, 10-year survival, validation set log-rank p = 0.0016). The 
authors assessed ß-catenin protein expression by evaluating a 600 case cohort of breast 
cancer tumours which were constructed into a single Tissue Microarray. The Tissue 
Microarray was assessed by AQUA with a series of array-embedded cell lines for which 
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the ß-catenin concentration was standardised by an ELISA assay. Total ß-catenin protein 
levels (as ng/mg protein lysate) were detected by ELISA and by AQUA analysis of the 
same cell lines embedded into a Tissue Microarray. Comparison of the AQUA scores of 
the embedded cell lines and the ELISA concentrations showed a correlation of r2 = 
0.853. The calculation of these cell line concentrations provided a standard curve for the 
conversion of ß-catenin AQUA scores to a specific concentration for each of the tumour 
samples.  X-tile software was also used to select optimal protein concentration cut points 
and to evaluate the outcome using a training set and a validation set (Dolled-Filhart et 
al., 2006).   
 
1.16.3 Computer-assisted quantification of immunohistochemistry 
compared with Biochemical techniques 
Computer-assisted quantification of immunohistochemistry is capable of determining 
the same level of protein expression as those obtained utilising quantitative bioassays. A 
number of studies that illustrate computer-assisted quantification of 
immunohistochemically stained tissue are described below: 
 
Tawfik et al. (2006) compared the results of HER-2 protein overexpression and gene 
amplification in the same patient specimens by immunohistochemistry (HercepTest™) 
using the ACIS system and by FISH. Whole section analysis was performed on 247 
primary breast cancers, by both ACIS and FISH. ACIS quantified at least 5 / 6 areas 
with the highest staining intensity. An average score for all selected areas was then 
calculated. The manufacturer of ACIS recommends that cases with an average score of 
2.2 or higher be considered to have HER-2 protein overexpression, while cases with 
average scores lower than 2.2 should be considered not overexpressed. FISH results 
were reported as the ratio of the mean copy number of HER-2 signals to the mean copy 
number of CEP 17 signals. Specimens with a ratio of ≥ 2.0 were designated as having 
HER-2 gene amplification and those with a ratio < 2.0 as having no gene amplification. 
A pathologist verified the signal pattern in each case. The concordance rate between 
immunohistochemical-ACIS and FISH HER-2 tests was 94% for the 247 cases. This 
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result was markedly improved from an overall 72% concordance rate between 
immunohistochemistry by manual microscopy using the same HercepTest™ and FISH 
as previously performed in the authors’ institution on 250 cases (unpublished data). The 
overall HER-2 2+ cases were 18.6% and 19% by immunohistochemistry-ACIS and 
FISH testing, respectively, which is significantly less than those reported in manual 
assessment. Despite the high levels of agreement between the tests there were still cases 
that fall into a grey zone in which there is disparity between the two tests. Accordingly, 
neither test can definitively guide clinicians in determining appropriate treatment for all 
patients (Tawfik et al., 2006). 
 
Ciampa et al. (2006) compared HER-2 expression by immunohistochemistry quantified 
by ACIS with that of the gene amplification by FISH. One hundred and eight whole 
sections of primary infiltrating ductal carcinomas were immunostained using the 
HercepTest™ and the cases were divided into four groups: group 1 with HER-2 
expression ACIS score ≤1.5; group 2 with a score 1.6-1.9; group 3 with a score 2.0-2.5; 
and group 4 with a score ≥2.6. FISH was performed on all of the 108 cases. All cases 
were also manually reviewed. Within the ACIS scoring system gene amplification was 
verified by FISH as follows: group 1: 4%, in group 2: 12%, in group 3: 11%, and in 
group 4: 86%. Furthermore, in group 4, 100% cases with an ACIS score of ≥3 were 
FISH positive. Correlation with manual immunohistochemical score and FISH showed 
that 9% immunohistochemical negative (0 and 1+) cases and 29% immunohistochemical 
positive (2+ and 3+) cases showed gene amplification by FISH. This study shows that 
the amplification of the HER-2 gene correlates better with overexpression of the HER-2 
protein by immunohistochemistry when the score is <1.5 or > 2.6 by ACIS. Therefore, 
FISH may be useful to better evaluate HER-2/neu status in breast cancer in cases where 
the ACIS score by immunohistochemistry is 1.6-2.5. Since the correlation is so good, 
FISH may not be needed for HER-2 evaluation in cases with ACIS scores < 1.5 and > 
2.6.(Ciampa et al., 2006) 
 
Messersmith et al. (2005) compared quantitative results from ACIS, ELISA and western 
blots for EGFR expression in one CMA composed of eight head and neck tumours. 
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Experiments indicated that ACIS obtained similar results as ELISA and western blots. 
Scatter plots of ELISA results compared to ACIS results illustrated good correlation (r2 
= 0.697). It was suspected that one cell lines with low level expression may have 
negatively affected agreement between ACIS and ELISA (Messersmith et al., 2005) 
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1.17 Defining the need for this project 
Despite the huge advances made by commercially available complete digital imaging 
devices, there are also prohibitive limitations to these systems. Currently, the cost of 
purchasing high-throughput scanners are extremely prohibitive, usually running at 
between 60,000 to 180,000 Euros (Rojo et al., 2006). As a result, commercial systems 
are not always viable in research or small laboratories (Camp, 2005, Camp et al., 2003, 
Camp et al., 2002). Collaborations can be created between institutions, where a scanner 
is purchased by a consortium of institutes and slides are posted for scanning. However, 
without access to a low cost web-based system for review, scoring and subsequent 
storage of images and data associated with virtual Tissue Microarrays, pathologists are 
reduced to recording results on worksheets and subsequently entering data into computer 
software applications. This system is completely counter-productive and negates the 
advantages and possibilities of virtual slide technology. 
 
There are numerous publications listing the merits of image analysis as a means to 
quantifying protein expression on Tissue Microarrays. However, the influx of 
commercially available image analysis applications utilised to quantitate protein 
expression are extremely complex and difficult to use. Virtual Slide technology is 
currently being introduced in pathology training; however, it will be a number of years 
before this is the norm. The objective of automated quantification of protein expression 
has always been to free pathologists from the mundane task of calculating the level of 
“brown” on a slide and, in doing so, to produce results at least as accurate as the 
pathologist can. The commercially available image analysis systems have succeeded in 
freeing the pathologist from their traditional role at the bench. However, pathology is a 
complex and highly skilled field and, with the introduction of some commercially 
available image analysis systems, it has forced the onus on pathologists to also become 
experts in computer image analysis.  
 
The majority of commercial image analysis systems are targeted at fluorescently-
labelled tissue, due to the relative ease of compartmentalisation by this means 
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identification compared with chromogen-based methods. However, chromogen-based 
immunohistochemistry is the most common application of Tissue Microarrays. The use 
of fluorescently-labelled tissue introduces a number of strains on analysis: slides have to 
be digitised as soon as possible before signal is lost, therefore eliminating the possibility 
of laboratory consortiums, techniques are difficult and cost of antibodies and scanning 
equipment is substantial compared to immunohistochemical applications. Therefore, the 
development of novel chromogen-specific image analysis methodology is crucial in the 
ongoing investigation of tumour tissue via Tissue Microarrays.   
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CHAPTER 2: MATERIALS AND METHODS 
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SECTION A: LABORATORY METHODS 
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2.1 Cell Culture 
2.1.1 Cell Lines 
All cell culture work described within this body of work was carried out in a class II 
laminar airflow cabinet (Holten LaminAir, Denmark). The laminar airflow cabinet was 
swabbed with 70% industrial methylated spirits (IMS) before and after use, as were all 
items used within the cabinet. Only one cell line was used in the laminar airflow cabinet 
at any one time. Each cell line was assigned specific waste and medium bottles. After 
cleaning, and when working with different cell lines, the laminar airflow cabinet was 
allowed to clear for at least 15 minutes before and after use. The cabinets were cleaned 
weekly with the industrial disinfectant Virkon (Antech International, UK) as were the 
incubators.  All of the cell lines included are anchorage dependent. Cell lines were 
maintained in 25, 75 and 175 cm3 flasks (Corning Life Sciences, USA) at 37°C and in an 
atmosphere of 5% CO2 , where required. All cell lines were fed every two to three days. 
A complete list of the cell lines utilised, their source and the medium used is illustrated 
in Table 2.1-1. Cell lines were sourced from the European Collection of Cell Cultures 
(ECACC), National Cell and Tissue Culture Centre / National Institute for Cellular 
Biotechnology (NCTCC/NICB), and American Type Culture Collection (ATCC). 
Within Table 2.1-1 the following acronyms are used; NEAA - Non essential amino 
acids, FCS - Fetal calf serum and NA - Sodium. 
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Table 2.1-1: Cell lines and basal medium used within this body of work. 
Cell Lines   Details Source Medium 
A549 Parent Lung Adenocarcinoma ECACC ATCC 5% FCS 
A549 Taxol Taxol-selected variant of A549 NCTCC/NI ATCC 5% FCS 
BT20 Invasive Ductal Carcinoma (Breast) ATCC RPMI 1640 10% FCS 
BT474 Invasive Ductal Carcinoma (Breast) NCTCC/NI RPMI 1640 10% FCS 
DLKP Parent Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLKP JC  Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLKP Txt RL  Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLKP Txt YL  Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLKP VCR Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLKP YL  Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLRP  Parent Poorly Differential Squamous Cell Lung NCTCC/NI ATCC 5% FCS 
DLRP Carboplatin Carboplatin-selected variant of DLRP Parent NCTCC/NI ATCC 5% FCS 
DMS 53 Parent Small Cell Lung Carcinoma ECACC RPMI 1640 10% FCS 
DMS 53 Taxol Taxol-selected variant of DMS 53 NCTCC/NI RPMI 1640 10% FCS 
DMS 53 Taxotere Taxotere-selected variant of DMS 53 NCTCC/NI RPMI 1640 10% FCS 
DMS 53 Carboplatin-selected variant of DMS 53 NCTCC/NI RPMI 1640 10% FCS 
H460 Parent Large Cell Lung Carcinoma ATCC RPMI 1640 10% FCS 
H460 Taxol  Taxol-selected variant of H460 NCTCC/NI RPMI 1640 10% FCS 
HCC 1419 Breast Primary Ductal Carcinoma ATCC RPMI 1640 10% FCS 
HCC 1954 Breast Primary Ductal Carcinoma ATCC RPMI 1640 10% FCS 
MCF-7 Invasive Ductal Carcinoma (Breast) ATCC RMPI 10% FCS 
MDA-MB-231 Breast Adenocarcinoma ATCC RPMI 1640 10% FCS 
MDA-MB-453 Breast Metastatic Mammary Gland ATCC RPMI 1640 10% FCS 
MDA-MB-468 Breast Adenocarcinoma ATCC RPMI 1640 10% FCS 
NCI-H1299 Parent Large Cell Lung Carcinoma ATCC RPMI 1640 1mM Na Pyruvate, 5% FCS 
NCI H1299 Taxol Taxol-selected variant of H1299 NCTCC/NI RPMI 1640 1mM Na Pyruvate, 5% FCS 
SK-BR3 Breast Adenocarcinoma ATCC RPMI 1640 10% FCS 
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SKLU-1 Parent Lung Adenocarcinoma ATCC MEM 1% NEAA, 1mM Na Pyruvate 2mM L-glutamine 
SKLU-1 Taxol Taxol-selected variant of SKLU-1 NCTCC/NI MEM 1% NEAA, 1mM Na Pyruvate 2mM L-glutamine 
SK-MES-1 Parent Squamous Cell Lung Carcinoma ATCC MEM 1% NEAA, 1mM Na Pyruvate 2mM L-glutamine 
SK-MES-1 Carboplatin-selected variant of SK-MES-1 NCTCC/NI MEM 1% NEAA, 1mM Na Pyruvate 2mM L-glutamine  
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2.1.2 Sub-culturing of adherent cell lines 
Waste cell culture medium was removed from the tissue culture flasks into sterile waste 
bottles, and the cells were rinsed with pre-heated trypsin / EDTA (TV) solution (0.25% 
trypsin (GIBCO®, Invitrogen Corporation, UK), 0.01% EDTA (Sigma-Aldrich, Ireland) 
solution in PBS (phosphate buffered saline) (Oxoid, UK). The cells were rinsed with TV 
to ensure any residual medium was removed, as the serum content could act as a trypsin 
inhibitor. Pre-warmed TV was added to the flask, which was incubated at 37°C for 
approximately 5 minutes, in order to detach the cells from the flask. Approximately 1, 2, 
or 5 ml of pre-warmed TV was added to 25, 75, or 175 cm2 flasks, respectively. The 
trypsin was deactivated by adding an equal volume of complete medium to the flask. 
The contents of the flask was then transferred into a sterile universal tube (30 or 50ml 
Sterilin, Barloworld Scientific, UK) and centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet was re-suspended in a pre-warmed fresh 
complete growth medium, and cells were used to re-seed a flask at the required density.  
   
2.1.3 Cell counting 
An aliquot of trypan blue (GIBCO®, Invitrogen Corporation, UK) was added to an 
aliquot of cell suspension at a ratio of 1:5. The trypan blue and cell suspension was 
incubated for 3 minutes at room temperature, after which a drop of this mixture was 
added to a chamber of a haemocytometer which was enclosed with a glass cover-slip. 
Viable cells remained unstained by the trypan blue, non-viable cells stained blue. Viable 
cells in the 16 squares of the four outer corners of the haemocytometer were counted 
microscopically. The average cell count was multiplied by the dilution factor and 104 to 
determine the number of viable cells per ml in the original cell suspension.  
 
2.1.4 Embedding Technique 
The detachment of cells from the culture flasks using TV (as described in Section 2.1.2) 
was only utilised when cells needed to be passaged. When two 175 cm2 flasks were 80% 
confluent, cells were collected in order to create a cell line pellet for Cell Microarray 
construction. It was not possible to use TV for detachment of cells from the flask at this 
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stage as trypsin potentially destroys cell surface protein markers. As a result, non-
enzymatic cell dissociation solution (Sigma-Aldrich, UK) was used, as it causes minimal 
damage to the surface proteins of the cell.  
 
To achieve this, waste cell culture medium was removed from the tissue culture flasks 
into sterile waste bottles, and the cells were rinsed with pre-heated PBS solution (Oxoid, 
UK). The cells were rinsed with PBS to ensure any residual medium was removed, as 
the medium could act as a cell dissociation solution inhibitor. Pre-warmed cell 
dissociation solution was then added to the flask, which was incubated at 37°C for 
approximately 15 minutes, in order to detach the cells from the flask. Approximately 5 
ml of pre-warmed cell dissociation buffer was added to each 175 cm2 flasks. The cell 
dissociation buffer was deactivated by adding an equal volume of medium to the flask. 
The contents of the flask was then transferred into a sterile universal tube (50 ml 
Sterilin, Barloworld Scientific, UK) and centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded and the cell pellet was re-suspended in pre-warmed PBS (20 
ml). The content of the universal was centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded, and 20 mls of formalin (Serosep Ltd, Ireland) was added 
very slowly to the universal, ensuring not to disturb the cell pellet. Cells were fixed 
overnight at 4°C.   
 
2.1.4.1 Agarose mold technique  
Cells were centrifuged at 1000 rpm for 5 minutes, formalin was removed and the cell 
pellet was then packed into agarose molds as follows. Conventional agarose (2% 
Agarose Type I, Low EEO, Sigma-Aldrich, Ireland) was prepared in TE buffer. The 
agarose was poured into a Petri dish and allowed to set firmly, while placed on an even 
surface. After setting, cork borers (size 6 Sigma-Aldrich, Ireland) were used to cut dish-
shaped molds out of the agarose. Using a smaller diameter cork borer (size 2), a central 
core was removed from each dish of agarose. The result was a donut-shaped agarose 
mold. Using a spatula, cell pellets were packed into the centre of the agarose mold and 
were wrapped in Bio-Wraps (Surgipath, UK), which had been moistened in 1% low 
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melting point agarose (Sigma-Aldrich, Ireland). The agarose molds where then placed 
into embedding cassette (Lennox, Ireland), submerged in 10% formalin (Serosep, 
Ireland), and sent for tissue processing (2.1.4.2). 
 
2.1.4.2 Processing Cell Pellets 
Cell Line samples were processed using a Citadel™ 2000 tissue processor (Thermo 
Fisher Scientific Inc, USA). The purpose of processing the cells is to ensure fixation, full 
dehydration and paraffin wax infiltration. To achieve this, processing cassettes 
containing the specimens were transferred to the Citadel™ 2000 processing baskets. 
Baskets were then inserted into the Citadel™ 2000, and processed for 16 hours. The 
stages involved in processing the cell lines are illustrated in Table 2.1-2. 
 
Table 2.1-2: Stages of tissue processing performed to all tissue and cell lines samples 
assessed within this body of work. Tissue Processing was performed using Citadel™ 
2000 automated processor.  
 
Station Reagent Time (hrs) 
1 10% Formalin 1 
2 10% Formalin 2 
3 70% Spirit 1 
4 95% Spirit 1 
5 Spirit (99% IMS) 1 
6 Spirit 1 
7 Spirit 1 
8 Spirit 1 
9 Xylene 1.5 
10 Xylene 1.5 
11 Wax 2 
12 Wax 2 
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2.1.4.3 Paraffin wax embedding of cell line samples 
Dehydrated cell lines housed in agarose molds were embedded in paraffin (Tissue 
Embedding Medium, Kendall Tyco Healthcare / Paraplast, USA) using a 
HistoEmbedder TBS88 (Medite, Germany).  
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2.2 Construction of Microarrays 
2.2.1.1 Cell Microarrays 
Cell Microarrays were designed and constructed in Tissue Array Research Program 
(TARP), National Cancer Institute (NCI), National Institute of Health (NIH), 
Washington DC, USA in collaboration with Dr. Stephen Hewitt.  Cell Microarrays were 
constructed using the MTA-I manual arrayer (Beecher Instruments, USA) using 0.6 mm 
needles, following the protocol supplied by the manufacturer and as described in 
literature (Kononen et al., 1998). The array design included 31 cell line specimens and 
one liver control spot which was utilised for orientation. Sections were cut (4 µm) using 
a microtome (RM2155, LEICA Microsystems, Germany) and placed on adhesive coated 
slides (PSA-1X Paraffin tape transfer system, Instrumedics Inc, USA). Slides were 
vacuum packed and stored at 4°C until immunohistochemical staining was performed.  
 
2.2.1.2 Tissue Microarrays  
Tissue Microarrays were designed and constructed by staff of the Histopathology 
Department, Beaumont Hospital, Royal College of Surgeons Ireland (R.C.S.I). Tissue 
Microarrays were constructed using the MTA-I manual arrayer (Beecher Instruments, 
USA) using 0.6 mm and 2.0 mm needles, following the protocol pioneered by Kononen 
et al., 1998. Formalin-fixed-paraffin-embedded tissue blocks containing tumour material 
were retrieved from the archives, along with their respective haematoxylin and eosin 
(H&E) stained sections. Using the H&E stained slide as a template, representative areas 
of carcinoma were identified and marked. Sections were cut (4 µm) using a microtome 
(RM2135, LEICA Microsystems, Germany) from each Tissue Microarray mounted on 
to charged adhesive slides (Plus slides, Vision Biosystems, UK) using the water bath 
transfer technique and were air dried overnight at 55°C.  
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2.3 Experimental analysis of Tissue / Cells 
Manual and Automated immunohistochemical staining was performed as part of this 
body of work. Fluorescent in situ hybridisation (FISH), Western blots and Enzyme 
Linked Immunosorbent Assay (ELISA) were not performed by the author.  
 
2.3.1 Immunohistochemical staining  
Both automated and manual immunohistochemistry was performed. In total, 6 primary 
antibodies were applied to sections of the Cell Microarrays and 4 primary antibodies 
were applied to Tissue Microarrays. All antibodies targeted antigens on the cell 
membrane. In addition, ß-catenin targeted the cytoplasm and PhosphoMet targeted the 
cytoplasm and nucleus.  A list of primary antibodies utilised in this study is illustrated in 
Table 2.3-1. 
 
Table 2.3-1: Primary antibodies and the dilutions utilised within this body of work. 
Primary Antibody Dilution Microarrays 
EGFR (Novocastra/Vision Biosystems, UK, NCL-L-EGFR-384) 1:75 CMA 
MDR-1 (National Institute for Cellular Biotechnology, 6/1C) Neat CMA 
MDR-3 (National Institute for Cellular Biotechnology, 6/1G) Neat CMA 
MRP-1 (National Institute for Cellular Biotechnology, P268) Neat CMA 
E-cadherin (Novocastra/Vision Biosystems, UK, NCL-E-Cad) 1:50 CMA/TMA 
HER-2 (DakoCytomation, Code K5204) Neat CMA/TMA 
PhosphoMet (Cell Signalling Technology, Tyr1234/1235) 1:50 TMA 
ß-catenin (Labvision Corp, RB-9035-P1) 1:50 TMA 
 
2.3.1.1 Manual Immunohistochemical Staining 
Immunohistochemical staining for MDR-1/Pgp, MDR-3 and MRP-1 with the NICB 
antibodies (anti-MDR-1, anti-MDR-3 and anti-MRP-1) was performed manually using 
the technique described by (Hsu et al., 1981), using an avidin-biotin horseradish 
peroxidase (HRP) conjugated kit (ABC) plus an appropriate secondary antibody. 
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Briefly the protocol utilised is as follows; Paraffin-embedded tissue samples were 
dewaxed in xylene (2 x 5 minutes) rehydrated in grading alcohols 100%, 90% and 70% 
(2 x 3 minutes) and placed in Tris Buffered Saline (TBS/0.05% Tween-20). Endogenous 
peroxidase activity was quenched by placing tissue sections in 3% (vol/vol) 
H202/distilled water for 5-7 minutes at room temperature. All slides were blocked for 
non-specific staining with 20% normal rabbit serum (DakoCytomation, UK)/TBS for 20 
minutes at room temperature. Primary antibodies optimally diluted in TBS/0.05% 
Tween-20 where applicable (antibody MDR-1 clone 6/1C, MDR-3 clone 61/G and 
MRP-1 clone P268) were applied to each sample. Primary antibodies were incubated 
overnight at 4oC. Samples were then washed (3 x 5 minutes) with TBS/0.05% Tween-
20. This was followed by a 30 minute incubation with biotinylated secondary antibody 
(rabbit anti-mouse IgG (1/300 dilution in TBS/0.05% Tween-20) (DakoCytomation, 
UK) or rabbit anti-rat (1/500 dilution in TBS/0.05% Tween-20). Finally, following 
another (3 x 5 minutes) wash step, Vectastain Elite ABC reagent (HRP conjugated) 
(Vector Laboratories, UK) was applied for 25 minutes at room temperature. The 
peroxidase substrate, 3’,3-daminobenzidine tetrahydrochloride (DAB) containing 0.02% 
H202 (Vector Laboratories, UK) was added for 10 minutes at room temperature. All 
slides were then washed (3 x 5 minutes) TBS/0.05% Tween-20. Tissue sections were 
then lightly counter stained with haematoxylin (Vector Laboratories, UK). 
 
Slides were subsequently dehydrated in grading alcohols 70%, 90% and 100% (2 x 3 
minutes). Samples were then cleared in xylene and mounted in DPX (BDH, UK). 
Negative control samples in which primary antibody were replaced by 1x TBS/0.05% 
Tween-20 were included in all experiments. Positive controls (normal breast and lung 
tissue), using the same experimental conditions, were included in all experiments. 
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2.3.1.2 HercepTest™ Immunohistochemical Staining 
The assessment of HER-2 protein overexpression was carried out using the 
HercepTest™ kit according to the manufacturer’s instructions. The HercepTest™ 
protocol differs from that described in section 2.3.1.1 as follows; after dewaxing in 
xylene and rehydration through graded alcohols to distilled water, the section was 
subjected to heat induced epitope retrieval by immersion in preheated epitope retrieval 
solution (95 – 99°C) in a waterbath for 40 minutes. The sections were then allowed to 
cool down for 20 minutes at room temperature. Endogenous peroxidase activity was 
blocked by a five minute treatment with peroxidase blocking agent. Sections were then 
incubated with the anti-HER-2 polyclonal antibody for 30 minutes at room temperature, 
followed by incubation with a visualisation reagent (labelled streptavidin–biotin–
immunoperoxidase). The antigen–antibody reaction was visualised using 3-3'-
diaminobenzidine as chromogen and counterstaining was performed with haematoxylin. 
Suitable negative and positive control slides were treated in a similar manner to ensure 
appropriate staining (Gulmann et al., 2004).   
 
2.3.1.3 Automated Immunohistochemical Staining 
Immunohistochemical staining of Microarrays with E-cadherin, EGFR PhosphoMet and 
β-catenin  was performed using the automated stainer BondMax™ (Vision 
Biosystems™, UK) and according to manufacturers instructions. 
 
2.3.2 Western Blots 
Western blotting was performed by fellow post-graduate / post-doctorate members of the 
NICB (Brigid Browne, Denis Collins, Brendan Corkery and Norma O’Donovan), and as 
described in literature (Moran et al., 1997a). Western blot analysis was performed on 
cell lines within 5 – 10 passages of those used to construct the Cell Microarray. 
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2.3.3 Enzyme-Linked Immunosorbent Assay  
Protein expression, when quantified by ELISA. ELISA testing was performed by fellow 
post-graduate / post-doctorate members of the NICB (Brigid Browne, Denis Collins, 
Brendan Corkery and Norma O’Donovan) as part of a wider study and results were 
made available for comparison within this study. Commercially available ELISA 
systems were utilised for quantification of total HER-2 (Calbiochem®, UK) and EGFR 
(DuoSet® IC Human Total EGFR ELISA, R&D Systems Inc., USA) expression. 
ELISAs were performed on cell lines within 5 – 10 passages of those used to construct 
the Cell Microarray. ELISA results were classified as positive (> 20 ng/mg) or negative 
(≤  20 ng/mg). 
 
2.3.4 Fluorescent in situ hybridisation 
The PathVysion® HER-2 DNA probe kit and paraffin wax pre-treatment kit (Vysis Inc, 
UK) were used in accordance with the manufacturer’s recommended protocol. Slides 
were stored at –20°C in the dark before signal enumeration with a Nikon Eclipse E600 
Microscope (Nikon Inc, USA) using x 100 magnification (oil immersion) and 
appropriate multiband pass filters. Appropriate positive (HER-2 gene amplification) and 
negative (non-amplification) control slides were included in the staining run. Analysis of 
the FISH score was carried out by comparing the ratio of the average copy number of the 
HER-2 gene with that of the chromosome 17 centromere in 60 nuclei/case (Kay et al., 
2004).   
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SECTION B: COMPUTER APPLICATIONS 
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2.4 Digitisation of Slides 
Slides within this body of work were digitised using a number of techniques. The 
digitisation techniques utilised were updated with advances in technology. The most 
advanced technology was utilised toward the end of the thesis. The technologies utilised 
to digitised slides are listed below, and are arranged in chronological order. 
 
2.4.1 Olympus BX-40 Microscope 
An Olympus BX–40 microscope (Olympus, USA) incorporating a Prior H101 motorised 
stage was used to capture digital images of tissue within the initial creation of the Virtual 
Tissue Matrix in Chapter 3. Images were captured at 4 x using a Plan Achromatic lens, 
and at 20 x using a Plan Fluorite lens. The camera used to scan the immunostained 
Tissue Microarrays was a 3-chip JVC KY 55 B 3 CCD. The camera has a red, green and 
blue (RGB) digital signal output to an Imaging Technologies IC RGB frame grabber 
(Coreco Imaging Incorporated, USA), which was housed in a Silicon Graphics ZX10 
imaging workstation. A software algorithm was constructed using the Optimas 
development environment (Media Cybernetics, USA) that facilitated the remote control 
of the stage and the construction of wide field-of-view images from a montage of 
smaller fields. Scanning time at 20 x was approximately 12 - 16 minutes for a 20 mm x 
20 mm biopsy. All software was written in-house by previous members of the Medical 
Informatics Group, Dublin City University (Johnston, 2005b).  
 
2.4.2 Aperio ScanScope T3 Scanner™ 
Immunohistochemically stained Tissue Microarrays were digitised using an Aperio 
ScanScope T3 Scanner™ (Aperio Technologies, USA). Images were captured at 20 x 
magnification, saved in SVS format utilising JPEG compression and were approximately 
90 Mb per Tissue Microarray. Scanning time at 20 x was approximately 6 - 8 minutes 
for a 20 mm x 20 mm biopsy. The Aperio ScanScope T3 Scanner™ was used to digitise 
slides within Chapters 4 and 5. 
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2.4.3 NanoZoomer Digital Pathology System 
Immunohistochemically stained Tissue Microarrays and whole sections within Chapter 6 
were digitised using a NanoZoomer Digital Pathology (NDP) System (Hamamatsu, 
UK). The NDP system utilises CCD TDI technology to achieve scans with a spatial 
resolution of 0.46 µm / pixel. Scanning time at 20 x was approximately 3 minutes for a 
20 mm x 20 mm biopsy. Images were approximately 90 Mb per Tissue Microarray and 
ranged from 55-487 Mb per whole section biopsy.  
 
2.4.4 Nikon Eclipse E600 Microscope 
Fluorescently labelled tissues described in Chapter 6 were digitised using Nikon Eclipse 
E600 Microscope (Nikon Inc, USA), by members of staff at Beaumont Hospital /Royal 
College of Surgeons. Slides were stored at –20°C in the dark before signal enumeration 
using x 100 magnification (oil immersion) and appropriate multi-band pass filters.  
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2.5 Development of an Algorithm 
2.5.1 Image-Pro Plus® 
Image analysis was performed in Image-Pro Plus® (Media Cybernetics, USA). The 
image analysis algorithm was developed to perform the following functions: 
 
• To isolate positive membrane staining only. 
• To create a histogram of intensity of pixel values and output the histogram 
values, mode, mean and standard deviation. The algorithm also recorded the 
background lighting staining intensity value, and the number of positive 
membrane and tissue pixels. 
 
The algorithm was a combination of AutoPro™, Media Cybernetics own programming 
language and Visual Basic. Once created and extensively validated, the algorithm was 
saved as a macro. The macro facilitated automated analysis of the images. Human 
intervention was reduced to selecting the Tissue Microarrays to be analysed. On 
average, image analysis required four minutes per Tissue Microarray spot. The image 
analysis was performed on networked laptop computer with a 40 GB hard drive, 1.0 GB 
of RAM and an Intel® Pentium ® M processor 1.50GHz.   
 
The key aspect of the algorithm is the detection of membrane staining only, which was 
accomplished using a combination of filters and a colour cube. The sequence of the 
algorithm is divided into three stages and is depicted in Figure 2.5-1. The algorithm was 
tested on numerous images to ensure it was equally effective on varying degrees of 
staining intensities. 
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Figure 2.5-1: Sequence of the image analysis algorithm, which isolates membrane-
bound immunohistochemical staining. Colour cube is used to identify brown staining. 
Filters are used to isolates areas of membrane-bound staining (Well, Sobel, Prune, 
Dilate, Thin, Sharpen, Open and Close). 
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Stage 1 involves the creation and application of a colour cube, which represents the 
range of colours present when tissue stained positive for immunohistochemical staining. 
Using the eyedropper tool within Image-Pro Plus®, colours were selected from 
numerous images to comprehensively represent all colour intensities present for each of 
the antibodies under assessment.  The colour cubes were then applied to the original 
images and a mask was created, as illustrated in Figure 2.5-2. The mask converted pixels 
within the original image that were not a colour present within the colour cube to black, 
and those with pixels colours within the colour cube were converted to white. 
 
Stage 2 involves applying a number of filters to the image in order to identify membrane 
staining only; the types of filters used are as follows: 
 
• Well: detects and emphasises points that are darker than the background.  
• Sobel: enhances the principal edges, this identifies the membrane.  
• Thin: reduces a binary image to its skeleton. 
• Prune: reduces a binary image to its skeleton and removes protrusions. 
• Dilate: enlarges the edges of bright objects and erodes dark edges. 
• Sharpen: enhances fine details. 
• Close: Fills gaps and enlarges protrusions to connect objects that are close 
together. 
• Open: Smoothes object contours, separates narrowly connected objects and 
removes small dark holes. 
 
The filters “Sobel” and “Well” were of particular importance in identifying membrane 
staining.  
 
Stage 3 involved a number of operations which were used to combine multiple images. 
The “And” function performs a logical operation between two images, in which only bit 
values that were on in both images will be present in the output image. The “Or” 
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function performs a logical operation between two images, in which bit values that are 
on in either image will be present in the output image. The operations resulted in a single 
image which encompassed all the filters performed on the original image, as in Figure 
2.5-2. An example of the original and final images after image analysis quantification of 
E-cadherin and is illustrated in Figure 2.5-2.   
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Figure 2.5-2: Various stages of the image analysis algorithm, which detects membrane-bound E-cadherin immunohistochemical 
staining (A) Original image, (B) Mask of the colour cube, (C) Sobel filter, (D) Well filter, (E) thinning and (F) final image of 
membrane staining. The tissue has been immunohistochemically stained for E-cadherin. 
A B C 
D E F 
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2.5.2 Distiller 
Distiller (SlidePath, Ireland) is a web-enabled image informatics management system. It 
has been used as a replacement to the Virtual Tissue Matrix to facilitate virtual online 
reviews, store images and associated information. The Virtual Tissue Matrix is described 
in detail in Chapter 3. In addition, Distiller also provides the functionality of automated 
de-arraying. De-arraying is the process of fragmenting a Tissue Microarray image and 
locating each individual core, with minimal human intervention.   
 
Due to file size restrictions it is not possible to perform high-throughput analysis across 
large images using Image-Pro Plus®. Therefore, the algorithm was recreated in Java and 
integrated into Distiller. Java code was created using ImageJ, an open source software 
library (Rasband, National Institutes of Health, USA). Netbeans was used as the 
development environment (Sun Microsystems Inc., USA). The creation of the algorithm 
in Java was performed by SlidePath engineers. Distiller provides a harness for 
manipulating virtual images. The harness divides images into tiles of 1000 X 1000 
pixels, and performs image analysis on a tile by tile basis. From example, a 90 Mb 
whole section slide when divided into 1000 X 1000 pixels generates 721 tiles. Using the 
harness it is possible to output staining data per tile or per complete image. An example 
of the original and final images after image analysis quantification of ß-catenin is 
illustrated in Figure 2.5-3. A histogram of staining intensity values is generated from 
image analysis; an example of a histogram of staining intensity is illustrated in Figure 
2.5-4. 
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Figure 2.5-3: Original and Final images from the image analysis assessment of tissue 
immunohistochemically stained for ß-catenin. Images A and B, represent, Weak and 
Strong staining respectively. A1 and B1 are the original input images, and A2 and B2 
are the final membrane stained only output images. 
 
 
 
 
 
 
A1 A2 
B1 B2 
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Figure 2.5-4: Illustrates the distribution of positive membrane-bound 
immunohistochemical staining observed within Figure 2.5-3, when assessed by image 
analysis. 
 
After image analysis was performed, intensity values were uploaded into the Distiller 
database. Once in the database, intensity values were downloaded into Microsoft 
Excel™ and SPSS for statistical analysis. The fully automated image analysis workflow 
is depicted in Figure 2.5-5. DLL refers to dynamic link library; which is a collection of 
small programs that is called upon by a larger program running on the computer; CSV 
refers to comma-separated values, which is a format of data representation. 
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Figure 2.5-5: Fully-automated image analysis workflow facilitating digitisation, de-arraying and image analysis quantification of 
membrane-bound immunohistochemical staining intensity. In this example an Aperio Scanscope™ has been used to digitise the slides. 
However, the flow is independent from the scanning system used. 
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2.6 Interpretation of Image Analysis Results 
Using image analysis the intensity of membrane staining was classified on a continuous 
scale, ranging from 0 to 255 staining intensity values, where 0 is strongest staining 
possible and 255 is the lightest staining intensity possible. The staining intensity value 
was calculated as the mode of greyscale intensity for all the “membrane” pixels. The 
mode was calculated by automatically generating a histogram of recorded membrane 
intensity values per Tissue Microarray spot, or whole section biopsy using an eight point 
intensity interval. The mode was recorded as the value that appeared most often in the 
histogram and, therefore, the most commonly occurring pixel intensity value. The 
average of the modal value from replica cores was used to calculate the membrane 
staining intensity value for each patient within the Tissue Microarrays. In addition, the 
number of positive membrane pixels, tissue pixels, and background lighting intensity 
was also recorded.  
 
2.6.1 Normalisation 
To account for variance in immunohistochemical staining across multiple slides, and 
variance from slide-to-slide background lighting intensity, all staining intensity mode 
values were normalised. Figure 2.6-1 illustrates the process of normalising image 
analysis data. Utilising image analysis, staining intensity values were quantified for all 
tissue cores (Tissue Core Value) and control cores (Control Core Value) present across 
each Tissue Microarray. In addition, using image analysis the background lighting 
intensity of each Tissue Microarray was also recorded (Slide Background Lighting 
Value). As a result of normalisation, staining intensity data was converted into natural 
logarithm values (Ln). During whole section analysis and where control cores were not 
present slides normalisation was performed by obtained the natural log of the Modal 
staining intensity value / background lighting intensity (Ln(I/Io). 
 
Io
ILnNormalised =  
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Staining Intensity Assessed by Image Analysis
Tissue Core Value Control Core ValueSlide Background Lighting Value
Ln (Value 3 / Value 2)
Value 1 Value 2 Value 3
Ln (Value 1 / Value 2)
Modal value of  Ln (Value 3 / Value 2)
Normalised Data
Modal value of  Ln (Value 3 / Value 2)
______________________________
Ln (Value 3 / Value 2)
X
 
Figure 2.6-1: Process of normalising data generated from image analysis quantification 
of immunohistochemical staining. Results are converted into a natural log (Ln). 
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2.6.2 Generating Cut-Points 
In order to compare continuous (image analysis results) and nominal datasets (human 
analysis), image analysis results where converted into categorical results. Using 
prognostic information and quantitative results from alternative assays it was possible to 
create optimal cut-points within image analysis datasets. The optimal cut-points were 
created as follows: 
 
2.6.2.1 Prognostic Data 
In theory, associations between tumour biomarker expression and patient outcome 
should reveal the existence of biologically meaningful tumour classifications; however, 
in practice there is no universal methods for discovering such associations (Camp et al., 
2004). As a result, studies often group tumour into set divisions, for example, upper and 
lower quartiles, which fails to reflect the underlying biology of most biomarkers. 
Therefore, this study utilised X-tile which is a freeware software application that 
facilitates optimum cut-point selection of continuous data sets. X-tile plots provide a 
single, global assessment of every possible way of dividing a population into categories. 
As illustrated in Figure 2.6-2 , X-tile software allows the user to move a cursor over a 
histogram of continuous data (C) and provides on the fly subsets of populations with an 
associated Kaplan-Meier curve (D) and statistical analysis data (B), whiles displaying 
the distribution of cases (A) (Camp et al., 2004).  
 
As it is statistically invalid to test multiple divisions and accept the best P-Value, within 
large cohorts of patients, X-tile provides the functionality of dividing the data set into 
“training set” and then validating results in a separate patient cohort, known as the 
“validation set”. The application of X-tile in prognostic evaluations is expanding in 
literature (Camp et al., 2004, McCabe et al., 2005, Dolled-Filhart et al., 2006, Zerkowski 
et al., 2007, Rajput et al., 2007). 
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Figure 2.6-2: X-tile application selecting optimum cut-point of continuous data sets. X-
tile provides a distribution of cases (A), statistical values (B), histogram of results (C) 
and Kaplan-Meier curves (D). 
 
 
2.6.2.2 Quantitative / Qualitative Assays 
Optimal cut-points can be generated by comparing image analysis results with data 
obtained from alternative quantitative assays performed on the same tissue set. Staining 
intensity values were quantified using image analysis, and the normalised image analysis 
results were compared with protein overexpression data quantified by Western 
blots/ELISA or gene amplification data quantified by FISH.  The output from image 
analysis was categorised into positive or negative for protein overexpression, based on 
the modal staining intensity value and the number of positive membrane pixels.  
A B 
C D 
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SECTION C: STATISTICAL ANALYSIS METHODS 
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2.7 Statistical Analysis 
Statistical analysis was performed using SPSS version 14.0 Windows (Chicago, IL, 
USA). ANOVA, Tukey HSD tests, T-tests and Pearsons Chi squared were used to 
compare human and image analysis assessments. Where applicable, confidence intervals 
(CI), degrees of freedom (df), and relative risk (RR) are included in the results. 
Statistical significance for all tests was set at p < 0.05. Statistical Analysis was 
predominantly used to illustrate levels of correlation between multiple reviewers, assays 
(see section 2.7.1), and measuring time related events (see section 2.7.2).  
 
2.7.1 Cohen’s Un-weighted Kappa 
Cohen’s un-weighted kappa values was one of two methods used to quantify the level of 
agreements achieved when comparing two datasets generated from human and image 
analysis reviews. Kappa was not the primary statistics used in the dataset comparisons 
involved in this body of work; however; Kappa has been included as it is widely used in 
comparisons of observer agreement of this type. Landis and Koch kappa interpretation 
scale was used to evaluate the level of kappa agreements; the interpretation scale is 
illustrated in Table 2.7-1 (Landis and Koch, 1977). However, within this body of work, 
the predominant method used to quantify the levels of agreement achieved when 
comparing two datasets generated from tissue / cell line reviews was the percentage of 
cases where the two datasets were in complete agreement.   
 
Table 2.7-1: Interpretation of Landis and Koch 1977 kappa values. Ranges of Cohen’s 
Kappa values are described within the table. 
Kappa Value Interpretation 
0-0.2 Slight 
0.2-0.4 Fair 
0.4-0.6 Moderate 
0.6-0.8 Substantial 
0.8-1.00 Almost Perfect 
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2.7.2 Survival Statistics 
Overall survival analysis was assessed by Kaplan-Meier curves with statistical 
significance assessed by Mantel-Cox log rank test. Kaplan-Meier curves were used as a 
univariate test to assess the rate of death due to Urothelial cell carcinomas of the 
Bladder. Kaplan-Meier curves facilitate the analysis of patients with varying lengths of 
follow-up information. Therefore, patients can be mathematically removed from the 
curve at the end of their follow-up period. Patients were deemed uncensored if they died 
of the disease under assessment during the follow-up period. Patients that were alive or 
dead due to other cancers or causes within the follow-up period were censored. The 
interpretation of Kaplan-Meier curved is illustrated in the following example. 
 
Figure 2.7-1 illustrates a typical Kaplan-Meier curve. Within this curve, the effect of two 
treatments on a particular disease is assessed. The two lines represent treatment 1 and 2. 
Censored patients are signified within the curves by the following symbol (+). A decline 
within the curves represents a death due to the disease under assessment. The depth of 
decline within the curve signifies the total number of deaths at that time point. The y-
axis represents the percent survival of patients, and the x-axis presents the time of 
survival under assessment.  Within this example, approximately 59% of all patients 
receiving treatment 2 were alive after the 5 year follow-up period, whereas, 80% of 
patients were alive after receiving treatment 1.  
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Figure 2.7-1: The effect of two different treatment types on disease is represented in this 
Kaplan-Meier curve. Survival time from disease under assessment is illustrated on the 
X-axis. Percent survival from the disease under assessment is illustrated on the Y-axis.  
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CHAPTER 3: DESIGN AND VALIDATION OF THE 
VIRTUAL TISSUE MATRIX; A SOFTWARE 
APPLICATION WHICH FACILITATES ONLINE REVIEW 
OF TISSUE MICROARRAYS 
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3.1 Introduction  
Tissue Microarrays provide high-throughput analysis of tissue samples for in situ 
hybridisation and immunohistochemistry, by means of arranging multiple tissue samples 
in a uniform structure on the surface of a glass slide.  Tissue Microarrays allow for large 
numbers of tissue samples to be analysed simultaneously at DNA, RNA or protein level. 
 
Kononen et al. (1998) first illustrated the use of Tissue Microarrays in 1998 (Kononen et 
al., 1998). The technique involves the excision of cores of varying diameter (0.6 mm to 
2.0 mm) from regions of histological importance on donor tissue blocks and the 
subsequent insertion of these excised cores into precise co-ordinates on a recipient 
block. This process is repeated until a two-dimensional matrix of cores is inserted into 
the recipient block. Once the block is complete, sections can be cut from the block, 
which are then available for any analysis currently performed on full-face tissue 
sections. 
 
A large amount of data is associated with Tissue Microarrays, ranging from information 
on the tissue (patient information), to their construction, subsequent staining and 
assessment. It is becoming apparent that applications to assist in pathologist’s reviews of 
Tissue Microarrays are required, as bottlenecks in the storage and manipulation of the 
data generated are beginning to emerge.  
 
There have been previous attempts to create software applications that facilitate review 
of Tissue Microarrays (Sharma-Oates et al., 2005). The technology has varied from 
using Microsoft Excel™ spreadsheets, to the creation of complex databases. Manley et 
al. (2001) developed a relational database to store data and images, which focus on 
clinical outcome (Manley et al., 2001). This system consisted of several databases to 
store Tissue Microarray images, Tissue Microarray information and pathological and 
clinical information, in Microsoft Access. All data was manually entered into a main 
online form and then transferred into the relevant database table.  Each image was 
scanned using a grid structure that overlaid the image of the array.  The images were 
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composed of six separate 10 x fields, stitched together to form a single image, which 
was saved as a JPEG image (200-300 kb).  However, despite the advances made by this 
system, rapid file sharing over the internet was limited by large image sizes with slow 
internet connections. Also, as the software utilised were commercial applications, 
adaptations to the functionality of the programs were not possible. 
 
Liu et al. (2002) utilised a combination of commercial and in-house applications to store 
data, digitise images and perform statistical analysis. Information was stored in 
Microsoft Excel™ spreadsheets and reformatted by a program called Tissue Microarray 
deconvoluter, into a structure that can be further manipulated to allow statistical analysis 
and hierarchical clustering. Although Microsoft Excel™ spreadsheets are traditionally 
used by scientists to store data, there is always a significant risk of human error, as large 
amounts of data entry are required and the object-oriented nature of the data does not 
lead to optimal data storage in spreadsheets (Liu et al., 2002). 
 
The ability to interpret, review and grade histology in Tissue Microarray images across 
the Internet was assessed by Bova et al. (2001). This study evaluated the reviewer’s 
ability to interpret images of Tissue Microarray cores, in order to assess the presence or 
absence of prostate cancer and to Gleason grade tumours. In 99% of cases, the images 
were deemed interpretable; this was done by visual inspection. However, it was 
suggested that, on occasion, lengthy downloading times would limit the system’s 
practical use. The authors recommended that compressed files of less than 200 kb should 
be evaluated for viable image quality, as using files of this size would reduce 
downloading times. Inter- and intra-observer variability was found to be no greater, and 
in some cases less, than that reported when using traditional microscope-based Gleason 
grading. This was evaluated by comparing inter- and intra-observer variability observed 
in their study of online analysis with those previously reported in literature for inter- and 
intra-observer of Tissue Microarray microscope-based analysis. When evaluating levels 
of inter- and intra-observer agreement, the authors used percentage of complete 
agreement, and Cohen’s un-weighted kappa coefficient of agreement. They concluded 
that web-based technology was an acceptable means to review Tissue Microarrays.  The 
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authors believed that a limitation of their study was that web-based analysis was not 
directly compared with their microscope-based review and so recommended that this 
technology be tested using data resulting from immunohistochemical and in situ 
hybridisation reviews (Bova et al., 2001).  
 
The advent of virtual slides permitted the review of whole tissue slides across the 
Internet (Johnston et al., 2005). Virtual slides provide users with all the functionality of a 
microscope, but with numerous additional benefits, including concurrent access for 
multiple users, tracking of review movements and image annotation. Virtual slides are 
reminiscent of microscope use and they are favoured by pathologists over static digital 
images, due to the ability to change magnification and scroll laterally while reviewing 
the image.  
 
The aim of this chapter was to develop and validate a software application that would 
combine the benefits of virtual slides and online relational database technology, to 
facilitate Tissue Microarray reviews and scoring via the Internet. Unlike existing 
applications, the software system developed provides a relational database for data 
storage and smaller image tiles for rapid image access across the internet. To validate the 
software system developed, a study was created to ensure the system could achieve 
comparable results to those obtained from traditional glass slide analysis. The study 
examined users’ ability to agree when performing virtual-based and microscope-based 
(glass) reviews of six immunohistochemically stained Tissue Microarrays, across eight 
parameters. 
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3.2 Study Design 
3.2.1 Patient Cohort 
Forty eight bladder tumours were used in this evaluation.  Urothelial cell carcinomas of 
the Bladder (UCB) were selected from the files of the Mater Hospital histopathology 
department. A total of 6 Tissue Microarrays were constructed, with 48 cases and 196 2.0 
mm cores, including 12 control spots composed of liver tissue applying the technique 
pioneered by Kononen et al. (1998). Tissue Microarrays were probed with three 
antibodies, E-cadherin (Novocastra/Vision Biosystems, UK), ß-catenin (Labvision 
Corp., USA) and PhosphoMet (Cell Signalling Technology, Inc., USA). The 
immunohistochemical staining procedure has been described in Chapter 2 section 
(2.3.1.3). The antibody to E-cadherin shows membrane staining; the antibody to ß-
catenin shows membrane and cytoplasmic staining (Wijnhoven et al., 2000) and the 
antibody to PhosphoMet shows membrane staining, cytoplasmic staining and nuclear 
staining (Moran et al., 1997b). Tissue Microarrays were digitised using an Olympus 
BX–40 microscope (Olympus, USA) incorporating a Prior H101 motorised stage, the 
technology used was described in Chapter 2 section (2.4.1). 
 
3.2.2 Validation of Image Quality 
Tissue Microarrays were initially scanned at 4 x to create a tiled ‘thumbnail’ image of 
the entire array. This overview image was used to locate cores manually through a 
custom Graphical User Interface. The user clicked on the centre of each core on the 
overview image and the coordinate generated was used to seed an automatic scanning 
algorithm for all cores at 20 x. The array of captured images (6 × 8) were then tiled 
together to form a montage bitmap image of approximately 60.5 Mb (4607×4592 
pixels).  
 
The Macromedia Flash application, Zoomify, was used to display images within the 
Virtual Tissue Matrix (VTM) framework. Zoomify Droplet, a software tool provided 
by Zoomify, uses the original scanned BMP image as an input and converts it into a 
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set of JPEG image tiles. This tileset, once uploaded to a webserver, can be displayed via 
the Internet using the Zoomify-embedded object within a conventional web page. 
Zoomify initially presents the user with a low power view of each Tissue Microarray 
spot. The users can then scroll around the image, and when required, zoom into a 
maximum magnification of 20 x.  
 
When using a lossy compression algorithm, such as JPEG, image quality is reduced 
when compared with that of uncompressed images. To ensure that the compression rate 
used by Zoomify provided images of sufficient quality, a series of consultations with 
pathologists and scientists were performed where compressed and uncompressed images 
were compared. The outcome of this consultation was that the images generated by 
Zoomify were suitable for scoring. Figure 3.2-1 illustrates the quality of images 
available in the VTM. 
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Figure 3.2-1: Digital image of Tissue Microarray spot presented in VTM using Zoomify application. On the top left corner of image 
is the thumbnail overview; the red box identifies selected location within the spot. The key at the bottom of the image allows the user 
to change position or magnification, which can also be controlled by the cursor. 
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3.2.3 Design Phase of the VTM 
The design objectives of the VTM system were to provide Tissue Microarray images of 
sufficient quality to review over the World Wide Web, to present scoring forms to 
record Tissue Microarray results and to create a relational database that can store and, 
subsequently, retrieve data gathered during scoring.   
 
PHP, Javascript, HTML and Oracle were used to create the VTM. PHP is a server side 
scripting language, which creates dynamic web pages, through embedding PHP code in 
HTML pages. Through the use of SQL queries, it can also extract data from many 
conventional databases (Oracle, MySQL, etc). Javascript adds interactive client side 
functionality to otherwise static HTML pages. An Oracle relational database was used to 
store all the information generated in this study. 
 
3.2.4 Database Design 
The construction of Tissue Microarrays facilitates the generation of hundreds of Tissue 
Microarray slides from a single Tissue Microarray block; therefore, every Tissue 
Microarray slide produced can potentially be stained with a unique immunostain. A 
major benefit of storing Tissue Microarray images and results within a relational 
database is the ability to extract all the results associated with a single core, which 
potentially may have been immunostained hundreds of times. This functionality is 
available within the VTM. 
 
Based on analysis of conventional Tissue Microarray datasets, it was established that ten 
groupings of data would be sufficient to record all relevant information; therefore, ten 
tables where created in the VTM relational database. Each table contains information 
relating to a specific aspect of a Tissue Microarray review. For example, the USER table 
contains information relating to users only; SCORE table contains information relating 
to the Tissue Microarray analysis results only.   A unique identifier interlinks all tables 
and, by using SQL statements, information can be retrieved from multiple tables 
simultaneously. For example, results relating to a specific user can be obtained by 
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creating an SQL statement that requests information from the SCORES and USER 
tables. Table 3.2-1  lists all the tables that exist in the database and examples of the 
information they record. A complete schema of the database is illustrated in Figure 
3.2-2. 
 
Table 3.2-1: Tables within the VTM database and examples of their content.  
Table Name Information held Examples 
User User details E- mail address 
TMA Manufacturer Manufacturer details Name 
TMA Tissue Microarrays Diagram of cores 
Patient Patient information Gender 
Biopsy Biopsy details Biopsy notes 
Core Core details Tissue type 
Spot Spots in a slide Magnification scanned  
Experiment Slide Experiment procedure Treatment name 
Score Results  % of Nuclear staining  
Intensity Table Staining intensity details Staining type 
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Figure 3.2-2: Complete Schema of the VTM database. 
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The database has been designed to eliminate replication of data input. For example, a 
manufacturer of Tissue Microarrays details are only entered into the database once 
regardless of the number of Tissue Microarrays they have constructed. When their 
account is created they can be associated with multiple blocks/slides and studies. There 
is also the ability to add information into the database after the initial study has been 
created. For example, if patient or biopsy information is not known at the time of 
entering the Tissue Microarray review results into the database, they may be entered at a 
later date by simply entering the patient or biopsy information and then selecting the 
cores to which the information applies. However, users are unable to overwrite the 
Tissue Microarray review results already present in the database. 
 
Depending on the internet connection used (times described here are for LAN settings of 
10 Mbps), it takes approx 5 seconds to download the thumbnail overview of a Tissue 
Microarray slide; once a core has been selected it takes approx 2-3 seconds to view the 
individual core in the Zoomify™ window. There are no restrictions on the number of 
images that can be displayed within the VTM, currently there are 196 images. However, 
the number of images displayed is dependent on the capacity of the server available to 
the users.  
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3.2.5 Interface Design 
The user interface had to be easily navigated, interpretable and provide images at 
sufficient speed and resolution for review. There are two types of user account within 
the VTM, namely administrator or user. A user has restricted access to the site; they can 
only review and score images. An administrator has additional privileges within the site; 
they can create new studies, add new images and scoring forms and they can view all 
data stored in the database.  
 
The VTM was constructed so that the user is lead through the site, not having to 
concentrate on the sequence of events, freeing up analysis time for the reviewing 
process. Figure 3.2-3 illustrates the options available to both user and administrator 
within the VTM.  
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Figure 3.2-3: Options available through the VTM interface. Schematic diagram 
showing options available to administrators and users within the VTM interface. DB: 
Database, and SQL:  Structure Query Language. 
 
Figure 3.2-4 illustrates the user’s view of a Tissue Microarray slide before a specific 
spot is selected. A spot must be clicked on to view a scaleable image. Once selected, the 
spot is reviewed in a pop-up window and the option to record results via a scoring form 
is presented. Figure 3.2-5 illustrates the spot with the associated scoring form. The 
administrator has the ability to create new scoring forms, depending on the user’s 
specifications.  
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Figure 3.2-4: Overview of digital Tissue Microarray slide as presented in the VTM 
interface. Clicking on any spot will result in an enlarged version of the spot being 
provided, as in Figure 3.2-5.  
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Figure 3.2-5: Scoring form presented to users within the VTM interface. Results can be entered into the scoring form on the left, the 
image can be magnified and scrolling is possible via the controls provided.  
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3.2.6 Users, Scales and Parameters recorded 
Two pathologists and one research scientist scored the immunohistochemically stained 
Tissue Microarray slides. One of the former was an external examiner, completing a 
virtual review of one slide from an international location. This review was conducted to 
ensure the VTM functioned in a remote location and to ensure that a user who had no 
contribution to the design phase could use the VTM software system. As a result of 
having only one data set from this user, their observations were not included in the 
results that follow. 
 
Review methods included a microscope-based review (glass slide) and a virtual slide 
review. The glass slide review was a traditional microscope-based process; the virtual 
review was performed over the World Wide Web using the VTM. Eight parameters 
were examined for each spot. The amount and intensity of membrane, cytoplasmic and 
nuclear staining, as well as the amount of core and tumour present in each spot, were 
recorded. A five-point scale was used to record the staining intensity. Within the five-
point scale, grade 0 represented no staining, grade 1 was weak staining, grade 2 was 
moderate staining and grade 3 was strong staining. Grade 4 was included to record 
variable staining; this option was only available when scoring membrane staining.  
 
A four-point scale was used to record the amount (%) of staining present in tumour-
containing regions of each spot. Grade 0 represented no staining, grade 1 represented 1-
30% of relevant cells staining, grade 2 represented 31-50% staining and grade 3 
represented greater than 50% staining. An eleven-point scale was used to record the 
amount of core and tumour present. Grade 0 was negative/no tissue, and grade 1 to 10 
increased in 10% increments to 100%.  
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3.3 Results  
Two reviewers (Users A and B) examined 183 Tissue Microarray spots (196 minus 12 
control spots and one un-reviewed spot) stained with 3 immunostains using both review 
methods (microscope and VTM). Neither user reported any technical difficulties when 
performing virtual or glass analysis. The levels of intra- and inter-observer variability 
between virtual and microscope-based (glass) Tissue Microarray reviews were assessed 
for parameters examining the amount of core and tumour present, the amount and 
intensity of membrane, cytoplasmic and nuclear staining.  Table 3.3-1 illustrates the 
intra-observer variability between virtual and glass Tissue Microarray reviews. Good 
levels of agreement (> 60%) between methods were observed when quantifying the 
amount of core present, the amount of membrane, nuclear and cytoplasmic staining and 
nuclear intensity. Low levels of agreement between methods were observed when 
quantifying the amount of tumour present and membrane intensity. 
 
Virtual vs. Glass was the average of two users’ agreements when comparing virtual with 
glass Tissue Microarray reviews. User A vs. B Virtual was User A virtual Tissue 
Microarray review compared with User B virtual Tissue Microarray review. User A vs. 
B Glass was User A glass Tissue Microarray review compared with User B glass Tissue 
Microarray review. 
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Table 3.3-1: Agreement levels (%) and un-weighted kappa values by measured parameter for each comparison of Tissue Microarray 
reviews.  Agreement levels which are extremely low have been highlighted in grey. 
Parameters Intra-Observer Inter-Observer 
 Virtual vs. Glass User A vs. B Virtual User A vs. B Glass 
 % Agreement Kappa % Agreement Kappa % Agreement Kappa 
% Core Present 71.3 0.507 67.1 0.414 67.4 0.448 
% Tumour Present 47.3 0.407 37.9 0.283 33.0 0.244 
% Membrane Staining 81.2 0.577 78.2 0.553 78.6 0.520 
% Cytoplasmic Staining 64.0 0.373 42.8 0.198 65.9 0.280 
% Nuclear Staining 85.0 0.226 84.9 0.524 95.8 0.239 
Membrane Intensity 32.4 0.167 25.3 0.153 77.1 0.447 
Cytoplasmic Intensity 58.2 0.306 50.8 0.263 65.2 0.234 
Nuclear Intensity 82.1 0.109 83.3 0.474 89.2 0.234 
114 
Table 3.3-1 illustrates the inter-observer agreement achieved when performing both 
virtual and glass Tissue Microarray reviews. Inter-observer agreements achieved when 
performing virtual Tissue Microarray reviews were comparable with inter-observer 
agreements achieved when performing glass Tissue Microarray reviews, for four out of 
eight parameters. The virtual Tissue Microarray review of the amount of tumour present 
achieved greater levels of inter-observer agreement than the glass Tissue Microarray 
review, of this parameter; however, the level of agreement between users for this 
parameter was very low for both methods of assessment. The glass Tissue Microarray 
review of the amount of cytoplasmic staining and intensity, and membrane staining 
intensity achieved greater levels of inter-observer agreement than the virtual Tissue 
Microarray review, of these parameters. 
 
The parameter, % Tumour present, was difficult to assess, with low agreement recorded 
for inter- and intra-observer agreements across virtual and glass Tissue Microarray 
reviews. As this parameter has equivalent levels of inter-observer variability for both 
virtual and glass Tissue Microarray reviews, it has to be assumed that poor performance 
is not based on the method, but more likely the size of the range used. A 10% interval 
was used to quantify the amount of tumour present, which appears to have been too 
restrictive for this parameter.  
 
Reviewers found quantification of the parameter membrane intensity difficult to 
reproduce between virtual and glass Tissue Microarray reviews. When users assessed 
membrane intensity using a microscope, they predominantly used two categories of 
staining intensity, negative and moderate. With the virtual Tissue Microarray review, 
users appeared to use the classifier more extensively, as illustrated in Figure 3.3-1. The 
assessment of intensity of immunohistochemistry, particularly the intensity of 
membrane-bound immnunostains is inherently difficult. For example, problems with 
HER-2 assessment by immunohistochemistry are well documented (Hoang et al., 2000, 
Ellis et al., 2005). 
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Figure 3.3-1: Distribution of the results for virtual and glass TMA reviews of 
cytoplasmic / membrane staining intensity and % cytoplasmic staining. Illustrates the 
distribution of the classifiers when using virtual and glass methods to (1A) Amount of 
cytoplasmic staining assessed by glass TMA review (1B) Amount of cytoplasmic 
staining assessed by virtual TMA review (2A) Cytoplasmic staining intensity assessed 
by glass TMA review (2B) Cytoplasmic staining intensity assessed by virtual TMA 
review (3A) Membrane staining intensity assessed by glass TMA review (3B) 
Membrane staining intensity assessed by virtual TMA review. 
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3.4 Discussion 
The objective of this chapter was to design and validate an online software application 
that presents Tissue Microarray images and stores associated review and clinical data. 
The result was the Virtual Tissue Matrix (VTM), which consists of Tissue Microarray 
images available at multiple magnifications, scoring forms to gather Tissue Microarray 
review data and a relational database to store the generated results.  
 
The VTM displays virtual Tissue Microarray images via a web site and facilitates the 
storage of Tissue Microarray data via a relational database. There are numerous 
advantages of using the VTM over other proposed software systems of its type. 
Downloading of the images is rapid. Only views that are requested by the user are 
returned at maximum resolution, thereby downloading the minimum required dataset. 
The VTM was designed in consultation with scientists and pathologists and, as a result, 
the reviewing process emulates the workflow involved in conventional Tissue 
Microarray reviews. The VTM interface is delivered in HTML, via a conventional web 
browser, allowing for intuitive user interaction. The VTM database is relational; a 
structure more suited to the storage of the object oriented dataset generated from Tissue 
Microarray experimentation than previous efforts incorporating flat files and 
spreadsheets for data storage. 
 
The ability to interpret virtual images using the VTM was validated, via assessment of 
inter- and intra-observer variability on two users’ evaluations of immunohistochemically 
stained Tissue Microarrays, using digital and microscope analysis. Eight parameters 
were evaluated, the amount of core and tumour present, the amount and intensity of 
membrane, cytoplasmic and nuclear staining. Comparisons evaluated in this study 
illustrated that intra- and inter-observer virtual Tissue Microarray reviews produced 
equivalent levels of agreement as intra- and inter-observer glass Tissue Microarray 
reviews, for four out of the eight parameters examined. Where discrepancies occurred it 
was dependent on the parameters and users involved. In all comparisons, low levels of 
agreement for the amount of tumour present were observed.  This was not surprising, as 
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the application of classifiers to any data continuum (data that does not naturally fall into 
discrete clusters) results in scoring variability around the interfaces of the classifier. This 
variability is increased when the number of classes are increased creating more 
interfaces. Also, of the two reviewers used, one was a scientist and one a pathologist. 
The scientist’s accurate interpretation of tumour/non tumour may potentially be 
questioned as a result of this work. 
 
Of particular interest were a large number of observations that were considered 
positively stained by virtual Tissue Microarray reviews, which were considered 
negatively stained when reviewed using a microscope. This was particularly evident 
when quantifying the amount of cytoplasmic staining, where virtual Tissue Microarray 
reviews observed substantially more positively stained spots than glass Tissue 
Microarray reviews. The additional positively stained spots were largely considered to 
stain between 1-30% of the tumour area and/or to be weakly stained. This suggests that 
virtual Tissue Microarray reviews may be more successful in allowing the identification 
of small areas of staining and/or where staining intensity is low. 
 
One proposed reason for the identification of staining when using digital images that 
was not observed with a microscope was the use of correcting adjustments to the image 
data during the digitising of Tissue Microarrays. Bulbs used in microscopes have a 
characteristic tint; in general this is yellow or straw coloured. However, this tint is 
removed when digitising slides using a corrective algorithm, potentially unmasking 
weak staining that would otherwise be attributable to background tint. Also, with 
microscope-based analysis, background light is adjusted to best suit each individual spot. 
When digitising the slides for this study, a constant background light intensity was used 
to digitise all slides for this study. 
 
Excluding nuclear staining, where positive staining was infrequent, agreement levels 
were low when examining staining intensity. When using a conventional microscope, in 
general, users failed to utilise all grades within the classifier to characterise positive 
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staining intensity; the category of moderate staining was repeatedly used when positive 
staining was observed, particularly for membrane staining. However, with digital 
reviews, all grades within the classifier were utilised more extensively, which suggests 
that the review of digital images gives a user more confidence to discriminate between 
different intensities and that subtle differences in intensity may be easier to detect when 
evaluating digital slides, than when using a microscope. This may be due to the 
standardisation in lighting while preparing the images. 
 
Exceptionally low levels of inter- and intra-observer agreement for both methods of 
review were observed when assessing membrane staining intensity. Users had difficulty 
on agreeing on the presence and degree of membrane staining intensity when using a 
four grade scale, and when agreement was observed membrane staining intensity was 
negative. The level of agreement achieved for membrane staining intensity was also 
influenced by the immunostain assessed. Intra-observer agreements levels differed by 
46.8% between users when comparing virtual and glass slide assessments of membrane-
bound E-cadherin staining intensity. Due to the level of inter- and intra-observer 
variability recorded for the quantification of membrane-bound immunohistochemical 
staining intensity, it is assumed that the accurate quantification of this parameter is 
inherently difficult. Therefore, the application of a computer-assisted image analysis 
algorithm for the quantification of membrane-bound immunohistochemical staining 
intensity may be beneficial. Image analysis would be particularly applicable to 
immunostains that prove difficult to assess; in this case E-cadherin staining. 
 
Human observers, while excellent at object classification, are inherently poor at 
quantifying intensities and areas to any degree of accuracy. Studies have shown that 
image analysis produces more reproducible results than pathologists for quantifying the 
intensity of staining, in relation to ß-catenin expression in Tissue Microarrays for colon 
cancer (Camp et al., 2002). Image analysis systems may identify subtle differences in 
staining intensity, which are not quantifiable by a human reviewer, thus leading to the 
better correlation of expression data to prognostic indicators. 
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Since the creation of the VTM there have been numerous advances in the technologies 
used for image acquisition (Gomez et al., 2006, Stelldinger and Kothe, 2006, Yasuda et 
al., 2005) and image analysis techniques and applications have been well documented in 
literature (Warford et al., 2004, Ho et al., 2006, Hansen et al., 2004, Patton et al., 2006, 
McCullough et al., 2004, Della Mea et al., 2005). Integrated intuitive systems such as 
Aperio or Dmetrix are now available that rely on minimal human intervention when 
scanning slides (Weinstein et al., 2004). Numerous commercial image acquisition 
applications are now available (Aperio Technologies Inc., USA: D.Metrix, USA: 
Applied Imaging, USA); however, cost of purchase is often high for these integrated 
systems, putting them out of reach for many research laboratories. 
 
The validation of the VTM illustrated the need for online databases which integrate 
Tissue Microarray images and an associated database for information storage.  Since the 
VTM was created, the software has been developed considerably and released as a 
commercially available software application called Distiller by a Dublin City University 
based company (SlidePath, Ireland). Distiller is not constricted to Tissue Microarray 
images or data. It is a fully configurable and customisable web-enabled image 
informatics management system for life sciences data. Distiller also provides statistical 
analysis capabilities. Due to the extra functionalities available within Distiller, it has 
been used in subsequent chapters as an alternative to the original VTM technology. 
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3.5 Conclusions 
The Virtual Tissue Matrix (VTM) was created to assist in Tissue Microarray analysis, by 
providing digital Tissue Microarray images at multiple magnifications online and 
submitting Tissue Microarray review data from an online form into an associated 
database. The VTM illustrated that digital Tissue Microarray analysis obtained 
equivalent levels of agreement as microscope-based analysis, for four out of eight 
parameters. The remaining four parameters achieved greater levels of agreement when 
performed using microscope analysis. However, on further investigation of the four 
parameters, it is proposed that the digital reviews may be providing the user with greater 
capability to accurately assess staining presence and intensity. Results illustrate that 
users were incapable of agreeing when comparing digital and microscope Tissue 
Microarray reviews. Particularly when classifying staining intensity. Results illustrated 
that staining was identified when using digital images that was not observed with 
microscope-based reviews. It is suggested this is due to the background correction step 
involved in digitising the slides. 
 
Comparisons of digital with standard glass reviews of immunohistochemistry stained 
slides is well documented in literature; however, in order to validate the VTM, it was 
necessary to perform this study. As previously reported in literature, there was some 
degree of inter- and intra-observer variability. However, the ability of users to observe 
more positive staining when performing digital reviews, and the inability of users to 
utilise all categories within the classifiers provided when performing glass reviews are 
previously unreported in literature.  
 
Membrane staining intensity proved to be inherently difficult to assess, and high levels 
of inter- and intra-observer variability were observed for this parameter. The type of 
immunostain under assessment also influenced the level of inter- and intra-observer 
agreement. Inter- and intra-observer agreement was particularly low for E-cadherin 
staining, compared to the two alternative antibodies (ß-catenin and PhosphoMet). It is 
suggested that the introduction of a computer-assisted image analysis algorithm for the 
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quantification of membrane-bound immunohistochemical staining intensity may be 
beneficial, especially for immunostains that prove difficult to assess. 
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CHAPTER 4: CREATION OF CELL MICROARRAYS; 
PROTEIN PROFILING PERFORMED BY AUTOMATED 
IMAGE ANALYSIS 
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4.1 Introduction 
Worldwide, lung cancer is the most common cancer in terms of both incidence and 
mortality with 1.04 million new cases diagnosed per year and 921,000 deaths, with the 
highest rates currently observed in Europe and North America. Once diagnosed, the 5-
year survival rate for lung cancer in Europe fluctuates between 8-12% (Guessous et al., 
2007). Breast cancer is a leading cause of cancer deaths in women all over the world, 
with approximately 12% of women directly affected by this disease (O'Driscoll and 
Clynes, 2006). Between 40-50% of patients diagnosed with breast cancer will eventually 
die of the disease, despite advance in treatment (Jemal et al., 2002). In order to decrease 
disease-related mortality, it is vital to determine the optimal treatment method for each 
individual patient and to identify subgroups of patients who might benefit from 
individualised treatment strategies. Identification of prognostic and predictive biological 
markers will facilitate this (Larkin et al., 2004).  
 
Cell culture is an important research tool. It plays a vital role in assessing the 
characteristics of tumour cells, it helps us to determine how their growth can be 
manipulated by different culture conditions and also aids in the identification of 
potential therapeutic agents (Waterworth et al., 2005). The most commonly applied 
technique for the study of proteins in cultured cells are immunoprecipitation and 
Western blotting, which use protein-antibody interactions to qualify protein levels. 
These techniques are qualitative but do not provide information on the subcellular 
localisation of proteins, unless cell fractionation is performed first (Li et al., 2005).  
Immunocytochemical study of cultured cells has the advantage of directly visualising 
intact cells and enables localisation of the target proteins to subcellular compartments, 
but it is associated with many technical difficulties (Li et al., 2005). However, due to the 
heterogeneity of most tumours it is important to use an investigational technique such as 
immunohistochemistry, that can provide direct morphological confirmation of the 
presence of protein rather than “bulk” methods such as Western blotting (Moran et al., 
1997b). 
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Tissue Microarrays facilitate gene expression and copy number surveys of large cohorts 
of tumours simultaneously (Kononen et al., 1998). Utilising Tissue Microarrays, 
disease-specific expression of a gene can be identified and, therefore, a possible 
diagnostic test and treatment against a specific target can be developed (Simon et al., 
2003). In general, current knowledge regarding mechanisms underlying malignant 
transformation, differentiation, and other cellular processes originates from experiments 
performed on cell lines (Stromberg et al., 2007). Microarrays constructed from cell lines 
are an adaptation of the traditional Tissue Microarray format. Such Cell Microarrays 
(CMAs) are useful for rapid characterisation of the expression profiles of multiple cell 
lines relevant for cancer research. Cell Microarrays are powerful tools for the screening 
of new reagents, including hybridisation probes and antibodies. The standardisation of 
staining procedures and reduction of intra-assay variability can also be significantly 
improved with this technique (Hoos and Cordon-Cardo, 2001).   
 
Image analysis algorithms, which quantify immunohistochemical staining intensity, can 
be developed using cell lines, rather than using complex heterogeneous tissue 
(Stromberg et al., 2007). The application of image analysis algorithms to quantify 
immunohistochemically stained cell lines has been described in literature (Pick et al., 
2007, Brown et al., 2004, Stromberg et al., 2007, Messersmith et al., 2005, Dolled-
Filhart et al., 2006).  Automated Quantitative Analysis (AQUA) was used to compare 
protein expression levels of HSP90 across 10 cell lines and 655 human breast 
carcinomas. HSP90 protein expression is reported as being high in breast cancer cell 
lines; however, expression levels had not been previously reported in human tumours.  
Results illustrated that greater variability in HSP90 expression was seen in tumours than 
in cell lines. Subsequently, AQUA was used to evaluate the correlation of HSP90, ER, 
PR and HER-2 protein expression with breast carcinoma-specific survival across the 
entire patient cohort. Results indicated that HSP90 expression retained its prognostic 
significance in a multivariate setting. Within this study, utilising AQUA the authors 
identified a potential biomarker in breast carcinoma (Pick et al., 2007). 
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The prognostic value of ß-catenin in breast cancer has been assessed using AQUA 
(Dolled-Filhart et al., 2006). ß-catenin protein expression across 8 cell lines created into 
a Cell Microarray was assessed using ELISA and AQUA. A standard curve of protein 
expression was generated from ELISA and AQUA results. Comparison of AQUA and 
ELISA results showed a high level of correlation (r2 = 0.728).  The standard curve was 
subsequently used to quantitatively evaluate ß-catenin protein concentration in breast 
tumour Tissue Microarrays from AQUA results. The creation of the standard curve for 
ß-catenin expression was possible as the 8 cell lines selected showed a range of protein 
expression levels by ELISA. Using the standard curve model and AQUA, the authors 
concluded that ß-catenin is an independent predictor of patient outcome in breast cancer 
(Dolled-Filhart et al., 2006).  
 
Quantitative assessment of protein expression across Tissue and Cell Microarrays 
composed of colorectal tumour and normal colon tissue was performed by Automated 
Cellular Imaging System (ACIS), and compared against cell line Western blotting, 
ELISA and human scoring by a pathologist (Messersmith et al., 2005). Cell Microarrays 
were immunohistochemically stained with 6 antibodies for 6 antigens (EGFR, pEGFR, 
Akt, MAPK and pMAPK). Similar protein expression levels were observed when 
assessed by ACIS and Western blots, for all 6 targets. However, protein expression was 
only compared for a single cell line. ELISA results from 8 cell lines indicated variable 
expression of EGFR was compared with ACIS analysis. A scatter plot of ACIS scores 
and ELISA results demonstrated good correlation between the two methods of 
assessment (r2 = 0.697). A total of 99 normal and cancerous colon tissue samples were 
examined for total protein expression by ACIS and human analysis using a semi-
quantitative scale (0-3+). A significant correlation was observed when comparing ACIS 
and human analysis scores for all six antibodies (ANOVA, p < 0.001) (Messersmith et 
al., 2005). 
 
This chapter describes the creation of a Cell Microarray from 31 cell lines (lung and 
breast). Sections from the Cell Microarray were immunohistochemically stained with 6 
antibodies. Slides were digitised and protein expression was quantified by image 
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analysis, human analysis and Western blot/ELISA, in order to validate the application of 
the low cost high-throughout algorithm for Cell Line analysis. To date, this is the largest 
cohort of cell lines which has been analysed by automated image analysis. Using image 
analysis, protein expression which was previously unpublished has been quantified. A 
brief description of the antigens under assessment within this Chapter follows: 
 
A major problem encountered during chemotherapy treatment of many tumour types is 
the development, by the target tumour cells, of resistance to a broad spectrum of drugs, a 
phenomenon known as Multidrug Resistance (MDR) (Moran et al., 1997b). MDR 
occurs in approximately 84% of patients who receive chemotherapy (Larkin et al., 
1999).  Multidrug resistance is characterised by resistance to a broad range of 
structurally and functionally unrelated chemotherapeutic drugs including antracyclines, 
vinca, alkaloids, epipodophyllotoxins, and taxanes. Having prior knowledge of the 
presence of such resistance would decrease morbidity from unsuccessful therapy and 
allow for the selection of individuals who may benefit from the co-administration of 
MDR-inhibiting drugs (Kurdziel et al., 2007).  
 
Several mechanisms of resistance have been identified including; disruption in cell 
signalling, alterations in drug targets or activation of de-toxifying systems. One of the 
mechanisms that may be clinically active in lung and breast carcinomas is the prevention 
of intracellular drug accumulation by the expression of transporter proteins that pump 
drugs out of cells before they can reach their sites of action. Several of these proteins 
belong to the ATP (adenosine triphosphate)-binding cassette (ABC) transmembrane 
protein superfamily that utilise energy from ATP hydrolysis to translocate substrates 
across cell membranes (O'Driscoll and Clynes, 2006, Leonessa and Clarke, 2003). 
 
Multidrug resistance is mediated by P-glycoproteins (P-gp). P-gp belongs to the ATP-
binging cassette (ABC) transmembrane proteins. P-gp is an energy-dependent pump, 
capable of transporting hydrophobic compounds out of the cell (Ambudkar et al., 1999). 
P-gp is frequently found to be overexpressed in post-chemotherapy tumours and its 
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expression is associated with decreased cellular uptake of chemotherapy drugs. 
Therefore, allowing cells to survive in the presence of higher drug concentrations. At 
least three P-gp genes have been identified in humans, MDR-1/P-gp, MDR-3 and MRP-
1.  
 
The Multiple drug resistance 1 (MDR-1) gene encodes P-glycoprotein a 170 kDa plasma 
membrane protein consisting of 12 transmembrane domains and 2 ATP-binding 
domains. MDR-1/P-gp is expressed in a large number of normal tissues including, 
gastrointestinal tract, brain, testes, ovaries, kidney, adrenal glands, large intestine and 
liver. The physiological role of MDR-1/P-gp has not been clearly defined; however, it 
may include detoxification and excretion of xenobiotics, as well as hormone transport 
(O'Driscoll and Clynes, 2006). Tumours arising from tissues that normally express 
MDR-1/P-gp may be intrinsically resistant to chemotherapeutic agents or, alternatively, 
tumours that were initially responsive to chemotherapy may develop multidrug 
resistance during the treatment regimen and subsequently not respond to therapy (Moran 
et al., 1997b). MDR-1/P-gp gene and protein expression in untreated breast carcinomas 
have been reported to range from 0-100% (Larkin et al., 2004, Leonessa and Clarke, 
2003, Kroger et al., 1999). The role of MDR-1/pgp in lung cancer has not been widely 
reported in literature. 
 
MRP-1 is a plasma membrane protein involved in the active efflux of cytotoxic 
materials from the cell (Moran et al., 1997b), the protein may play a role in the 
prediction of response to chemotherapy of breast cancer. MRP-1 is expressed by a 
considerable number of untreated breast tumours (range 10-100% by 
immunohistochemistry) (Leonessa and Clarke, 2003, Trock et al., 1997, O'Driscoll and 
Clynes, 2006). MRP-1 expression is an important predictor of poor prognosis in patients 
with recurrent breast cancer (Nooter et al., 1997). Both MDR-1/P-gp and MRP-1 were 
found to be frequently expressed in non small cell lung carcinomas (38 cases); however, 
MDR-1/P-gp was predominant over MRP-1 protein (Roy et al., 2007).  
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MDR-3 is thought to be the most highly conserved P-gp gene amongst various 
mammalian species (Larkin et al., 1999, Matthews et al., 2006, Morita et al., 2007, 
Russell et al., 1994, Swales et al., 2006). MDR-3 is highly expressed in liver and is 
thought to function as a hepatic transporter of phospholipids into bile.  There is evidence 
to suggest that the overexpression of MDR-3 may be a potential prognostic indicator in 
chronic lymphocytic leukaemia (Matthews et al., 2006). However, MDR-3’s role in 
breast or lung carcinoma, if any, remains undefined. 
 
The epidermal growth factor receptor (EGFR), a member of the ErbB / HER family of 
receptor proteins, initiates a complex signalling cascade which influences many facets of 
tumour cell biology including growth, survival, and responsiveness to chemotherapy 
(Messersmith et al., 2005, Mendelsohn and Baselga, 2003, Baselga and Arteaga, 2005). 
EGFR protein is overexpressed in 16 - 48% of human breast carcinomas and up to 80% 
in non small cell lung carcinomas (Klijn et al., 1992, Tsutsui et al., 2002, Grenier and 
Soria, 2007). The validity of EGFR as a useful prognostic factor for breast cancer is still 
uncertain. The lack of standardized assessment methods and interpretation criteria for 
EGFR expression may contribute to the conflicting results in the prognostic role of 
EGFR expression in breast cancer (Park et al., 2007).  However, in non small cell lung 
carcinoma, EGFR mutational analysis is an excellent predictor of responsiveness to 
treatment with tyrosine kinase inhibitors, such as gefitinib (Daniele et al., 2007). At least 
three anticancer agents targeting EGFR are already FDA-approved and several others 
are in development (Messersmith et al., 2005).  
 
HER-2/neu is a member of the human epidermal growth factor (HER-2) receptor family. 
The overexpression of this gene has been found to contribute to oncogenic 
transformation, tumourgenesis and metastatic potential and it is reported to be a negative 
prognostic factor (Tawfik et al., 2006). HER-2 is amplified and overexpressed in 10–
30% of women with breast cancer (Slamon et al., 1987, Slamon et al., 1989, Borresen et 
al., 1990). HER-2 as a prognostic indicator in breast carcinomas has been extensively 
investigated in literature. A humanised monoclonal antibody (HerceptinTM) targeting the 
oncogene shows therapeutic benefits especially when combined with conventional 
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chemotherapeutic agents in treatment of patients with metastatic breast carcinoma 
(Camp et al., 2003, Slamon et al., 1987, Seidman et al., 2001, Winer and Burstein, 2001, 
Baselga et al., 1996, Carter et al., 1992). HER-2 amplification is observed in 2-23% of 
non small cell lung carcinomas (Swanton et al., 2006). HER-2 gene amplification and 
protein overexpression are a indication of poor prognosis in non small cell lung 
carcinoma (Szelachowska et al., 2006, Zeng et al., 2006). 
 
E-cadherin is a transmembrane glycoprotein involved in intercellular adhesion 
(Mahnken et al., 2005, Bukholm et al., 1998). E-cadherin mediates the selective 
adhesion of epithelial cells that is required for the interaction and maintenance of normal 
integrity (Takeichi, 1991). Reduced expression of the E-cadherin adhesion complex in 
lung cancer cells is associated with dedifferentiation, increased invasiveness, metastasis, 
and poorer survival (Bremnes et al., 2002b, Shibanuma et al., 1998, Sulzer et al., 1998). 
Loss of E-cadherin expression also correlates with poor prognosis in breast carcinoma 
(Jeschke et al., 2007). Reduced expression levels of E-cadherin has been observed in 
invasive lobular carcinoma, but not in invasive ductal carcinoma of the breast 
(Turashvili et al., 2007). 
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4.2 Study Design 
Cell Microarrays were created from 31 cell lines (lung and breast). The creation and 
immunohistochemical staining of the Cell Microarrays is described in detail in Chapter 2 
section 2.3.1. Protein expression was quantified by human/image analysis and compared 
with Western/ELISA data. See Chapter 2 section 2.3.2 and 2.3.3, respectively. Cell 
Microarrays were digitised at 20 x magnification using an Aperio ScanScope T3 
Scanner™ (Aperio Technologies, USA). Images were approximately 30 Mb per Cell 
Microarray.  
 
4.2.1.1 Human Analysis 
Human analysis of the immunohistochemically stained cells was performed by one 
reviewer, utilising Distiller (SlidePath, Ireland). Protein expression was categorised as 
positive or negative. Cases that were deemed positive by human analysis were further 
assessed by image analysis.  
 
4.2.1.2 Image Analysis 
Image analysis categorised staining intensity on a continuous scale between 0 and 255, 
were 0 is the strongest staining possible and 255 is the weakest staining possible. 
Subsequently, cut-points were created to classify staining intensity as Weak (> 140), 
Moderate (84 - 140) and Strong (< 84). Cut-point selection was based on human 
interpretation of image analysis data.  Normalisation was not performed on image 
analysis data, as inter-slide comparisons were not performed. Therefore, the variance of 
background light or staining procedure did not affect results. 
 
4.2.2 Sample Cohort 
In total, this study consisted of 186 tissue spots immunohistochemically stained for 6 
antibodies (31 cell lines x 6 antibodies). However, a number of spots were lost or 
damaged due to tissue processing (n = 14). Therefore, 172 cases were available for 
analysis. Protein expression, as quantified by Western blot (n = 39) or ELISA (n = 23), 
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was available for 62 cases in total.  The distribution of samples available for analysis per 
antibody is illustrated in Table 4.2-1. 
 
Table 4.2-1: Distribution of cell lines available for immunohistochemical analysis and 
protein expression results available when assessed by Western blot /ELISA. 
Antibody Cell Lines  Western blot ELISA Total Assays 
E-cadherin 22 2 0 2 
EGFR 31 2 10 12 
HER-2 30 4 13 17 
MDR-1 29 15 0 15 
MDR-3 30 4 0 4 
MRP-1 30 12 0 12 
Totals 172 39 23 62 
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4.3 Results 
Cell Microarrays composed of 31 cell lines were immunohistochemically stained with 
six antibodies targeting MRP-1, MDR-3, MDR-1/P-gp, HER-2, EGFR and E-cadherin 
proteins. Protein expression was qualified by human analysis of immunohistochemistry, 
Western blots, ELISA and image analysis. The level of agreement between human 
analyses of immunohistochemically stained cell lines and Western blot/ELISA was 
assessed. Across this cohort of cell lines, previously unreported protein expression was 
determined utilising high-throughput image analysis.  
 
4.3.1 Comparison of Protein Expression 
The expression levels of six proteins across 31 cell lines were assessed utilising 
immunohistochemistry, Western blots and ELISA. Immunohistochemistry was assessed 
visually by a single reviewer (the author) using Distiller. Protein expression recorded by 
the three classification methods were categorised as positive or negative. The level of 
agreement between immunohistochemistry and Western blots/ELISA assessments is 
illustrated in Table 4.3-1. Overall agreement between immunohistochemical reviews and 
Western blot/ELISA was 70.96%. The highest levels of agreements were observed when 
HER-2 and EGFR protein expression was assessed. There was no agreement observed 
when E-cadherin protein expression was assessed. However, only two Western blots 
were available for comparison. Generally, the majority of disagreement arose when 
protein expression was considered positive by Western blots/ELISA methods and 
negative when assessed by immunohistochemistry. In addition, disagreement between 
Western blot and ELISA results was observed for one case out of a total 6 cases where 
results were available for both assays (83.33% agreement). In this one case of 
disagreement between Western blot and ELISA, image analysis results correlated with 
ELISA results. 
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Table 4.3-1: Complete agreement between protein expression levels when quantified by immunohistochemistry and Western 
blots/ELISA. Disagreement between review methods occurred when protein expression was observed by immunohistochemical 
analysis and not Western blot/ELISA (IHC Pos+) or protein expression was observed by Western blot /ELISA and not 
immunohistochemical analysis (Western blot /ELISA Pos+). 
Antibody % Agreement Cases Compared IHC  
Pos+  
Western blot /ELISA 
Pos+  
E-cadherin 0.00 2 - 2 
EGFR 91.66 12 1 - 
HER-2 88.23 17 1 1 
MDR-1 60.00 15 1 5 
MDR-3 75.00 4 - 1 
MRP-1 50.00 12 - 6 
Totals 70.96 (Overall) 62 3 15 
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Figure 4.3-1 and Figure 4.3-2 illustrate cell lines immunohistochemically stained. For all 
cases illustrated in Figure 4.3-1 and Figure 4.3-2 the level of protein expression differed 
when assessed by immunohistochemistry and Western blot/ELISA. E-cadherin protein 
expression was not observed for DLKP Parent and DLKP VCR when assessed by 
immunohistochemistry (Figure 4.3-1). However, both of the cell lines apparently 
expressed E-cadherin protein when assessed by Western blots. Figure 4.3-2 illustrates 
the immunohistochemical staining of BT20 and DLKP Txt YL with HER-2 and EGFR, 
respectively. BT20 and DLKP Txt YL expressed HER-2 and EGFR protein, 
respectively, when assessed by immunohistochemistry. However, no expression of these 
proteins was observed when BT20 and DLKP Txt YL were assessed by Western blot 
and ELISA, respectively.  
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Figure 4.3-1: DLKP VCR and DLKP Parent do not express membrane E-cadherin when 
assessed by immunohistochemistry. However, when assessed by Western blot/ELISA 
protein expression was observed. 
DLKP VCR – E-cadherin 
DLKP Parent – E-cadherin 
136 
 
Figure 4.3-2: DLKP Txt YL and BT20 expressing membrane EGFR and HER-2, 
respectively, when assessed by immunohistochemistry. However, neither cell lines 
express EGFR or HER-2 proteins when assessed by Western blot or ELISA. 
 
 
 
BT20 - HER-2 
DLKP Txt YL - EGFR 
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4.3.2 Protein Expression assessed by Image Analysis 
Table 4.3-2 illustrates membrane expression levels for 6 membrane proteins across the 
31 cell lines, when assessed by image analysis. Cases where immunohistochemical 
assessment and Western blot/ELISA differed have been noted within the Table. Staining 
intensity was categorised as Weak (> 140), Moderate (84-140) or Strong (< 84), based 
on cut-offs generated by comparisons with human analysis of immunohistochemical 
staining. The majority of positive staining was classified as weakly stained. There were a 
number of cell line cores which were lost due to processing and are noted in the Table as 
(-). The majority of protein expression illustrated in Table 4.3-2 is previously 
unpublished. Cases where Western blot or ELISA data was available for comparisons 
are shaded within Table 4.3-2. 
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Table 4.3-2: Protein expression of 6 membrane proteins across 31 immunohistochemically-stained cell lines. Cases where 
immunohistochemistry disagrees with Western blot/ELISA have been noted within the Table.  Cases were protein expression was 
observed when assessed by Western blot/ELISA methods, and not during immunohistochemical analysis are denoted as 1 within the 
table.  Cases were protein expression was observed when assessed by immunohistochemistry and not during Western blot/ELISA 
analysis are denoted as 2 within the table. Cases were Western blot/ELISA results were known are shaded within the table. 
Cell Lines   MRP-1 MDR-3 MDR-1/P-gp HER-2 EGFR E-cadherin 
A549 Parent Negative 1 Weak Negative Negative Strong  Negative 
A549 Taxol Negative 1 Weak Negative Negative Moderate Negative 
BT20 Weak  Weak Weak Moderate 2 Weak      - 
BT474 Negative  Weak Negative Moderate Negative Moderate 
DLKP Parent Negative 1 Weak Negative Negative Negative Negative 1 
DLKP JC  Negative Negative      - Negative Weak      - 
DLKP Txt RL       -      -      -      - Weak      - 
DLKP Txt YL  Weak Weak Negative 1 Negative Weak 2 Negative 
DLKP VCR Negative 1 Weak Negative Negative Weak Negative 1 
DLKP YL  Negative Weak Negative Negative Weak      - 
DLRP  Parent Negative Negative Negative Negative Moderate      - 
DLRP Carboplatin Negative Weak Negative Negative Strong       - 
DMS 53 Parent Negative Negative 1 Negative Negative      - Negative 
DMS 53 Taxol Negative Negative Negative 1 Negative Negative Negative 
DMS 53 Taxotere Negative Negative Negative 1 Negative      - Negative 
DMS 53 Carboplatin Weak Negative Weak Negative Negative Negative 
H460 Parent Negative 1 Weak Negative Negative Weak      - 
H460 Taxol  Negative 1 Weak Negative Negative Moderate      - 
HCC 1419 Negative Negative Negative Weak Negative Moderate 
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HCC 1954 Negative Weak Negative Strong  Weak Moderate 
MCF-7 Weak Weak Weak Negative 1 Negative Moderate 
MDA-MB-231 Negative Negative   Negative Negative Moderate Negative 
MDA-MB-453 Negative Weak Negative Weak Negative Negative 
MDA-MB-468 Negative Negative Negative Weak Negative Negative 
NCI-H1299 Parent Negative Weak Negative 1 Negative Weak Negative 
NCI H1299 Taxol Negative Weak Negative 1 Negative Weak Negative 
SK-BR3 Negative Weak Negative Moderate Weak Negative 
SKLU-1 Parent Negative Weak Negative Negative Strong  Negative 
SKLU-1 Taxol Weak Weak Weak 2 Negative Weak Negative 
SK-MES-1 Parent      -      -      - Negative Weak      - 
SK-MES-1 Carboplatin Weak Weak Negative Negative Weak Negative 
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4.4 Discussion 
Thirty-one lung and breast cell lines were cultured and created into a Cell 
Microarray. Sixteen cell lines were uniquely developed within the NICB. Sections 
were cut and immunohistochemically stained with 6 antibodies targeting cellular 
membrane proteins. Immunohistochemical staining was qualified by human analysis 
and compared to expression data obtained from Western blots and ELISAs. Positive 
membrane staining across all Cell Microarrays was classified using high-throughput 
automated image analysis. 
 
When membrane staining intensity was qualified by human analysis, agreement 
levels between Western blot/ELISA and immunohistochemistry varied greatly 
depending on the antibody assessed. Agreement levels between methods were lowest 
when assessing the P-glycoproteins (MRP-1, MDR-1/P-gp and MDR-3). No 
agreement was observed between methods when assessing E-cadherin expression. 
However, only two cell lines were compared for E-cadherin expression (DLKP 
Parent and DLKP VCR). No E-cadherin protein expression was observed for either 
of the cell lines when assessed by immunohistochemistry (Figure 4.3-1); however, 
protein expression was observed for both cell lines when assessed by Western blots. 
In this instance, literature would suggest that immunohistochemical analysis was 
correct when qualifying E-cadherin expression in DLKP Parent (Liang et al., 2004); 
however, protein expression for DLKP VCR is unreported in literature. On average, 
agreements between immunohistochemistry and Western blot/ELISA were high 
when assessing protein expression with the 6 antibodies.  
 
The majority of disagreements between Western blot/ELISA and 
immunohistochemistry occurred when protein expression was observed by Western 
blot/ELISA and not observed when assessed by immunohistochemistry. For a 
number of cases, the positivity observed when assessed by Western blot/ELISA was 
also reported in literature (DLKP Parent - MRP-1, DLKP VCR - MRP-1, DLKP 
VCR - MDR-1, DLKP Parent - MDR-1, DLKP Txt YL - MDR-1 (Liang et al., 2004) 
and H460 Parent - MRP-1 (O'Connor et al., 2004)). There were cases where both 
Western blot/ELISA and immunohistochemistry suggested the protein was not 
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expressed, which contradicted reports in literature (MDA-MB-468 - EGFR (Konecny 
et al., 2006) and DLKP VCR- MDR-1/P-gp (Liang et al., 2004)).  
 
One proposed reason for the identification of staining when using Western 
blot/ELISA that was not observed with immunohistochemical analysis was the 
threshold created to identify positive membrane staining was set too high. The 
presence of positive staining was identified by a single reviewer’s assessment of the 
immunohistochemically stained cell lines. Human analysis, as previously described, 
is highly flawed when quantifying staining intensity, and in this study may have 
failed to identify expression which was identified by Western blots or ELISA. Direct 
comparison between quantitative ELISA and image analysis data within this study 
was not possible, due to the narrow range of protein expression observed within the 
23 cases assessed by ELISA. In future cell line assessments, it may be beneficial to 
have a validation set of samples with a complete set of quantitative data available in 
order to generate optimal cut-points. In addition, using the same antibody for ELISA 
and immunohistochemistry may prove beneficial, as differing affinities of antibodies 
for an antigen may contribute greatly to such discrepancies. However, the application 
of a single antibody for immunohistochemistry, Western blots and ELISAs analysis 
may prove difficult to achieve. 
 
Digital assessment of immunohistochemically stained cell lines, rather than tissue, 
adds an additional layer of complexity for human analysis. Consistent and high 
image quality is a prerequisite for reliable and accurate scoring of digital images. To 
ensure high-throughput and high quality images, all immunohistochemically stained 
Cell Microarrays were scanned using an automated slide scanning system. Certain 
cell types within the cell lines are compact cells with little cytoplasm, which are 
features complicating the process of obtaining well-focused images (Stromberg et al., 
2007). During the digitisation of all spots in the Cell Microarrays, it is likely that a 
subset of images with suboptimal focus may have been included and, therefore, 
possibly adversely affecting the analysis. In addition, the density of the cells was 
extremely high. Cell Microarrays were constructed from cell pellets created by 
packing cell line pellets into agarose molds (as described in Chapter 2, section 
(2.1.4.1)). This resulted in a very dense cell pellet, which may have been too high 
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density of cells for immunohistochemical analysis. Control cell lines present within 
the Cell Microarrays were constructed within the Tissue Array Research Program 
(USA), using cell suspension techniques. This technique appeared to be better suited 
to Cell Microarray creation as cells were evenly distributed within the cores.  
  
High-throughput image analysis was performed in order to quantify protein 
expression across all cell lines which were immunohistochemically stained with 6 
antibodies. For the majority of these, protein expression was previously unreported in 
literature. Utilising image analysis, protein expression was quantified on a 
continuous scale, which was subsequently divided into a semi-quantitative scale 
(Weak, Medium and Strong); thus, allowing comparison with previous and 
subsequently published expression levels, the majority of which are classified semi-
quantitatively. Utilising the harness provided by Distiller, image analysis was 
extremely high-throughput. Analysis required approximately 5-8 minutes per Cell 
Microarray. Construction, immunostaining and image analysis on low density Cell 
Microarrays, such as the one described in this study, greatly increases the speed, 
standardisation and uniformity of analysis compared to Western blots/ELISA.  
 
Cell culture plays a critical role in tumour characterisation and the identification of 
novel therapeutic targets. Once the Cell Microarray block is created, the cell lines are 
formalin-fixed paraffin-embedded and are, therefore, preserved for future analysis. 
The Cell Microarray generated in this study provides a repository of cells available 
for subsequent protein expression profiling, optimisation of newly-developed 
antibodies, and identification of positive controls. To the best of our knowledge this 
is the largest repository of immunohistochemically-stained cell lines which have 
undergone protein expression profiling via automated image analysis. 
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4.5 Conclusion 
Cell Microarrays composed of 31 lung and breast cancer cell lines were 
immunohistochemically stained with 6 antibodies. Protein expression was qualified 
by human analysis, Western blots, ELISA and image analysis. The level of 
agreement between human analyses of immunohistochemically stained cell lines and 
alternative assays (Western blots and ELISA) was assessed.  
 
Overall, results illustrated a high level of agreement between immunohistochemistry 
and Western blots/ELISAs testing when assessing protein expression. Agreement 
was hugely influenced by the antigens under assessment. When disagreement 
between methods was observed, it was largely when immunohistochemistry failed to 
identify protein expression which was present when assessed by Western blots. 
Results illustrate the importance of creating optimal cuts-points when validating 
image analysis algorithms.  
 
In order to optimally validate the image analysis algorithm, a complete set of 
quantitative data would ideally be available. In addition, the application of a single 
antibody across Western blot/ELISA and immunohistochemistry if possible may 
introduce a high standard of uniformity into the analysis of protein expression. 
 
A Cell Microarray has been created which provides a repository of cells available for 
subsequent protein expression profiling. Utilising automated image analysis, a high-
throughput method for protein profiling of immunohistochemically-stained cell lines 
in a Tissue Microarray format has been achieved.  
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CHAPTER 5: APPLICATION OF AUTOMATED IMAGE 
ANALYSIS IN THE QUANTIFICATION OF 
IMMUNOHISTOCHEMICALLY STAINED BLADDER 
CANCER BIOPSIES 
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5.1 Introduction 
Immunohistochemistry is a well-established and versatile technique, which is 
routinely used in molecular and surgical pathology (Kononen et al., 1998, Cregger et 
al., 2006). Immunohistochemistry allows for the identification and localisation of 
cell-bound antigens and can be performed on numerous cells and tissue preparations 
(Fejzo and Slamon, 2001). Immunohistochemistry is widely used due to its relatively 
low cost, availability of materials in routine pathology laboratories and relatively 
rapid turn around. However, at best, immunohistochemistry is a semi-quantitative 
technique. 
 
Traditionally, human analysis has been considered the optimal method for qualifying 
immunohistochemical staining. However, the ability to quantify staining intensity by 
human analysis has produced varied results and is inherently flawed (Conway et al., 
2006). In addition, results from previous chapters indicate that the quantification of 
immunohistochemical staining is greatly influenced by the complexity of the 
immunostain under assessment.  Human analysis generally quantifies staining 
intensities into broad categories, rather than assigning exact staining intensity values. 
At present, alternative methodologies can accurately quantify protein signal when 
performed in conjunction with computer-assisted analysis. However, in some 
instances immunohistochemistry remains the primary technique utilised (Bartlett et 
al., 2003, Ellis et al., 2004, Hsi and Tubbs, 2004, Ellis et al., 2000, Hicks and Tubbs, 
2005, Kay et al., 2004).  
 
It has been proposed that computer-based analysis can quantify staining intensities 
more accurately and with greater reproducibility, than human-based analysis 
(Weaver et al., 2003, Johansson et al., 2001). There are numerous commercially 
available, computer-based systems designed for the quantification of 
immunohistochemical staining, including BLISS and IHCscore of Bacus 
laboratories, Inc (Lombard, USA); Ariol SL-50 Applied Imaging Corporation (San 
Jose, USA); AQUA, HistoRx Inc (New Haven, USA) (Cregger et al., 2006). 
However, automated quantification systems can be expensive, time-consuming and 
extremely complex.  
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Tissue Microarrays provide high-throughput analysis of immunohistochemically 
stained tissue (Kononen et al., 1998). Tissue Microarrays have numerous benefits 
over whole section analysis including uniform experimental conditions, conservation 
of scarce tissue and a reduction in the volume of reagents used (Simon and Sauter, 
2002, Al Kuraya et al., 2004, Milanes-Yearsley et al., 2002, Hoos and Cordon-
Cardo, 2001). Image analysis of Tissue Microarrays provides a high-throughput, 
reproducible and quantitative means of analysing immunohistochemically stained 
tissue. 
 
Urothelial cell carcinoma of the Bladder (UCB) is the 7th most common cancer 
worldwide in men (10.1 new cases per 100,000 person per year) and the 17th in 
women (2.5 new cases per 100,000 person per year) (Murta-Nascimento et al., 2007). 
There is quite a difference between incidence and mortality rates for patients with 
UCB; this would suggest that UCB has a long progression period. In the USA, the 5 
year relative survival rate ranges from 97% for those diagnosed with stage 1 UCB, to 
22% for those with stage 4 UCB, according to the Tumour Node and Metastasis 
(TNM) classification (Gloeckler Ries et al., 2003, Murta-Nascimento et al., 2007).  
The tumour stage and grade are already recognised as significant indicators of 
prognosis; more reliable and more useful indicators are required for the prognosis of 
patients with invasive bladder cancer (Kashibuchi et al., 2007). 
 
As described in Chapter 4; E-cadherin is a transmembrane glycoprotein involved in 
intercellular adhesion (Mahnken et al., 2005, Bukholm et al., 1998) which mediates 
the selective adhesion of epithelial cells for the interaction and maintenance of 
normal integrity (Takeichi, 1991). The correlation between E-cadherin expression 
and survival data continues to be debated (Campos et al., 2006, Kase et al., 2000, 
Zhou et al., 2002, Gamboa-Dominguez et al., 2005, Nakopoulou et al., 2000, Tamura 
et al., 2005, Chow et al., 2001, Brecelj et al., 2005, Bremnes et al., 2002a, Bringuier 
et al., 1993, Byrne et al., 2001, Shariat et al., 2001).  However, as evident from the 
previous chapter, high levels of inter- and intra-observer variability are present when 
E-cadherin staining is assessed by human analysis. Therefore, E-cadherin assessment 
performed by image analysis maybe of benefit.  
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E-cadherin is known to play a role in cell-cell adhesion through an intercellular Ca++ 
dependent hemophilic junction. E-cadherin associated molecules, including α-, ß- 
and γ-catenin, link the E-cadherin to the actin cytoskeleton. The dysfunction of cell-
cell adhesion molecules is related to the initial step of the invasion of the surrounding 
tissues and metastasis to distant organs. It has been recognised that the reduced 
expression of E-cadherin is closely related to the cell differentiation status and 
invasiveness of a tumour (Kashibuchi et al., 2007, Frixen et al., 1991, Vleminckx et 
al., 1991). The association of the catenins with E-cadherin is an essential requirement 
for the correct function and maintenance of cell adhesion within a tissue (Kashibuchi 
et al., 2007). α–catenin mediates the interaction of the cadherin and ß-catenin 
complexes with the cytoskeleton (Nathke et al., 1993), while ß-catenin directly binds 
to the cytoplasmic domain of E-cadherin and regulates cadherin-mediated cell 
recognition and adhesion (Peifer, 1993). Evaluation of effect of loss of E-cadherin 
and ß-catenin expression on prognosis in bladder cancer has previously been 
investigated (Moyano Calvo et al., 2006, Clairotte et al., 2006, Romanenko et al., 
2006, Nakopoulou et al., 2000). Both E-cadherin and ß-catenin loss of expression 
correlates with poor prognostic outcome; however, in a multivariate setting, poorer 
prognostic outcome is associated with E-cadherin expression only (Nakopoulou et 
al., 2000). Also, tumours which lack E-cadherin or ß-catenin have lower recurrence-
free time (Moyano Calvo et al., 2006).  To date, no fully automated quantitative 
analysis of urothelial cell carcinoma of the bladder stained for E-cadherin and ß-
catenin has been correlated with survival. 
 
The validation of an image analysis algorithm which quantifies membrane-bound 
immunohistochemical staining intensity is described in detail in this chapter. The 
validation of the algorithm involved performing quantification of membrane-bound 
E-cadherin protein expression across 26 Tissue Microarrays composed of urothelial 
cell carcinoma of the bladder. In order to access the optimal method of review and to 
verify the prognostic value of E-cadherin expression, human and image analysis 
were correlated with survival data. In addition, the correlation between E-cadherin 
and ß-catenin expression with prognostic outcome has been assessed across 25 of 
theses 26 Tissue Microarrays. As previously mentioned, the VTM has been replaced 
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with a commercially available software application know as Distiller, which was 
derived from the VTM prototype.  
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5.2 Study Design 
5.2.1 Patient Cohort 
A total of 26 Tissue Microarrays were constructed, comprising of 418, 2.0 mm cores 
from 145 consecutive cases of urothelial cell carcinomas of the bladder. The Tissue 
Microarrays were constructed and immunohistochemically stained for E-cadherin 
(Novocastra/Vision Biosystems, USA) and ß-catenin (Labvision Corp., UK) as 
described in Methods Chapter 2 section 2.3.1.3. A single slide was not available for 
the assessment of ß-catenin; therefore, the sample size was decreased to 141 for ß-
catenin assessment. A liver control spot derived from one biopsy was present on all 
slides. The liver control spot stained positive for E-cadherin and ß-catenin, and was 
used as a positive control to verify uniform staining across all Tissue Microarrays. 
Tissue Microarrays were digitised using an Aperio ScanScope T3 Scanner™ (Aperio 
Technologies, USA) at 20 x magnification, as described in Chapter 2 (section 2.4.2). 
 
5.2.2 Tumour Heterogeneity 
Multiple cores were sampled from different tumour areas to account for 
heterogeneity within any one tumour. The number of replicate cores from a single 
biopsy ranged from 1-5. Table 5.2-1 illustrates the number and distribution of replica 
cores taken from a single biopsy. The majority of biopsies were sampled 4 times (n = 
72 biopsies).  All cores could not be used for image analysis assessment of E-
cadherin and ß-catenin staining intensity. Cores were excluded from image analysis 
based on amount of core present. In order to eliminate mis-representation of the 
staining intensity present, all cases with less than 45% of the core present were 
excluded from this study. Cases available for image analysis assessment of E-
cadherin are within (brackets) in Table 5.2-1. An equal number of biopsies were 
assessed by human and image analysis. However, the number of cores assessed by 
human and image analysis differed slightly (418 and 386 cores respectively).  
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Table 5.2-1: Distribution of replica cores taken from a single biopsy. Cases within 
the (brackets) are the number of cases available for image analysis assessment of E-
cadherin staining intensity. Cases without brackets are the number of cases assessed 
by human analysis. 
Replication Number of biopsies Number of Cores 
1x 44 (48) 44 (48) 
2 x 9 (16) 18 (32) 
3 x 16 (21) 48 (63) 
4 x 72 (57) 288 (228) 
5 x 4 (3) 20 (15) 
Total 145 418 (386) 
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5.2.3 Normalisation of Image Analysis Results 
A liver control spot was present on all Tissue Microarrays. The control spot was used 
to verify uniform staining across all Tissue Microarrays. When assessed by human 
analysis, the level of E-cadherin staining present on the control spots was deemed 
constant across all Tissue Microarrays.  Image analysis was performed across all 
control spots in order to quantitatively assess staining intensity variations.  
 
Figure 5.2-1 illustrates the modal intensity of E-cadherin staining present on control 
tissue present across 26 Tissue Microarrays, when assessed by image analysis. It was 
expected that staining intensity would have been constant across all control spots, as 
immunohistochemical staining was performed by an automated staining. The 
majority of slides (n = 18) obtained identical staining intensity values. However, 
there was a range of staining intensity observed for the remainder of slides (n = 8).  
 
Image analysis was performed across all control spots immunohistochemically 
stained with ß-catenin. The level of staining variation was comparable to that 
observed across Tissue Microarrays immunohistochemically stained for E-cadherin. 
As a result, it was deemed necessary to perform normalisation of data obtained from 
the quantification of both E-cadherin and ß-catenin staining intensity. Image analysis 
data was normalised as described in Chapter 2 section (2.6.1). 
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Figure 5.2-1: The level of E-cadherin staining intensity present on control tissue 
across 26 Tissue Microarray sections when assessed by image analysis. As a result of 
a certain degree of staining intensity variance image analysis results were 
normalised. 
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5.2.4 Categorisation of Staining Intensity 
5.2.4.1 Human Analysis Categories 
Originally, assessment of E-cadherin membrane staining intensity was performed by 
a single research scientist, using traditional microscope-based assessments. A three-
point scale was used to quantify E-cadherin membrane staining intensity. However, 
on closer examination of these results the review was deemed unusable, due to the 
fact that 77% of all Tissue Microarray spots were categorised as moderately stained 
when assessed by this reviewer. The over reliance of the moderate category skewed 
the data and therefore, using this data to correlate E-cadherin staining intensity with 
prognosis would have negatively affected the results. 
 
Therefore, one Professor of Pathology, highly experienced in the review of 
immunohistochemistry, scored the Tissue Microarrays, using virtual slide review 
methods for the assessment of E-cadherin membrane staining intensity. In order to 
validate standards, a research scientist performed a 10% review in conjunction with 
the histopathologist. A two and three-point scale was used to quantify E-cadherin 
membrane staining intensity, when performed by human analysis. The two and three-
point scales are classified as follows: (1) weak staining and (2) strong staining / (1) 
weak staining, (2) moderate staining and (3) strong staining.  
 
5.2.4.2 Image Analysis Categories 
The image analysis scale ranges from 0.55 to 1.71 for E-cadherin membrane staining 
intensity and 0.27  to 1.55 for ß-catenin staining intensity.  Utilising X-tile, cut-points 
were identified for E-cadherin at ≥  0.8 (Strong Staining) and < 0.8 (Weak Staining). 
Cut points for ß-catenin were identified at ≥  0.71 (Strong Staining) and < 0.71 
(Weak Staining). 
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5.3 Results  
Membrane-bound immunohistochemical staining intensity was classified using 
automated image analysis as follows: Twenty six Tissue Microarrays were stained 
for E-cadherin; membrane staining intensity was assessed by virtual-based analysis 
and the image analysis algorithm. The level of correlation between human and 
automated analysis were assessed and both methods were compared with prognostic 
outcome. In addition, the relevance of utilising E-cadherin expression in conjunction 
with ß-catenin expression as a prognostic indicator in UCB was assessed.  
 
5.3.1  E-cadherin expression correlated with prognostic outcome 
5.3.1.1 Staining Intensity Assessed by Human Analysis 
As previously mentioned, E-cadherin protein expression was originally assessed by 
one research scientist. There were 16 more cases examined during the research 
scientist evaluation, than subsequent assessments. However, when staining intensity 
was assessed using three categories by the research scientist there was no significant 
difference in survival rates over 5 years (p = 0.817, 95% CI, 2 df, 1.00/1.31/1.04 
RR)(Figure 5.3-1). The poor correlation between membrane E-cadherin staining and 
prognosis was attributed to the over use of the moderate staining intensity category. 
Therefore, it was deemed necessary for a more experienced individual to reassess 
immunohistochemical staining intensity. 
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Figure 5.3-1: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years 
across 26 UCB Tissue Microarrays, where E-cadherin staining intensity was 
reviewed by a research scientist utilising three categories: Weak (n=17), Moderate 
(n=124) and Strong (n=20). 
 
 
The Kaplan-Meier curves illustrate the correlation between intensity of membrane E-
cadherin staining with prognostic outcome over 5 years, where intensity was 
reviewed by human analysis (performed by a Professor of  Pathology) (Figure 5.3-2). 
Staining intensity was assessed utilising two and three categories. When staining 
intensity was classified by human analysis utilising two categories, there was a 
significant difference in survival rates (p = 0.027, 95% CI, 1 df, 2.35/1.00 RR). In 
addition, when staining intensity was classified by human analysis utilising three 
categories, there was also a significant difference in survival rates (p = 0.010, 95% 
CI, 2 df, 3.44/1.59/1.00 RR).  
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Figure 5.3-2: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years across 26 UCB Tissue Microarrays, where E-cadherin 
staining intensity was reviewed by human analysis utilising two and three categories. Two categories: Weak (n=16), and Strong (n=129). Three 
categories: Weak (n=9), Moderate (n=43) and Strong (n=93). 
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5.3.1.2 Staining Intensity Assessed by Image Analysis 
The Kaplan-Meier curve illustrates the correlation between intensity of membrane E-
cadherin staining with prognostic outcome over 5 years, where intensity was 
reviewed by image analysis (Figure 5.3-3). Within this cohort of patients, there was a 
significant difference in survival rates for the two classes identified by image 
analysis, over 5 years (p = 0.013, 95% CI, 1 df, 2.06/1.00 RR).  Utilising image 
analysis and X-tile, a class of patients which have a strong correlation with improved 
survival has been identified, when staining intensity is categorised by image analysis 
into two groupings.  
 
 
Figure 5.3-3: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years 
across 26 UCB Tissue Microarrays, where E-cadherin staining intensity was 
reviewed by image analysis utilising two categories, Weak (n=34) and Strong 
(n=111). 
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5.3.2 Distribution of Staining Intensity Values: Human vs. Image 
Analysis  
Figure 5.3-4 illustrates results from image analysis of Tissue Microarrays 
immunohistochemically stained with E-cadherin, sorted into human analysis 
intensity categories. Human analysis classified staining intensity utilising both two 
and three categories. The median of the staining intensity results illustrate the 
correlation between increasing staining intensities observed in both image and 
human analysis. The range of staining intensities categorised as strongly staining by 
human analysis, completely encompasses the alternative staining categories when 
intensity is classified by two or three categories. The majority of cores were 
classified as strongly stained when assessed by human analysis using two or three 
staining categories (89.0% and 64.1% respectively). There were a number of outliers 
present outside the normal distribution within the box plots, the majority of which 
were present when intensity was classified as moderately stained. 
 
ANOVA illustrated in general there was a highly significant difference between the 
image analysis staining intensity values, when sorted by three human intensity 
categories (p = 0.000, 95% CI, 144 df). There was no significant difference between 
image analysis staining intensity values when comparing the human intensity 
categories weak and moderate staining (p = 0.327, 95% CI, 144 df). However, when 
comparing weak with strong staining and moderate with strong staining, there was a 
significant difference (p = 0.000 and p = 0.000 95% CI, 144 df, respectively).  T-tests 
illustrated there was a significant difference between the image analysis staining 
intensity values, when sorted by two human intensity categories (p = 0.000, 95% CI, 
144 df). However, in both cases the strong category expands the entire image 
analysis range. 
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Figure 5.3-4: Box-plot representing image analysis results when sorted by human analysis categories for the quantification of E-cadherin 
expression across 26 UCB Tissue Microarrays. Human analysis was assessed using virtual slides by a Histopathologist utilising two (Weak or 
Strong) and three (Weak, Moderate or Strong) categories. Within the image analysis scale, 0.6 is the lightest staining possible and 1.8 is the 
strongest. The symbols (○ and *) signify the outliers present within he dataset. The numbers within the box-plots represents the patients 
identification number.  
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5.3.3 Cancer Stages and Grades 
Tumour grade is the system used to classify cancer cells in terms of how abnormal 
they appear. Tumour grade gives an indication of how fast the tumour is likely to 
grow and spread. Grade is usually described as low (well differentiated), medium 
(intermediate differentiated) or high (poorly differentiated/undifferentiated). 
Differentiated cells resemble normal cells and tend to grow and spread at a lower rate 
than undifferentiated cells, which lack the structure and function of normal cells and 
grow uncontrollably. Therefore, patients with low grade cancers are expected to have 
a better prognosis than those with high grades. To evaluate the effect of tumour grade 
on prognosis within this study, cells were classified as (1/2) well/intermediate 
differentiated or (3) poorly/undifferentiated cells.  
 
Tumour stage refers to the extent or severity of the cancer, based on factors such as 
the location of the primary tumour, number and size of tumours, lymph node 
involvement, and presence or absence of metastasis. Tumour stages are mostly 
commonly categorised by TNM system. TNM refers to primary tumour (T), regional 
lymph nodes (N), and distant metastasis (M). Within this cohort of patients, the 
primary tumour stages (T) were known, and the following stages of UCB were 
observed, pTa, pT1, pT2, pT3, and pT4. pTa and pT1 denoted superficial bladder 
cancer, or early stage bladder cancer. The cancer is in early stage of development and 
is situated in the innermost layer of the bladder, in the lining. pT1 is slightly more 
developed than pTa. pT1 tumours have started to grow further into the bladder wall 
than the lining. pT2 and pT3 bladder cancer denote invasive bladder cancer.  pT2, the 
cancer has grown through the connective tissue into the muscle.  pT3, the cancer has 
grown through the muscle layer. pT4 is known as advanced bladder cancer, the 
cancer in this case has spread outside of the bladder. To evaluate the effect of tumour 
stage on prognosis within this study, cells were classified as (pTa-pT1) superficial or 
(pt2/3/4) invasive. Tumour stage and grade information was only available for 141 
(of the 145) patients within this dataset.  Figure 5.3-5 illustrates the primary tumour 
stages of bladder cancer.   
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Figure 5.3-5: Primary tumour stages of bladder cancer. CIS-carcinoma in situ, Ta, 
and T1 denote superficial bladder cancer. T2 and T3 are invasive bladder cancer. T4 
is known as advanced bladder cancer. Image was sourced from CancerHelp UK. 
 
5.3.4 Stage and Grade correlated with Prognosis 
The Kaplan-Meier curves illustrate the correlation between tumour stage and tumour 
grade of UCB with prognostic outcome over 5 years (Figure 5.3-6). Within this 
cohort of patients, there was a significant difference in survival rates between the two 
classes used for both tumour staging and grading of cancer (Figure 5.3-6). There was 
a significant difference in survival rates between patients with tumour grades that 
were well / intermediate differentiated (1/2), and poorly / undifferentiated (3), (p = 
0.000, 95% CI, 1 df, 1.00/3.18 RR). There was also a highly significant difference in 
survival rates between patients with tumour stages that were superficial (pTa-pT1) 
and invasive (pT2/3/4) (p = 0.000, 95% CI, 1 df, 1.00/4.80 RR). 
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Figure 5.3-6: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years across 26 UCB Tissue Microarrays, when outcome is 
categorised by stage and grade of tumours. Tumour Stage is categorised as pTa-pT1 (Superficial, n=101), and pT2/3/4 (Invasive, n=40). 
Tumour Grade is categorised as 1/2 (well/intermediate differentiated, n=83), and 3 (poorly/undifferentiated, n=58).  
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5.3.5 Distribution of Tumour Stage, Grade and E-cadherin Expression 
The distribution of cases when categorised by E-cadherin expression, tumour stage and 
grade is illustrated in Table 5.3-1 and Table 5.3-2, respectively. E-cadherin intensity was 
reviewed by image analysis. Overall there was a good correlation between E-cadherin 
expression and tumour stage and grade, (Pearson Chi Squared = 5.46, and 10.28, 
respectively). The majority of correlation between E-cadherin expression and tumour 
stage was observed when E-cadherin intensity was strong and cancers were superficial 
(pTa-pT1).  
 
Table 5.3-1: Stage of UCB cancer compared with E-cadherin protein expression when 
quantified by image analysis.  
  Image Analysis 
  Strong Weak Total 
Stage pTa-pT1 82 19 101 
  pT2/3/4 25 15 40 
Total 107 34 141 
 
  
 
The majority of correlation between E-cadherin expression and tumour grade was 
observed when E-cadherin intensity was strong and cancers were well/intermediate 
differentiated (1/2, Table 5.3-2).  
 
 
 
Table 5.3-2: Grade of UCB cancer compared with E-cadherin protein expression when 
quantified by image analysis. 
  Image Analysis 
  Strong Weak Total 
Grade 1/2 71 12 83 
  3 36 22 58 
Total 107 34 141 
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5.3.6 Tumour Stage (pT2/3/4) categorised by E-cadherin expression levels 
As illustrated in Figure 5.3-6, patients with invasive tumours (pT2/3/4) have a 
considerably poorer prognosis than those with superficial tumours (pTa-pT1).  The 
effect of E-cadherin staining intensity on invasive tumours was examined, in order to 
assess if a distinct sub-population with a poorer prognosis was in existence. The Kaplan-
Meier curves illustrate the correlation between weak and strong E-cadherin staining of 
invasive UCB tumours (pT2/3/4) with prognostic outcome over 5 years, where staining 
intensity was assessed by image (Figure 5.3-7, A) and human analysis (Figure 5.3-7, B).  
Within this cohort of patients, there was not a significant difference in survival rates 
between the two classes used for quantifying E-cadherin staining intensity. However, the 
difference in survival rates between patients with weak and strong expressing tumours 
where at their greatest when E-cadherin staining was assessed by image analysis (p = 
0.087) compared to human analysis (p = 0.290). 
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Figure 5.3-7: Kaplan-Meier curve evaluating rate of death due to UCB over 5 years across 26 Tissue Microarrays, where E-cadherin 
staining intensity was reviewed by image (A) and human (B) analysis. In all cases tumour stage was invasive (PT2/3/4). E-cadherin 
staining was categorised as weak (n=15) and strong (n=25) during image analysis (B), and weak (n=6) and strong (n=34) during 
human analysis (B). 
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5.3.7 ß-catenin Expression in Cancer 
Cadherins found in all tissue, are mediators of cell-cell adhesion. A cadherin molecule 
on one cell binds to a cadherin molecule of the same type on another cell (Takeichi, 
1991, Gontero et al., 2004). E-cadherin is expressed by all normal epithelia cells (Smith 
and Pignatelli, 1997). Cadherin binding occurs via members of the catenin family of 
molecules. Defects in catenin molecules may abolish cadherin binding at the cell 
surface. The three catenins that have been identified (α, ß and γ) link E-cadherin to the 
actin cytoskeleton and are important for maintaining its role in cell-cell adhesion 
(Behrens et al., 1989, Gontero et al., 2004). A  reduction or loss of adhesion in human 
malignancy allows cells to detach from the primary site and thereby initiating the first 
steps in the metastatic process (Shimazui et al., 1996, Nakopoulou et al., 2000, van Oort 
et al., 2007, Frixen et al., 1991, Gontero et al., 2004). Therefore, a loss of either E-
cadherin or a member of catenins would negatively affect prognosis.  
 
Several studies have reported the associations between E-cadherin and ß-catenin 
expression levels with prognosis in bladder cancer (Nakopoulou et al., 2000, Shimazui et 
al., 1996, Clairotte et al., 2006, Kashibuchi et al., 2007). However, reported prognostic 
values of these antigens have varied. In a univariate setting, both E-cadherin and ß-
catenin expression have been found to have a significant effect on prognosis 
(Nakopoulou et al., 2000, Shimazui et al., 1996, Clairotte et al., 2006). However, in a 
multivariate setting, only E-cadherin expression was a significant indicator of prognosis 
(Nakopoulou et al., 2000). Literature has reported that E-cadherin and ß-catenin have 
similar prognostic values and that staining for either of these antigens is acceptable 
(Shimazui et al., 1996).  
 
The application of combining E-cadherin and ß-catenin expression levels as a prognostic 
indicator in bladder cancer, when intensity is assessed by image analysis, has not been 
reported in literature. Therefore, we extended our previous observations on E-cadherin, 
by combining E-cadherin and ß-catenin expression levels and correlating results with 
prognostic outcome. The objective is to clarify whether or not the expression levels of ß-
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catenin could provide additional prognostic value over and above E-cadherin alone in 
UCB. 
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5.3.8 ß-catenin expression correlated with prognostic outcome  
The Kaplan-Meier curve illustrates the correlation between intensity of membrane ß-
catenin staining with prognostic outcome over 5 years, where intensity was assessed by 
image analysis (Figure 5.3-8). Within this cohort of patients, there was a significant 
difference in survival rates for the two classes identified by image analysis, over 5 years 
(p = 0.044, 95% CI, 1 df, 2.20/1.00 RR) As with E-cadherin expression, the optimum 
cut-points were generated using X-tile.  
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Figure 5.3-8: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years 
across 25 Tissue Microarrays, where ß-catenin staining intensity was reviewed by image 
analysis utilising two categories, Weak (n=20) and Strong (n=121). 
 
p = 0.044 
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5.3.9 E-cadherin and ß-catenin expression correlated with prognostic 
outcome 
Table 5.3-3 illustrates the distribution of E-cadherin and ß-catenin membrane staining 
intensity when assessed by image analysis, utilising two categories to classify staining 
intensity (Weak and Strong).  There was a high level of correlation between E-cadherin 
and ß-catenin membrane expression (Kappa = 0.60), particularly when strong staining 
was observed. 
 
Table 5.3-3: Correlation between E-cadherin and ß-catenin expression levels, when 
assessed by image analysis. 
 E-cadherin Staining 
 
 Weak Strong Total 
ß-catenin Staining  Weak 6 14 20 
 Strong 27 94 121 
Total  33 108 141 
 
The Kaplan-Meier curve illustrates the correlation between intensity of E-cadherin and 
ß-catenin staining with prognostic outcome over 5 years, where intensity was assessed 
by image analysis (Figure 5.3-9). Membrane staining intensity was classified using three 
categories. Cases where both E-cadherin and ß-catenin staining was strong, cases where 
both E-cadherin and ß-catenin staining was weak, and cases where either E-cadherin or 
ß-catenin staining was strong. Within this cohort of patients, there was a significant 
difference in survival rates for the three classes identified by image analysis, over 5 
years (p = 0.009, 95% CI, 2 df, 4.18 RR (Both Weak) / 1.68 RR (Either Strong) / 1.00 
RR (Both Strong)).  
 
 
170 
Figure 5.3-9: Kaplan-Meier curves evaluating rate of death due to UCB over 5 years 
across 25 Tissue Microarrays, where E-cadherin and ß-catenin staining intensity was 
reviewed by image analysis utilising three categories. Cases where E-cadherin and ß-
catenin staining intensity were Both: Strong (n=94), Weak (n=6) or Either were Strong 
(n=41). 
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5.4 Discussion and Conclusions 
The image analysis algorithm was validated using Tissue Microarrays stained for E-
cadherin and ß-catenin. E-cadherin and ß-catenin have a characteristic brown tint, which 
is particularly difficult to isolate as it is dispersed across the colour spectrum and not 
ideal as such for colour thresholding. A colour cube was used to isolate colour, as it 
allows vastly different colours to be grouped together in the same domain. It is 
conceivable that the algorithm could be easily adapted to help quantify other biomarkers 
with predominantly membrane staining patterns. The algorithm is adapted by simply 
updating the colour cube. This process does not require any knowledge of computer 
programming and simply requires highlighting the range of colours specific to the 
biomarker of interest. This process is ideally suited to pathologists or clinical scientists 
and is therefore versatile and accessible to all those who would traditionally perform 
microscope-based analysis.  
 
The concept of the algorithm is uncomplicated; areas that are considered membrane and 
brown are segregated from the rest of the image, and the intensity of grey in positive 
pixels is quantified. The creation of the algorithm in Image-Pro Plus® was 
straightforward as it facilitates recording and replaying of image processing sequences. 
However, not all laboratories have access to Image-Pro Plus®; therefore, the algorithm 
could be re-created with non-proprietary software, thus reducing the cost of the 
application and improving the algorithm’s performance. For example, by utilising Java 
image library the speed of image analysis would be increased due to code compilation. 
 
The algorithm alone was not enough to achieve high-throughput. A workflow was 
utilised to facilitate the automation of the algorithm. The workflow incorporated 
numerous stages including: digitisation and de-arraying of Tissue Microarrays, image 
analysis, storage of results, and finally statistical analysis was performed. In order to 
facilitate high-throughput, human intervention must be as limited as possible. In this 
study the first fully automated de-arraying process of its kind has been utilised. Thus 
fully automated image analysis of Tissue Microarrays was achieved.  
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When used in conjunction with Tissue Microarrays constructed solely from tissue of 
interest, image analysis has numerous advantages including speed, automation, accuracy 
and efficiency in quantifying staining intensity, providing an alternative to human 
analysis. Image analysis is completely objective and does not compare the image under 
analysis with those previously reviewed, which inevitably occurs with human analysis. 
Therefore, values are a true reflection of intensity, rather than a value of comparison. 
Once the macro has been created and recorded, analysis is fully automated. Images can 
be analyzed without human intervention, utilising a continuous scale. Therefore results 
are truly quantitative, in contrast to human analysis which at best is semi-quantitative. 
However, it should be noted that image analysis is only as good as the algorithm 
implemented. 
 
Commercial applications are available to quantify immunohistochemical staining. The 
merits of utilising commercial applications are illustrated in literature (Ciampa et al., 
2006, Camp et al., 2002, Divito et al., 2004, Camp et al., 2003, Berger et al., 2004, 
Charpin et al., 2004). However, most image analysis applications can quantify 
fluorescent or chromatic staining, but not both. As a result of this and high initial 
purchase costs, commercial applications are not always viable in research laboratories. 
The image analysis system described in this study utilises an algorithm, which is capable 
of quantifying chromatic rather than fluorescent staining. Therefore, the algorithm 
described provides a low cost alterative to many commercial image analysis 
applications.  
 
At present, human analysis is considered the gold standard for immunostain 
quantification. During statistical analysis, image analysis results were grouped by human 
reviewing categories. The range of image analysis results within each of the human 
analysis categories cast doubts on the usefulness and reliability of human analysis to 
quantify immunostain intensity. Strong staining completely encompassed all other 
categories available when staining intensity was classified on a two and three grade 
scale, as illustrated in Figure 5.3-4.  In addition, there were numerous outliers present 
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outside the normal distribution, when image analysis results were grouped by human 
reviewing categories. 
 
The expertise of the reviewer greatly impacted the quality of results obtained within this 
study. Originally all tissue was assessed by a research scientist; however, no correlation 
between E-cadherin protein expression and prognosis was observed. However, when 
assessed by a Professor of Pathology correlation was observed. In addition, 77% of all 
cases were deemed moderate when assessed by the research scientist, whereas this value 
was greatly reduced during the pathologist review (43%). 
 
Quantification of E-cadherin staining intensity performed by human and image analysis 
was compared with prognostic outcome, over 5 years. Within this cohort of patients, 
when E-cadherin staining intensity was classified into weak, moderate or strong by 
human analysis, there was a significant difference in survival times between the three 
classes over 5 years. In addition, when staining intensity was classified into two groups 
by human and image analysis, there was a significant difference in survival times 
between the two classes over 5 years. The continuous scale used by image analysis to 
quantify expression was divided into two categories, representing weak and strong 
expression. The continuous scale of intensity values was split using X-tile (Camp et al., 
2004). This type of categorisation proved to be as effective as human categorisation 
where intensity is split into weak and high. In addition, image and human analysis 
proved to be almost as effective as tumour stage and grade for predicting prognosis in 
UCB. However, these findings only apply to this cohort of patients and require a test set 
for true validation of the correlation. 
 
Both tumour stage and grade were significant indicators of prognosis in UCB. Using 
image analysis it was possible to identify a sub-population of invasive tumours with 
considerably poorer prognosis, when E-cadherin staining was weak. Although not 
significantly different, invasive tumours with strong E-cadherin staining when identified 
by image analysis had a better prognosis than strong cases identified by human analysis. 
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Quantification of ß-catenin staining intensity assessed by image analysis was compared 
with prognostic outcome, over 5 years. Within this cohort of patients, when staining 
intensity was classified into weak or strong by image analysis there was a significant 
difference in survival times between the two classes over 5 years.  Correlations between 
the expression pattern of both E-cadherin and ß-catenin staining intensity with prognosis 
were also assessed. Staining intensity was categorised as follows, both proteins were: 
highly expressed; weakly expressed, or either proteins were strongly expressed. Results 
illustrate that combining E-cadherin and ß-catenin expression levels is marginally better 
as a prognostic indicator than either E-cadherin or ß-catenin expression alone. Utilising 
image analysis we found E-cadherin, ß-catenin and the combination of E-cadherin and 
ß-catenin expression levels to have similar prognostic values. Therefore, staining for 
either of these proteins could be used as a prognostic indicator in UCB. However, 
identifying cases with both weak E-cadherin and ß-catenin protein expression maybe of 
benefit when examining prognosis. 
 
Results confirm, in this patient cohort, the importance of varying E-cadherin and ß-
catenin protein expression for predicting survival in UCB. Traditionally, human analysis 
has been considered the gold standard for quantifying immunostaining; however, this 
may not be the case.  Image analysis has proven to be at least as effective as human 
analysis for quantifying E-cadherin intensity and has identified a cut-point which results 
in a statistically significant correlation with survival times. UCB stained for E-cadherin 
has been used as a model to illustrate the fully automated image analysis of 
immunohistochemistry. However, this model can be applied to all types of 
immunohistochemically stained tissue, as illustrated by the assessment of ß-catenin. 
Utilising image analysis we found E-cadherin and ß-catenin to have similar prognostic 
values. Fully automated workflows such as the one outlined, which is the first of its 
type, are unbiased, fast, efficient, quantitative and automated.  
 
The quantification of immunostain intensity is often a critical parameter in deciding the 
nature of cancer treatment for patients, for example in the administration of   
Herceptin™. Suitability for Herceptin™ is assessed by immunohistochemical analysis, 
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utilising a three-point scale similar to the one describe in this study. However, when 
samples are deemed to be moderately stained, further analysis is performed by FISH for 
definitive results. In light of the findings of this study, it is suggested that the application 
of image analysis of immunohistochemically-stained tissue could decrease the number 
of cases sent for FISH, therefore increasing throughput and reducing costs.  
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CHAPTER 6: HIGH-THROUGHPUT AUTOMATED 
IMAGE ANALYSIS FOR ASSESSING HER-2 STATUS IN 
BREAST CARCINOMA; A STUDY INVOLVING ANALYSIS 
OF TISSUE MICROARRAYS AND WHOLE SECTIONS 
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6.1 Introduction 
HER-2/neu is a member of the epidermal growth factor (HER-2) receptor family. Its 
gene is located on the long arm of chromosome 17 and encodes a 185-kDa 
transmembrane glycoprotein with tyrosine kinase activity. It has been found that the 17q 
region is susceptible to rearrangement mutations in breast carcinomas (Popescu et al., 
1989). The amplification and overexpression of HER-2 is associated with a shorter 
disease-free interval, shorter overall survival, higher incidence of metastasis, reduced 
response to certain chemotherapeutics and a more aggressive disease progression 
regardless of disease stage or nodal status (Andrechek and Muller, 2000, Climent et al., 
2001, Camp et al., 2003, Tawfik et al., 2006). HER-2 is amplified and overexpressed in 
10 – 30% of women with breast cancer (Slamon et al., 1987, Slamon et al., 1989, 
Borresen et al., 1990).  
 
The clinical significance of HER-2 gene amplification as a proto-oncogene in breast 
cancer was first described in 1987 (Slamon et al., 1987, Winer and Burstein, 2001).  
Trastuzumab (HerceptinTM), a humanised monoclonal antibody targeting the oncogene, 
showed therapeutic benefits especially when combined with conventional 
chemotherapeutic agents in treatment of patients with metastatic breast carcinoma 
(Camp et al., 2003, Slamon et al., 1987, Seidman et al., 2001, Winer and Burstein, 2001, 
Baselga et al., 1996, Carter et al., 1992). In 1998, the Food and Drug Administration 
approved HerceptinTM (Genentech, USA) targeted to the protein product of HER-2 gene, 
as a breast cancer therapeutic agent. HerceptinTM was later approved by the European 
authorities in 2000 (Winer and Burstein, 2001).  The association between HER-2 protein 
overexpression and HerceptinTM response has stimulated renewed interest in accurately 
assessing HER-2 status in breast cancer patients (Camp et al., 2003).  
 
Slamon et al. (2001) evaluated the clinical benefits of treatment with HerceptinTM for 
women with HER-2 positive metastatic breast carcinoma, by comparing the benefits of 
chemotherapy alone, and chemotherapy combined with HerceptinTM (Slamon et al., 
2001). The benefits of Herceptin™ included response rates of up to 50% when 
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combined with chemotherapy (paclitaxel and anthracycline plus cyclophosphamide) 
versus 32% with chemotherapy alone (p < 0.0001). There was also a significant increase 
in survival time (25 versus 20 months, p < 0.05) when assessed at 35 months of follow 
up, when chemotherapy and HerceptinTM was used (Slamon et al., 2001, Winer and 
Burstein, 2001).  
 
Original investigations of the effect of Herceptin™ on metastatic breast cancer 
illustrated a high incidence of congestive heart failure among patients who had received 
HerceptinTM in conjunction with alternative chemotherapeutics, particularly 
anthracycline (Slamon et al., 1987). In addition, HER-2 amplification has been 
associated with a negative response to widely used hormonal drugs such as tamoxifen 
(Muss et al., 1994). Therefore, it is imperative that patients suitable for HerceptinTM 
treatment are correctly identified.  
 
A correlation exists between HER-2 gene amplification and an increased level of HER-2 
protein overexpression (Slamon et al., 1989, Press et al., 2002). Current methods for 
evaluating HER-2 protein overexpression and gene amplification include measuring 
protein expression by immunohistochemistry, measuring gene copy number by either 
fluorescent in situ hybridisation (FISH) or chromogenic in situ hybridization (CISH), 
measuring the antigen in the serum by enzyme-linked immunosorbent assay (ELISA), 
by quantitative polymerase chain reaction methods and by Southern blot analysis. 
Analysing for protein overexpression or gene amplification of HER-2 in surgical 
specimens is most commonly accomplished by either immunohistochemistry or FISH 
testing (Tawfik et al., 2006). Establishing tumour HER-2 status is a prerequisite when 
evaluating the suitability of candidates for the administration of Herceptin™ (Press et 
al., 1994). However, a widely accepted and standardised single test for HER-2 status is 
not currently available (Rampaul et al., 2002, Ellis et al., 2000).  
 
When utilising immunohistochemical means to assess HER-2 protein overexpression, 
the majority of laboratories use HercepTest™ kit (DakoCytomation, UK)(Rhodes et al., 
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2002). Only invasive carcinoma regions are assessed and are scored semi-quantitatively 
(0-3+), based on intensity and percentage of membrane-positive cells. The semi-
quantitative scale used is interpreted as follows: No staining or weak membrane staining 
in < 10% of tumour cells (0/1+); therefore, the HER-2 protein is not overexpressed and 
patients do not qualify for HerceptinTM treatment. A strong complete membrane stain is 
observed in > 10% of tumour cells (3+); therefore, the HER-2 protein is overexpressed 
and patients qualify for HerceptinTM treatment. Cases with weak to moderate staining in 
> 10% of tumour cells are considered intermediate stained (2+) and require further 
definitive testing by FISH (Ellis et al., 2000, Ellis et al., 2004). As all cases are not 
routinely tested for FISH, there is a risk of under diagnosing cases with (0-1+) HER-2 
protein expression that have gene amplification or, alternatively, over diagnosing cases 
with 3+ protein overexpression with no gene amplification. As a consequence, patients 
could be either not offered treatment that may be beneficial or exposed to inappropriate 
and toxic treatment (Tawfik et al., 2006). 
 
There are several commercial systems available for FISH HER-2 testing (Abbott-Vysis, 
Cancer Genetics, DakoCytomation and QBioGene); however, recommendations on 
HER-2 testing in the UK advocate the PathVysion® assay (Vysis Inc, UK) for diagnostic 
testing (Ellis et al., 2000, Ellis et al., 2004).  The scoring protocol with the PathVysion® 
assay recommends the number of chromosome 17 and HER-2 gene signals are scored 
for 60 cells, where possible from three distinct tumour fields, and the mean HER-2 gene 
to chromosome 17 copy ratio is calculated. Where tumour heterogeneity is seen in 1 – 
2% of cases, more cells from the amplified regions should be scored. Samples with ≥  2.0 
copies of HER-2 gene for each chromosome 17 are considered to be amplified and those 
with < 2.0 are not gene amplified (Ellis et al., 2000). If the ratio of HER-2 gene to 
chromosome 17 is close to 2.0 (1.5 - 2.3) a larger number of cells should be assessed. 
 
There is no consensus on which method of assessment of HER-2 status is most 
predictive of patients' response to HerceptinTM in a clinical setting (Tawfik et al., 2006). 
Generally, FISH is considered the gold standard, as it is truly quantitative; and therefore, 
less susceptible to inter- and intra-observer variability. However, FISH is a highly 
180 
skilled technique, which is not widely available in routine pathology laboratories. 
Fluorescent probes are expensive, and signal is lost over time; therefore, expensive 
fluorescent image capturing devices must be used if results need to be preserved for 
future reference. In contrast, immunohistochemistry is relatively inexpensive and widely 
available in routine pathology laboratories. However, immunohistochemistry is 
susceptible to inter- and intra-observer variability and is semi-quantitative at best. There 
has been some concordance identified between the two assays, particularly with the 
strongly positive (3+) cases. However, interpretational problems still exist for the 1+ and 
2+ cases (Vera-Roman and Rubio-Martinez, 2004, Tawfik et al., 2006). The majority of 
the tumours that overexpression HER-2 protein (3+) will also have gene amplification 
(85 – 90%), and only a small percentage of the cases (5 – 25%) with borderline HER-2 
overexpression (2+)  have gene amplification (Ridolfi et al., 2000, Vincent-Salomon et 
al., 2003, Tawfik et al., 2006).  
 
Inter-observer agreement is significantly higher when assessing HER-2 status using 
FISH testing rather than immunohistochemistry (Bartlett et al., 2001). Bartlett et al. 
(2001) illustrated inter-observer agreement was lower for the immunohistochemical 
HercepTest™ (kappa = 0.67) than for FISH testing by PathVysion® assay (kappa = 
0.97), when assessing the same cohort of patients. Using immunohistochemistry, 81% 
concordance was observed between two reviewers when classifying normal expression 
(0/1+) or borderline/overexpression (2+/3+). Whereas using FISH, concordance when 
classifying amplified (≥  2) and non-amplified (< 2) cases was greater than 99% (Bartlett 
et al., 2001, Ellis et al., 2004). 
 
Lacroix-Triki et al. (2006) evaluated the inter-observer agreement when interpreting 
HER-2 immunostains performed in different laboratories, according to their in house 
techniques. A total of 74 HER-2 immunostains were evaluated by 16 pathologists and by 
a central review committee. The overall agreement was good (kappa = 0.75). Agreement 
was excellent for the 0/1+ group (kappa = 0.85) and for the 3+ group (kappa = 0.82). As 
expected, when  borderline expression was present (2+), poor agreement was observed 
(kappa = 0.38) (Lacroix-Triki et al., 2006).  
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Commercially available systems are in existence which quantify HER-2 gene 
amplification and protein overexpression, when evaluated by FISH and 
immunohistochemistry. High levels of correlation have been found between 
HercepTest™ and FISH analysis when immunohistochemical staining was assessed by 
automated systems (Wang et al., 2001, Luftner et al., 2004). Micrometastasis Detection 
System (MDS™, Applied Imaging, USA) is a computer controlled scanning microscope 
which captures either brightfield or fluorescence. In addition, MDS™ provides 
quantitative analysis of immunohistochemical or FISH images. Utilising MDS™, it was 
found that FISH proved to be a more accurate and consistent scoring system for 
determining HER-2 status compared to immunohistochemistry. In general, the authors 
found MDS™ to be more reliable and more consistent than visual FISH and 
immunohistochemical scoring systems (Ellis et al., 2005).  
 
Automated Cellular Imaging Systems (ACIS) and Automated Quantitative Analysis 
(AQUA) have been used to evaluate HER-2 status.  Tawfik et al. (2006) found a 
correlation of 94% between ACIS analysis of HercepTest™ and FISH (Tawfik et al., 
2006). The number of patients identified with HER-2 protein overexpression and gene 
amplification differed only by 1 case, when immunohistochemical staining was assessed 
by ACIS (Tawfik et al., 2006). In addition, high correlation between human scoring and 
the ACIS system has been observed (95.1%, kappa = 0.85) (Luftner et al., 2004). Using 
image analysis, it is possible to identify extremely weak staining, which is not observed 
when immunohistochemistry is assessed by human scoring (Camp et al., 2003).  In 
addition, studies have suggested that automated image analysis could be used to identify 
potential cases requiring FISH testing, rather than sending all borderline 
immunohistochemical cases (Ciampa et al., 2006).  
 
Within this chapter, the application of the previously described image analysis algorithm 
to quantify HER-2 protein overexpression will be assessed. HER-2 protein 
overexpression, when assessed by human and image analysis, will be compared to HER-
2 gene amplification data. In order to create and validate optimal cut-points, a training 
set and validation set of data will be used. Tissue Microarrays will be utilised as a 
182 
training set to create optimal cut-points within the continuous image analysis dataset. 
Whole section biopsies will be used as a validation set in order to validate the 
application of the algorithm. Results will indicate if a low cost algorithm could 
potentially be used to evaluate HER-2 protein overexpression.  
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6.2 Image Analysis Considerations 
As previously described the image analysis algorithm was created in Image-Pro Plus®; 
however, due to file size restrictions it is not possible to perform truly high-throughput 
analysis across large tissue sections using Image-Pro Plus®. Distiller (SlidePath, Ireland) 
provides the capabilities of rapidly processing large images; however, due to software 
restrictions it is not possible to use Image-Pro Plus® in combination with Distiller. 
Therefore, the algorithm was re-created using an open-access software language (Java). 
However, morphological filters that are common to both applications may differ slightly, 
and a number of image manipulations available in Image-Pro Plus® are not available in 
Java. Therefore, the algorithms are not identical. Utilising the code created in Java, two 
scenarios occurred that were not observed when using the algorithm generated in Image-
Pro Plus®. The two scenarios incurred include, the presence of staining artifacts and the 
presence of noise within the final output image, a description of both follow: 
 
6.2.1 Staining Artifacts 
Prior to dissection, edges of whole section biopsies are stained with tissue dye. The 
biopsies are then paraffin-embedded, sectioned using a microtome and transferred to a 
glass slide. On the surface of the slide, tissue dye is clearly visible around the boundary 
of the biopsy. The presence of tumour cells near the boundary suggests not all tumours 
regions were removed during surgery. The colour of the dye used to stain tumours varies 
with tumour type. Breast cancer is typically stained using a black/brown dye.  This 
procedure for processing biopsies influenced image analysis assessment during this 
study. 
 
Figure 6.2-1 (A) illustrates a section of immunohistochemically stained tissue; a verge of 
dark black/brown tissue dye is clearly visible. During image analysis, the black/brown 
verge was considered “edge” and “brown” and, therefore, interpreted as membrane 
staining. As a result, the colour cubed used within the algorithm was altered in order to 
exclude areas of black/brown tissue dye and image analysis results were corrected to 
account for this (see section 6.2.2). Therefore, the utility of tissue dye did not negatively 
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affect image analysis results, as evident from Figure 6.2-1 (B), where none of the tissue 
dye has been isolated as membrane staining when assessed by image analysis.   
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Figure 6.2-1: (A) Illustrates tissue immunohistochemically stained for HER-2. A 
black/brown verge of tissue dye that is routinely applied to tumour boundaries prior to 
tissue processing is visible within this slide. (B) Illustrates the final output image after 
image analysis. The colour cube was adjusted to exclude black/brown pixels, and 
therefore exclude the tissue dye. As a result, only areas of membrane brown staining are 
recorded. 
 
 
A 
B 
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6.2.2 Noise 
The range of “brown” staining which encompasses HER-2 immunohistochemical 
staining was much greater than previously assessed antigens within this thesis. As a 
result, the colour cube was adjusted to encompass a large range of colour intensities. 
This introduced a certain level of noise into the final output image, when assessed by the 
algorithm. Noise is any staining that was present in non-membrane regions. However, 
the staining was observed in regions of brown edges and, therefore, is interpreted as 
membrane during image analysis. Within this study, where noise was observed, the 
staining intensity was mostly weak. Weak staining is essential in HER-2 status 
assessment and is classified as 0/1+ status. However, within strongly stained tissue the 
weak staining appeared as noise, as is evident from Figure 6.2-2. Figure 6.2-2 illustrates 
strong HER-2 immunohistochemical staining (A), and the final output after image 
analysis (B). Both images are digitally zoomed to in order to visualise the level of noise 
present within the tissue. The red box highlights an area of staining which is not true 
membrane; however, it has been identified as such by the image analysis algorithm.  
 
 
 
 
187 
 
Figure 6.2-2: (A) Tissue immunohistochemically stained for HER-2. (B) Final output after image analysis. Red boxes highlight areas 
that are identified by image analysis as membrane staining; however, the areas of staining are clearly not membrane. Therefore, signal 
within these boxes is incorrectly identified as membrane-bound immunohistochemical staining. 
A B 
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Based on these observations it was deemed necessary to exclude the noise from image 
analysis results. Typically, histograms of staining intensity values are outputted for each 
sample assessed by image analysis. The modal value (peak) within the histogram 
represents the overall staining intensity value for the tissue under assessment. Figure 
6.2-3  illustrates a typical histogram outputted during image analysis assessment. The x-
axis represents the staining intensity scale, which quantifies the intensity of staining, and 
the y-axis represents the number of pixels staining positive. Figure 6.2-3 illustrates a 
normal distribution of staining intensity, where there is no evidence of noise, as only a 
single peak within the histogram is present. Therefore, the maximum bin within the 
histogram is recorded as the staining intensity value for the tissue under assessment. 
 
 
 
 
Figure 6.2-3: Histogram illustrating the number and staining intensity of membrane-
pixels when assessed by image analysis. The histogram has normal distribution, with a 
single peak. Therefore, the peak of the histogram is recorded as staining intensity value 
for the tissue under assessment. 
 
More than one peak within the histogram signifies the presence of noise within the final 
output image when assessed by the algorithm. Figure 6.2-4 illustrates a histogram with 
non-normal distribution, where three peaks of staining intensity are visible. The three 
peaks and their distribution have been coloured coded within the figure. A second peak 
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located toward the lighter end of the staining intensity scale (256) suggests noise due to 
non-membrane staining detection, visualised in white in Figure 6.2-4. Non-membrane 
noise was illustrated in Figure 6.2-2 (B). A peak located toward the stronger end of the 
staining intensity scale (0), suggests noise due to the identification of ink that is applied 
to tumour borders, visualised in black in Figure 6.2-4. Tumour ink was illustrated in 
Figure 6.2-1 (A). However, as the colour cube was adjusted to discount extremely black 
pixels, the occurrence of this type of noise was extremely infrequent. The central peak 
within Figure 6.2-4 (grey) represents the actual membrane staining presence. Within 
Figure 6.2-4, the two modal values of the noise were less than the actual membrane-
bound immunohistochemical signal. Therefore, in this case the presence of noise did not 
affect the overall staining intensity value; however, the presence of noise did affect the 
total positive pixel count.  
 
 
Figure 6.2-4: Tri-modal distributed histogram. Within the histogram there are 3 
distributions membrane-bound immunohistochemical staining (grey), and noise due to 
the presence of: tissue dye (black) and non-membrane staining (white). In this case the 
mode of membrane-bound staining is greater than the noise; therefore, the overall mode 
value in this is correct. However, overall the number of membrane positive pixels is 
artificially inflated due to the number of noise pixels. 
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Figure 6.2-5 illustrates a case where the mode of membrane-bound staining intensity 
(grey) is considerably less than either of the noise signals (black and white). In this case, 
taking the overall modal value of the histogram would incorrectly classify the 
membrane-bound immunohistochemical staining intensity value.  
 
 
 
Figure 6.2-5: Non-normal distributed histogram. Within the histogram there are 3 
distributions membrane-bound immunohistochemical staining (grey), and noise due to 
the presence of: tissue dye (black) and non-membrane staining (white). In this case the 
mode of membrane-bound staining is less than the noise; therefore, the overall mode 
value in this is incorrect.  
 
Therefore, in order to account for non-normal distribution, correction of data was 
performed. Correction was performed by modelling and subtracting the noise pixels 
from the histograms, therefore removing any non-membrane bound signal from the 
dataset. This resulted in only membrane positive pixels, remaining in the histogram. 
Therefore, the mode and number of positive pixels could be utilised to record the 
amount and intensity of HER-2 membrane bound staining.  
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6.3 Study Design 
6.3.1 Patient Cohort 
Forty-seven consecutive cases of breast carcinoma were selected from the files of the 
Histopathology Department of Beaumont Hospital. Three Tissue Microarrays were 
constructed by sampling 2 x, 4 x and 6 x cores (0.6 mm diameter) from the individual 
blocks using the technique pioneered by Kononen et al. (1998) and described in Chapter 
2 section 2.2.1.2. A total of 188 cores were included in this study and the distribution of 
the replica cores is illustrated in Table 6.3-1. One orientation spot composed of liver 
tissue was present on all slides. Replica cores were sampled from different tumour areas 
to account for heterogeneity in any one tumour and to minimise the number of lost cases 
during subsequent processing of the Tissue Microarrays. Tissue Microarrays were 
utilised as a training set to create optimal cut-points, based on comparisons with FISH 
data. A total of 46 different biopsies were also sectioned. Whole section biopsies were 
used to blindly test the application of the image analysis algorithm. Tissue Microarrays 
and whole sections were created as described in Chapter 2 section 2.2.1.1, and all slides 
underwent immunohistochemical staining and fluorescent in situ hybridisation as 
described in Chapter 2 section 2.3.1.2 and 2.3.4, respectively. Tissue Microarrays and 
whole sections were digitised using a NanoZoomer Digital Pathology (NDP) System 
(Hamamatsu, UK) as described in Chapter 2 section (2.4.3). Fluorescent in situ 
hybridisation was visualised using a Nikon Eclipse E600 microscope, as described in 
Chapter 2 section (2.4.4). 
 
Table 6.3-1: Three Tissue Microarrays were assessed within this study. Replica cores 
were extracted from 47 biopsies to generate the Tissue Microarrays. The number of 
replica cores extracted from each biopsy is illustrated within this Table. 
Replication Number of Patients Number of Cores 
2 x 1 2 
4 x 45 180 
6 x 1 6 
Total 47 188 
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6.3.2 Human Classification 
Scoring of the HercepTest™ immunohistochemically stained Tissue Microarrays was 
performed by one research scientist and one pathologist both were experienced in the 
review of immunohistochemistry, on a three point scale (0-3+) using the manual for 
interpretation provided by the manufacturer. Reviewer 1 (research scientist) assessed all 
Tissue Microarrays using microscope-based review. Reviewer 2 (pathologist) assessed 
all Tissue Microarrays using virtual slide methods of review. A combination of two 
individual reviews was used as the Tissue Microarray scores. In cases were the two 
individuals evaluations differed, the stronger staining intensity value was recorded as the 
overall result. However, inter-observer variability for the assessment of Tissue 
Microarrays was considerable less than those reported in previous chapters (kappa = 
0.845). Scoring of whole section biopsies was performed by a Professor of Pathology 
and a research scientist. Reviews were performed concurrently using virtual slides. For 
the purposes of Herceptin™ treatment, a HercepTest™ score of 0 /1+ is interpreted as 
negative for HER-2 protein overexpression. A score of 3+ is interpreted as positive for 
HER-2 protein overexpression, and a score of 2+ is inconclusive and must undergo 
FISH testing, for definitive results.  
 
Scoring of the tissue which underwent FISH testing was performed by one research 
scientist (Reviewer 1), across all whole sections and Tissue Microarrays. PathVysion® 
manual states that a ratio of ≥  2 is evidence of HER-2 gene amplification, and < 2 is 
evidence of non-amplification. Recommendations for interpretation of FISH state that if 
the ratio of HER-2 gene to chromosome 17 is close to 2.0 (1.5 - 2.3), a larger number of 
cells should be scored (Ellis et al., 2004).  
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6.3.3 Image Analysis Classification 
Tissue Microarrays generated from 47 patients biopsies were used to train the image 
analysis algorithm to classify HER-2 protein expression. Staining intensity values were 
quantified using image analysis, and the normalised image analysis results were 
compared with gene amplification data quantified by FISH. Utilising FISH data it was 
possible to create optimal cut-points within the normalised image analysis data. The 
output from image analysis was categorised into positive or negative for HER-2 protein 
overexpression, based on the modal staining intensity value and the number of positive 
membrane pixels. The modal staining intensity value was normalised across all slides, 
by obtaining the natural log (Ln) of the modal staining intensity value (I) divided by the 
background lighting intensity (Io), (Ln I/Io). Samples scoring a normalised staining 
intensity value of ≥ 0.54 were considered positive for HER-2 protein overexpression. 
Samples scoring normalised staining intensity value of < 0.54 were considered negative 
for HER-2 overexpression. The value of 0.54 was obtained as it is the mid-point 
between 0.47 and 0.59. Which is the split point where the least amount of cases were in 
disagreement between FISH and image analysis data. Tissue Microarray cores and 
whole biopsies with < 700 and < 100,000 membrane positive pixels respectively, were 
considered negative for HER-2 protein overexpression. The classification system used 
by HercepTest™, FISH and image analysis to quantify HER-2 expression is illustrated 
in Figure 6.3-1. 
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Figure 6.3-1: Classification of HER-2 gene amplification when assessed by fluorescent in situ hybridisation (FISH), and HER-2 
protein overexpression when assessed by immunohistochemistry and interpreted by human and image analysis, across all Tissue 
Microarrays and whole sections within this study.  
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6.4 Results 
The ability of the image analysis algorithm to classify HER-2 status within breast 
carcinoma, across Tissue Microarrays and whole sections were assessed. All slides were 
immunohistochemically stained with HercepTest™, and levels of HER-2 protein 
overexpression were assessed by four individuals and image analysis. Fluorescent in situ 
hybridisation was performed across all slides and levels of HER-2 gene amplification 
were assessed by one individual. Tissue Microarrays were used as a training set to create 
optimal cut-points within the continuous image analysis dataset. Whole sections were 
used as a validation set to verify the optimum cut-point to create. 
 
6.4.1 Tissue Microarrays - Training Material 
Cut-points were selected by comparing image analysis results with FISH data generated 
from Tissue Microarray reviews. Immunohistochemical reviews of Tissue Microarrays 
were performed by two individuals, and overall results were an average of the analyses 
performed. HER-2 gene amplification was assessed by FISH and quantified by a single 
individual.  
 
Figure 6.4-1 illustrates the correlation between FISH and image analysis across three 
Tissue Microarrays. The two cases where disagreement between FISH and image 
analysis assessment of HER-2 occurred is highlighted within the black box. In both 
cases, HER-2 gene amplification was observed by FISH; however, HER-2 protein 
overexpression was not present when immunohistochemical staining was assessed by 
human or image analysis. In both cases, HER-2 gene amplification was extremely close 
to the FISH analysis cut-point (2.2 and 2.11). 
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Figure 6.4-1: Correlation between image analysis and fluorescent in situ hybridisation 
(FISH) assessment of HER-2 status across three Tissue Microarrays. FISH analysis 
classifies HER-2 gene amplification as: < 2.0 non-amplified and ≥ 2.0 amplified. FISH 
cut-point (2.0) is illustrated by the horizontal line. Image analysis classified 
immunohistochemical HER-2 protein expression as: < 0.54 non-overexpressed and ≥ 
0.54 overexpressed. Image analysis cut-point (0.54) is illustrated by the vertical line. 
Data points have been colour coded according to the human HercepTest™ review. Cases 
where FISH and image analysis disagreed are highlighted within the black box.  
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Agreement between HER-2 protein overexpression and gene amplification across three 
Tissue Microarrays and whole section biopsies is illustrated in Table 6.4-1 and Table 
6.4-2, respectively. Depending solely on immunohistochemical staining to classify 
HER-2 status resulted in three scenarios with respect to patient treatments. “Correct 
treatment” occurred when HER-2 status assessed by immunohistochemistry and FISH 
agreed. “Referred cases” occurred when moderate immunohistochemical staining (2+) 
was observed and definitive testing was required to clarify HER-2 status. Referred cases 
would results in HER-2 status being accurately assessed; therefore referred cases have 
been classified with the “Correct Treatment”. “Over treated” occurred when HER-2 
protein overexpression was observed but the gene was not amplified, therefore, patients 
would incorrectly receive Herceptin™. “Under treated” occurred when HER-2 protein 
was not overexpressed and the gene was amplified, therefore, patients would incorrectly 
not receive Herceptin™.  
 
During Tissue Microarray analysis, there were no instances of over treatment when 
immunohistochemical staining was assessed by either human or image analysis. There 
was a slightly higher occurrence of under treatment when immunohistochemistry was 
assessed by image analysis (4.3%, n = 2) compared to human analysis (2.1%, n = 1). 
The number of correctly treated cases was marginally greater when 
immunohistochemistry was assessed by human analysis (97.9%, n = 46) compared to 
image analysis (95.7%, n = 45). The number of referred cases (n = 5) was relatively low. 
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Table 6.4-1: Agreement between HER-2 gene amplification (FISH) and protein overexpression (immunohistochemistry) when 
assessed by human and image analysis across three Tissue Microarrays. Tissue Microarrays were used as a training set to create 
optimal cut-points within the image analysis dataset. Over treated occurred when protein overexpression was observed and gene 
amplification was not present. Correct treatment occurred when HER-2 status assessed by immunohistochemistry and FISH agreed. 
Under treated occurred when gene amplification was observed but protein overexpression was not present. Referred cases occurred 
when borderline immunohistochemical staining (2+) was observed. Referred cases were categorised under Correct Treatment.  
TMAs Over Treated Correct Treatment Under Treated 
 % n % n Referred Cases % n 
Human Review 0.0 (0/47) 97.9 (46/47) 5 of 46 (10.6 %) 2.1 (1/47) 
Image Analysis 0.0 (0/47) 95.7 (45/47) N/A 4.3 (2/47) 
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6.4.2 Whole Sections – Validation Material 
In order to classify HER-2 protein overexpression across whole section biopsies, the cut-
points generated in the assessment of Tissue Microarrays were utilised. Assessment of 
immunohistochemical staining was performed concurrently by two individuals using a 
microscope. Figure 6.4-2 illustrates the correlation between FISH and image analysis 
across 46 whole sections. In total there are 8 cases (17.4%) where FISH and image 
analysis classification of HER-2 status disagreed, these cases are highlighted within the 
boxes in Figure 6.4-2. 
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Figure 6.4-2: Correlation between image analysis and fluorescent in situ hybridisation 
(FISH) assessment of HER-2 status across 46 whole section biopsies. FISH analysis 
classifies HER-2 gene amplification as: < 2.0 non-amplified and ≥ 2.0 amplified. FISH 
cut-point (2.0) is illustrated by the horizontal line. Image analysis classified 
immunohistochemical HER-2 protein expression as: < 0.54 non-overexpressed and ≥ 
0.54 overexpressed. Image analysis cut-point (0.54) is illustrated by the vertical line. 
Data points have been colour coded according to the human HercepTest™ review. Cases 
where FISH and image analysis disagreed are highlighted within the black box.  
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The majority of disagreement between FISH and image analysis occurred where HER-2 
protein overexpression was observed and gene amplification was not (n = 6). 
Disagreement between FISH and image analysis classification occurred to due the 
following reasons: 
 
Case 1: 
HER-2 gene amplification was borderline present (2.06) and HER-2 protein not 
overexpressed (0.44). Recommendations for interpretation of FISH state that if the ratio 
of HER-2 gene to chromosome 17 is close to 2.0 (1.5-2.3), a larger number of cells 
should be scored (Ellis et al., 2004). As a result, the FISH analysis of this specimen 
would be repeated, perhaps changing the HER-2 status.  
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Case 2: 
HER-2 gene amplification was present (3.01); however, clearly no 
immunohistochemical staining was present when assessed by human and image analysis. 
Immunohistochemical staining for this case is illustrated in Figure 6.4-3.  
 
 
Figure 6.4-3: Tissue recorded as having HER-2 gene amplification when assessed by 
fluorescent in situ hybridisation (FISH) (3.01). However, when immunohistochemical 
staining was assessed by human (0) and image analysis (< 0.54) protein overexpression 
was not observed.  
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Case 3: 
HER-2 gene amplification was not observed (1.03); however, HER-2 protein 
overexpression was clearly visible when assessed by human (3+) and image analysis 
(0.77). Immunohistochemical staining for this case is illustrated in Figure 6.4-4. 
 
 
Figure 6.4-4: Tissue recorded as having HER-2 protein overexpression when assessed 
by human (3+) and image analysis (≥ 0.54). However, when assessed by fluorescent in 
situ hybridisation (FISH) HER-2 gene amplification was not present (1.03). 
 
Case 4/5/6/7: 
There were four cases where HER-2 gene amplification was not present; however HER-
2 protein overexpressed was observed, and in all cases was recorded as 0.62 when 
assessed by image analysis. Human analysis classified 2 of these cases as 2+ and 2 cases 
as 1+. In all 4 cases staining intensity appears to be highly variable with staining 
intensity ranging from weak to moderate, as is illustrated in Figure 6.4-5 and Figure 
6.4-6. 
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Figure 6.4-5: (A) Case 4: HER-2 gene amplification was not observed (1.57); however, 
HER-2 protein overexpression was observed when assessed by image analysis (0.62). 
(B) Case 5: HER-2 gene amplification was not observed (1.19); however, HER-2 
protein overexpression was observed when assessed by image analysis (0.62). Both 
cases were referred (2+) when immunohistochemistry was assessed by human analysis. 
 
 
 
 
A 
B 
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Figure 6.4-6: (A) Case 6: HER-2 gene amplification was not observed (1.13); however, 
HER-2 protein overexpression was observed when assessed by image analysis (0.62). 
(B) Case 7: HER-2 gene amplification was not observed (1.33); however, HER-2 
protein overexpression was observed when assessed by image analysis (0.62). Both 
cases were considered weak (1+) when immunohistochemistry was assessed by human 
analysis. 
 
 
A 
B 
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Case 8: 
In addition to whole section biopsy analysis, areas of invasive tumour within the 
biopsies were isolated and immunohistochemical staining was assessed using image 
analysis. Figure 6.4-7 illustrates a whole section biopsy immunohistochemically stained 
for HER-2; areas of invasive tumour within the biopsy and are highlighted in red. FISH 
results performed across the whole biopsy recorded HER-2 gene amplification was not 
present (1.45); however, assessment of immunohistochemical staining by image analysis 
(0.76) observed protein overexpression. When image analysis was repeated on areas of 
invasive tumour only within the biopsy, protein overexpression was not recorded (0.50). 
Therefore, invasive tumour region selection agreed with FISH assessment. 
 
Figure 6.4-7: Whole section biopsy with no HER-2 gene amplification (1.45), and 
protein overexpression (0.76). However, when areas of invasive tumour only were 
assessed (red boxes), protein overexpression was not observed (0.50). HER-2 protein 
overexpression was assessed by immunohistochemistry and was quantified by image 
analysis.  HER-2 gene amplification was assessed by FISH and quantified by one 
individual.  
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Agreement between HER-2 status within whole section biopsies and regions of invasive 
tumours was extremely high when assessed by image analysis (r2 = 0.942). HER-2 status 
differed for only one case (Case 8 above) when whole biopsies analysis was compared 
with regions of invasive tumour only, as illustrated in Figure 6.4-8.  
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Figure 6.4-8: Correlation between image analysis assessment of HER-2 status within 
areas of invasive tumours only and across the entire whole section (n = 46). Image 
analysis classified immunohistochemical HER-2 protein expression as: < 0.54 non-
overexpressed and ≥ 0.54 overexpressed. Data points have been colour coded according 
to the human HercepTest™ review.  
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Table 6.4-2 illustrates the level of agreement between HER-2 gene amplification and 
HER-2 protein overexpression across 46 whole sections. Both under and over treatment 
was observed when HER-2 status was classified using immunohistochemistry across 46 
whole section biopsies. A considerably smaller number of patients were over treated 
when immunohistochemical staining was assessed by human (2.2%, n = 1) rather than 
image analysis (13.0%, n = 6). Compared to over treatment, a slightly higher percentage 
of patients were under treated, when assessed by human (8.7%, n = 4) and image 
analysis (4.3%, n = 2). The number of correctly treated cases was slightly higher when 
immunohistochemistry was assessed by human analysis (89.1%, n = 41) compared to 
image analysis (82.6%, n = 38). However, the agreement observed during the human 
analysis review was greatly inflated due to the number of referred cases (19.6%, n = 9). 
 
On average 10.6% (Tissue Microarrays, n = 5) and 19.6% (Whole section biopsies, n = 
9) of all immunohistochemically stained cases within this study were considered 
borderline overexpressed (2+) when assessed by human analysis. Therefore, FISH 
testing was required to definitively assess the HER-2 status within these cases. The 
majority of borderline cases (2+) did not have HER-2 gene amplification when assessed 
by FISH (Tissue Microarrays n = 3; Biopsies n = 5). Across all borderline (2+) cases 
within this study (n = 14), FISH and image analysis assessments differed in three cases. 
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Table 6.4-2: Agreement between HER-2 gene amplification (FISH) and protein overexpression (immunohistochemistry) when 
assessed by human and image analysis across whole section biopsies. Over treated occurred when protein overexpression was 
observed and gene amplification was not present. Correct treatment occurred when HER-2 status assessed by immunohistochemistry 
and FISH agreed. Under treated occurred when gene amplification was observed but protein overexpression was not present. Referred 
cases occurred when borderline immunohistochemical staining (2+) was observed. Referred cases were categorised under Correct 
Treatment.  
 
Biopsies Over Treated Correct Treatment Under Treatment 
 % n % n Referred Cases % n 
Human Review 2.2 (1/46) 89.1 (41/46) 9 of 41 (21.9%) 8.7 (4/46) 
Image Analysis 13.0 (6/46) 82.6 (38/46) N/A 4.3 (2/46) 
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6.5 Discussion and Conclusions 
HER-2 protein overexpression and gene amplification has been found to contribute to 
oncogenic transformation, and is associated with shorter disease free and overall 
survival in breast cancer. Therefore, accurate classification of HER-2 status within 
invasive breast carcinoma is crucial. Currently, the most common assay for evaluating 
HER-2 status is immunohistochemistry, with definitive FISH testing performed on 
borderline cases.  
 
Results illustrate image analysis is at least as accurate as human interpretation of 
immunohistochemistry when classifying HER-2 status. Image analysis classified 
staining intensity on a two-point scale, whereas human analysis utilised a three-point 
scale. Referred cases (2+) within this study were grouped with the correct treatment 
results. The utilisation of an intermediate staining intensity category (2+) clearly inflated 
the level of agreement observed between HER-2 gene amplification and HER-2 protein 
overexpression when assessed by human analysis. However, disagreement between 
FISH and immunohistochemistry when assessed by human and image analysis were 
comparable.  
 
When assessing HER-2 status within whole section biopsies, there was a high 
correlation between FISH testing and image analysis. Disagreement between methods 
occurred in 17.4% of cases (n = 8). Disagreement was attributed to results bordering the 
cut-points used in FISH classification (n = 1); false negative or positive HercepTest™ 
results (n = 2); non-invasive tumour regions influencing staining intensity values (n = 1), 
and image analysis recording protein overexpression as 0.62 (n = 4).  
 
The HercepTest™ has been shown to give false negative results in up to 28% of HER-2 
gene amplified cases (Ellis et al., 2005). False negative HercepTest™ occurred when 
gene amplification was present; but immunohistochemical staining was negative when 
assessed by image and human analysis. It has been suggested that this may be due to the 
destruction of the HER-2 epitope (Ellis et al., 2005). False positive HercepTest™ results 
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have been reported in up to 12% of cases (Bartlett et al., 2001, Hammock et al., 2003). 
False positive HercepTest™ occurred when gene amplification was not detected but 
immunohistochemical staining was very strong when assessed by human and image 
analysis. It is attributed to the overexpression of a single copy of the HER-2 gene. 
However, due to the heterogeneous nature of tumours in these instances it is possible 
that FISH analysis was performed on areas within the whole sections where no gene 
amplification or protein overexpression was observed.  
 
Areas of invasive tumours were marked and assessed by image analysis. Image analysis 
results from invasive tumour areas and whole sections differed in one case. In this case, 
protein overexpression was observed when the whole biopsy was assessed; however, 
protein overexpression was not present when invasive tumour areas within the biopsy 
were examined.  HER-2 gene amplification was not present for this one case. Therefore, 
this cohort of patients would suggest that pre-selecting areas of interest is of no real 
additional benefit with regard to patients’ prognosis. However, this should be further 
validated for a definitive conclusion. 
 
Only 14.9% (n = 7) of the Tissue Microarray dataset observed HER-2 protein 
overexpression (≥ 0.54). Also during Tissue Microarray analysis there were no cases 
with an image analysis result within the range of 0.60-0.76. Therefore, it is possible that 
within the range of 0.60-0.76 values a more optimum cut-point exists; however, due to 
the limited number of cases with HER-2 protein overexpression, it is not possible to 
verify this. Ideally, in future, a more comprehensive training set with a full range of 
image analysis results should be used to create optimal cut-points. 
 
The algorithm recreated in ImageJ was utilised to quantify HER-2 protein expression 
within this Chapter. The algorithm created with ImageJ utilised the same approach as the 
Image-Pro Plus® algorithm. However, the implementation was slightly different and as 
a result, a degree of noise was present in the final image. Therefore, correction of noise 
signal was required during statistical analysis of the data.  In addition, the procedure of 
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staining edges of tumours with tissue dye post-surgical extraction to identify tumour 
boundaries was found to influence image analysis assessment. These artifacts were not 
observed during Tissue Microarray analysis, and therefore were not a concern in 
previous Chapters. However, to avoid possible false positive results, black/brown tissue 
dye should be replaced with other colours, when image analysis assessment of 
immunohistochemistry is intended. The algorithm was used to assess whole section 
biopsies, therefore providing an automated and high-throughout analysis method. As a 
result, the application of the algorithm in a clinical context is possible. 
 
The application of image analysis to quantify HER-2 protein overexpression has been 
assessed within this study. Image analysis proved to be as accurate as human analysis 
when assessing HER-2 protein overexpression. Correlation between image analysis and 
quantitative FISH testing was high. In addition, the application of image analysis 
assessment of whole section biopsies was demonstrated. Results suggest image analysis 
could increase throughput and precision and decrease subjectivity when assessing HER-
2 protein overexpression. 
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CHAPTER 7: CONCLUSIONS AND 
RECOMMENDATIONS FOR FUTURE WORK 
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7.1 Discussion and Conclusion 
Human analysis of immunohistochemical staining intensity was proven to be inherently 
flawed, during the variety of assessments performed as part of this body of work.  Levels 
of intra- and inter-observer agreements were found to be extremely low, in particular, 
when assessing membrane-bound E-cadherin immunohistochemical staining intensity 
(32.4% and 25.3% agreement, respectively). The level of expertise of the reviewers 
performing the analysis was found to hugely affect inter-observer agreement when 
assessing membrane-bound immunohistochemical staining. As expected, the quality of 
results was greatly increased when assessments were performed by a Professor of 
Pathology rather than a research scientist. Also, using reference tissue which illustrated a 
range of staining intensities during immunohistochemical analysis increased inter-
observer agreements. The number of classifiers used to quantify membrane-bound 
immunohistochemical staining did not affect the quality of results when assessed by a 
Professor of Pathology. Traditionally, at least three classifiers are used to quantify 
staining intensity; however using two classifiers was proven to be as accurate.  
 
There are a number of factors that affect human interpretation of immunohistochemical 
staining intensity which are inherent to traditional microscope-based reviews. The 
human eye is extremely sensitive to contrasts in colour. When interpreting staining 
intensity, the extent of cytoplasmic staining can hugely affect the perception of the 
colour within the membrane. In addition, adjustments in lighting settings can introduce 
huge variability in the reviewing process. Consistency of microscope configuration 
between slides and reviews is extremely difficult during microscope-based assessments. 
Also the analysis of Tissue Microarrays under a microscope can lead to misplaced spot 
orientation. Accurate manual tracking of the Tissue Microarray cores during 
microscope-based reviews is challenging and prone to error. 
 
The Virtual Tissue Matrix (VTM) was a software application created to facilitate review 
and scoring of Tissue Microarrays via the Internet. The VTM alleviated variance of 
background lighting and disorientation within the Tissue Microarray slide. However, 
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inter- and intra-observer was still present when immunohistochemistry was assessed 
using the VTM. Ideally the assessments undergone within the VTM should have been 
performed by two experienced pathologist rather than comparing inter- and intra-
observer agreements between a research scientist and a pathologist. However, results 
illustrated that inter- and intra-observer agreements were particularly low when 
assessing membrane-bound immunohistochemical staining intensity over other 
parameters assessed. Therefore, it was concluded that computer-assessed methods 
maybe of benefit when assessing this parameter. 
 
For this reason, an image analysis algorithm was created to quantify membrane-bound 
immunohistochemical staining intensity. The algorithm was created using two different 
platforms (Image-Pro Plus® and ImageJ/Java). The algorithm proved simple to 
implement and facilitated effective analysis through integration into two different high-
throughput workflows. However, the algorithm had a number of limitations. The 
algorithm did not distinguish between tumour and non-tumour regions nor could it 
discriminate between invasive or non-invasive tumour components. This was not a 
concern when Tissue Microarrays constructed from tumour regions only, in the case of 
the Bladder cancer arrays; however, when whole section analysis was required, for 
example in HER-2 analysis, this limitation was discovered. In addition, the percentage 
of positive membrane staining could be quantified more accurately. Currently, the 
number of positive pixels within the image is utilised; however, a value based on the 
percentage of positive staining rather than pixel counts should be utilised. The creation 
of the algorithm using the second development platform (ImageJ) introduced noise 
within the final image which introduced a need for additional downstream data analysis. 
The algorithm can be further improved to remove noise from the final image rather 
relying on statistical analysis of the data to remove the noise. 
 
Cell Microarrays were constructed as part of this body of work. This enabled the Author 
to obtain invaluable practical laboratory experience in cell culture, tissue array design 
and construction within the National Institute for Cellular Biotechnology, Ireland and 
the National Cancer Institute, National Institute of Health, USA. Due to the absence of 
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comparative data, Cell Microarrays were assessed predominantly to validate the 
presence or absence of immunohistochemical staining for each of the biomarkers 
evaluated. Human and image analysis strongly agreed when qualifying staining presence 
or absence. The Author was dependant on retrospective data in relation to protein 
expression in these cell lines. Western blots were the predominant assay conducted on 
these cell lines. Greater use of ELISA in the original studies for protein quantification 
would have facilitated the correlation of image analysis intensity data with the extent of 
protein expression within the cell lines studied. In addition, protein expression was not 
evident in a large number of cases examined, and therefore, the level of agreement 
observed between methods was inflated by the number of negative cases present.  
 
Image analysis of Tissue Microarrays composed of Urothelial Cell Carcinoma of the 
bladder (UCB) illustrated that the level of E-cadherin and ß-catenin membrane 
expression had a significant effect on prognosis. However, no such correlation was 
observed when the Tissue Microarrays were originally assessed by a research scientist 
during routine laboratory examination. Tissue Microarrays were constructed, 
immunohistochemically stained and reviewed prior to the creation of the image analysis 
algorithm as part of a wider study examining the effect of E-cadherin / ß-catenin 
complex on prognosis. When no correlation was observed between E-cadherin / ß-
catenin protein expression and prognosis, Tissue Microarrays were assessed by image 
analysis. Once image analysis observed a significant correlation between expression and 
prognosis, the Tissue Microarrays were reassessed by a highly experienced Professor of 
Pathology resulting in the uncovering of a significant correlation between outcome and 
human review.  That said, the cohort of low expression cases identified by the 
experienced reviewer was much smaller and statistically less significant than the cohort 
identified by image analysis.  
 
However, as this was a retrospective study and all the materials existed prior to the 
Authors involvement, there were numerous difficulties encountered which could have 
been avoided if the study was designed optimally prior to Tissue Microarray 
construction. Firstly, the Tissue Microarrays were designed poorly. There was not 
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enough control standards present on each slide, which could be used to adequately 
calibrate the image analysis assessment. The Author had to make use of a single 
standard per slide, therefore forcing the assumption of an origin intercept and a linearity 
of relationship between signal and concentration. Cases were distributed across 26 
Tissue Microarrays when a single Tissue Microarray would have sufficed which 
introduced unnecessary slide-to-slide variability. Finally, due to the limited number of 
samples assessed, the study lacked statistical power. As the study required both training 
and test sets to validate findings in the general population, a larger cohort of patients was 
required. This was also noted when assessing the correlation between E-cadherin 
expression and outcome with respect to tumour stage. Despite the limitations of this 
study, image analysis proved to be a better method for identifying the correlation 
between E-cadherin / ß-catenin protein expression and prognosis in UCB. 
 
The HER-2 study allowed the Author better control of study parameters therefore 
allowing the application of training and test set principles lacking in the previous body 
of work. The quality of human review was considerably better when assessing HER-2 
protein expression, compared to E-cadherin assessments. However, image analysis 
proved to be as effective as human analysis when assessing HER-2 status. Especially, 
considering all borderline cases (2+) observed during human analyses were interpreted 
as correctly assessed. If borderline cases were either excluded from the review or 
classified as 3+, image analysis would have surpassed human assessment in both cases. 
In addition, image analysis had the additional benefit of being high-throughput.  
However, the fact that regions of tumour / non-tumour and invasive / non-invasive were 
not distinguishable by the algorithm was clearly a limitation within this study. 
 
In conclusion, an image analysis algorithm was created which compensates for inter-
observer variability in human interpretation of immunohistochemistry. The algorithm 
whilst simplistic clearly has room for improvement has proven to perform beyond the 
limit of human capabilities in the quantification of membrane staining intensity. When 
used in conjunction with Tissue Microarray constructed solely from regions of tumour, 
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the algorithm offers an effective alternative to human assessment of 
immunohistochemical staining intensity. 
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7.2 Future Work 
Moving forward the sophistication of the analysis performed by the algorithm could be 
greatly increased. In particular, the capabilities to identify regions of invasive / non 
invasive and tumour / non-tumour are of the utmost importance. The identification of 
tumour regions prior to quantification of staining intensity would result in reducing the 
time of analysis and increasing the accuracy of results obtained during tumour profiling. 
One proposed method for identifying tumour regions is to perform unsupervised 
clustering. There are numerous methods used to perform unsupervised clustering; 
however, in general the premise is to group entities with similar features together. For 
example, within tumour regions the nuclei are typically larger and more pleomorphic 
compared to normal tissue. Using unsupervised clustering, all similar shaped and size 
nuclei would be grouped together, therefore creating two distinct classes, normal and 
tumour regions. Ideally tissue types would be grouped by the algorithm, and an external 
review by a pathologist would be performed in order to classify the type of tissue within 
each grouping identified. Once a group has been classified by a pathologist, the criteria 
could be saved for future analysis. This method of tumour identification benefits from 
the experience of pathologist and the high-throughput nature of image analysis.  
 
The assessments performed on the Cell Microarrays should be further developed by 
comparing ELISA results with the image analysis results for the complete dataset. In 
addition, a Cell Microarray block has been created which can provide numerous sections 
for further immunohistochemical analysis thereby facilitating the application of this 
array to the determination of expression of a variety of new biomarkers.   
 
Using the UCB Tissue Microarrays as a training set, a larger cohort of samples should 
be assessed for E-cadherin protein expression. In addition, the Tissue Microarray blocks 
used within this study have been immunohistochemically stained with multiple markers. 
Membrane protein expression within these Tissue Microarrays should be assessed and 
correlated with prognosis. Only univariate analysis was performed within this body of 
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work. Multivariate analysis should be performed to examine the effect alternative 
parameters has on prognosis. 
 
Once the algorithm has been updated to account for noise signal and tumour region 
identification, the tissue examined during the assessment of HER-2 protein expression, 
should be reassessed. In addition, a larger cohort of patients should be examined, with a 
wide range of FISH data available for correlation with image analysis results. Finally, 
the whole sections pertaining to the Tissue Microarrays used within this study should be 
assessed, to examine if the range of HER-2 protein expression is truly represented within 
the Tissue Microarrays. 
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